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Abstract 
Asthma is characterised by airway inflammation, remodelling and bronchial hyperresponsiveness to 
normally innocuous stimuli. There is growing evidence that the airway smooth muscle (ASM) in asthmatic 
patients is altered and contributes to all three of these central pillars of the disease. Intracellular free 
calcium ions act as a secondary messenger within ASM in all of these processes and the expression of 
proteins regulating this tightly controlled process are altered in the disease. It has further been suggested 
that the long-term detrimental effect observed with some asthma therapies maybe associated with changes 
in calcium handling. The hypothesis of this study was that the calcium handling proteins SERCA2, 
TRPC3 and TRPC6 are altered by cytokines associated with asthma, or current therapies, leading to 
changes in calcium dynamics in the cell which contribute to the asthmatic phenotype. To investigate this 
hypothesis human primary healthy ASM cells were grown in culture and stimulated with either IL-13, 
TGF-β, TNF-α or a combination thereof or β2-adrenergic receptor agonists. The RNA and protein 
expression of the aforementioned calcium regulators were measured by qPCR and western blot and the 
calcium dynamics assessed by loading cells with fura-2. The impact of reduced SERCA2 expression, as 
observed in ASM derived from asthmatics, was investigated in a murine model of ovalbumin induced 
allergic airway disease using SERCA2
+/-
 mice. End-points included lung function measurements and 
inflammatory cell and cytokine infiltration. The key results found were that TGF-β differentially 
upregulates the expression of TRPC6 splice variants in a Smad2/3 dependent manner resulting in a 
reduction in flufenamic acid induced calcium entry. TNF-α upregulates TRPC3 expression while 
concomitantly down-regulating TRPC6 possibly conferring a switch in signalling from receptor operated 
calcium entry to store operated calcium entry. A reduction in SERCA2 in an in vivo model of asthma 
results in enhanced neutrophilia and an increase in sensitivity to methacholine to increase total airway 
resistance and decrease dynamic compliance. Finally it appears that chronic administration of β2-
adrenergic receptor agonists can lead to a variable decrease in SERCA2 expression however cAMP 
formation significantly increases it. Therefore β-arrestins may play a role in the detrimental effects 
observed with chronic dosing of this class of compounds. In conclusion the calcium handling proteins 
TRPC3 and TRPC6 are differentially altered by both TNF-α and TGF-β but unaffected by IL-13. The 
protein expression of SERCA2 on the other hand appears to be less regulated by the presence of asthmatic 
cytokines and its continued reduced expression in cultured asthmatic cells could be the result of genetic or 
epigenetic regulatory mechanisms.  
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Chapter 1 Introduction 
Since Robert Boyle and Robert Hooke’s experiments using a vacuum and a collection of unfortunate 
animals, described in the 1660 publication “New Experiments Physico-Mechanical: Touching the Spring 
of the Air and their Effects” it has been known that the presence of air is critical for respiration. A fact that 
is not lost on asthma sufferers worldwide today. Prior to that work, a direct link had not been established 
and it has since paved the way for hundreds of years of research aimed at increasing ventilation of the 
body. 
1.1 Asthma 
Asthma is a chronic inflammatory disease of the airways with over 5.4 million people in the United 
Kingdom receiving treatment for it in 2012 (NHS). The disease is characterised by airway remodelling, an 
enhanced inflammatory milieu in and around the airways, hypersensitivity and hypercontraction to 
allergens. The culmination of these effects results in impaired gaseous exchange between the pulmonary 
vasculature and the lung. The clinical manifestations of the disease arise as chest tightness, wheezing, 
cough and dyspnoea. 
1.1.1 Burden and prevalence 
The estimated annual cost of in-patient care, general practitioner consultations and prescriptions in the UK 
in a 2004 survey was £63.1M (Gupta et al., 2004) and Asthma UK estimates the NHS spends around £1 
billion a year in total on treating and caring for asthma patients. 
Asthma is least common in Africa and the Far East and most common in economically developed 
countries which are more urbanised (Masoli et al., 2004). The life-style that accompanies these countries 
favour the development of asthma as air quality is generally lower and common allergens such as house 
dust mites are more abundant. The “hygiene hypothesis” attempts to explain the causal relationships 
between early life pathogen exposure, close proximity to other children and other risk factors more 
commonly encountered in the developing world through demonstration of the inverse relationship between 
hay fever risk and family size (Strachan, 1989). Although many of these factors have been shown to be 
inversely correlated to asthma prevalence there are inconsistencies in the findings made (Ramsey et al., 
2005). For example it has been hypothesised that a TH1 stimulus in the first two years of life can suppress 
the over-development of the TH2 response which can lead to atopy (Arkwright et al., 2001; Erb et al., 
1999). However, helminth exposure generating a TH2 response can suppress an allergen specific response 
in the lung (Wang et al., 2001). Clearly there are links between allergy risk in later life and early exposure 
- 16 - 
to various antigens with evidence coming from epidemiological studies, however the underlying molecular 
pathways involved are still to be fully described (Wills-Karp et al., 2001). 
 
1.1.1-1 Global prevalence of asthma. Asthma’s prevalence is highest in urbanised “Western” countries and 
as more countries develop economically it is predicted there will be a further 100 million asthmatics 
globally by 2025 (Masoli et al., 2004). 
 
1.1.2 Definition and epidemiology 
Although asthma is termed as one disease there are many variations of it with some overlapping and non-
overlapping aspects between patients. Common to all asthmatics is a hypersensitivity to normally 
innocuous stimuli causing broncho-constriction and the extent of this correlates well with the severity of 
asthma (Holgate, 2004). 
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1.1.2-1 Typical dose response curves of patients suffering from severe asthma to the healthy population. 
The graph illustrates the bronchial hypersensitivity (left-ward shift) and hyperresponsiveness (increase in 
slope) present in asthmatics (Holgate, 2004). 
 
Asthma has a complex pathophysiology which was classically categorised into two broad different 
subsets: extrinsic, where a definite external cause can be identified to which the body generates a specific 
IgE response (Martinez et al., 2013); or intrinsic, where no such environmental stimuli exists (Turato et 
al., 2008). These terms are also known as atopic and non-atopic asthma respectively. It is now becoming 
increasingly clear that more specific “endotyping” is essential to developing novel therapies for severe 
patients who are not controlled by β2-adrenoceptor (β2-AR) agonists or steroids (Anderson, 2008; Wenzel, 
2013). Instead of basing research and diagnosis on set phenotypes such as propensity for exacerbations 
there has been a call to shift towards clearer biomarkers or genetic risk factors to define endotypes 
(Anderson, 2008). 
1.1.3 Genetic influence 
Many studies have shown that asthma runs in families, however not always in line with Mendelian 
inheritance patterns, suggesting both genomic and epigenetic heritable risk factors being passed on 
(Durham et al., 2011). Genome-wide association studies (GWAS) have discovered genetic loci linked 
with asthma prevalence at or near the genes of SMAD3, IL-6R, IL-18 and ORMDL3 (Ferreira et al., 2011; 
Moffatt et al., 2010) (see section 1.6.2 for more on ORMDL3). In addition, the human leukocyte antigen 
complex (HLA) is involved in immunomodulation and has been linked with asthma (Nicolae et al., 2005). 
It has been linked with maternal inheritance via allelic imprinting or other epigenetic mechanisms 
inducing bronchoconstriction (Durham et al., 2011; Nicolae et al., 2005), thus further adding to the 
complexity of inheritance of the disease amongst the population. 
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Another important genetic variation in asthma is the effect gender plays on its pathogenesis. It is well 
described that there is a higher incidence of asthma in boys than in girls, however around adolescence and 
puberty the pattern is reversed (Choi, 2011). It has been hypothesised that this occurs because of slower 
pulmonary development in males and also a potential role of sex hormones as those from males have been 
shown to suppress asthma whereas female sex hormones aggravate it (Osman, 2003). This hypothesis has 
been backed up in a murine model of asthma showing testosterone to have a protective effect in BALB/c 
mice displaying a reduced TH2 response (Hayashi et al., 2003). Female BALB/c mice have also been 
shown to experience more airway remodelling (discussed in more detail in section 1.4) than male mice, a 
factor of severe irreversible asthma (Takeda et al., 2013). However, the picture is not that straight forward, 
as estradiol administration has been associated with improving asthma symptom scores in mild to 
moderate asthmatics with premenstrual asthma (Chandler et al., 1997). Furthermore, the in vivo effects of 
androgens in mice appear to promote AHR by enhancing the vagally mediated reflex pathway affecting 
airway tone (Card et al., 2007). 
1.2 Inflammation and immunology 
Asthma is commonly characterised in many patients by an elevation of eosinophils, goblet cell hyperplasia 
and CD4+ T-cells secreting the classical TH2 cytokines IL-4, IL-5 and IL-13 and most recently regulatory 
T-cells (Treg) (Martinez et al., 2013). The innate immune system is also involved heavily, with the airway 
epithelium playing an important role limiting the early growth and expansion of microbes while antigen 
specific T-cell responses are established (Koyasu et al., 2013). In response to an allergen the epithelium 
produces thymic stromal lymphopoietin (TSLP), IL-25 (IL-17E), IL-33 and CC family cytokines  to 
activate CD4+ T-cells, mast cells, basophils, eosinophils and the newly discovered nuocytes (Locksley, 
2010; Neill et al., 2010; Smith, 2010). The nuocytes are capable of contributing to the inflammation by 
releasing IL-5 and IL-13 in response to IL-33 which could promote TH2 differentiation leading to IgE 
production (Martinez et al., 2013), eosinophilia and goblet cell hyperplasia (see 1.2.1 below). IL-33 acts as 
an alarmin and is localised in the nucleus of fibroblasts, epithelial and endothelial cells so that upon their 
necrosis it is released to stimulate a TH2 response (Koyasu et al., 2013). 
Symptoms manifest themselves often in a biphasic manner termed the early and late phase response (see 
Fig. 1.1.3-1). The early phase is short lived, up to 20 minutes, and involves the degranulation of mast cells 
through IgE crosslinking FcεR1 releasing numerous mediators including histamine, prostaglandin D2 and 
leukotrienes (Turner et al., 1999). The resulting impact of the degranulation is smooth muscle constriction 
(Dahlen et al., 1980) and inflammatory cell migration (Spada et al., 1994) see Fig. 1.2.2-1. The late phase 
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response occurs following a return to baseline of lung function several hours later and involves the 
adaptive immune response initiated though antigen presentation by dendritic cells leading to T-cell 
differentiation. The differentiated (TH2) cells release IL-4, IL-13 and CD40L act on naïve B-cells to 
induce IgE class-switching (Akdis et al., 2012). The cytokines released by TH2 cells lead to further 
eosinophil and neutrophil recruitment into the airways which release a variety of mediators leading to 
airway remodelling, mucus secretion, oedema and bronchoconstriction (all discussed in more detail later) 
contributing to the late phase effect. 
 
 
1.1.3-1 Typical response timeline of an atopic asthmatic to inhaled allergen, (Ward, Ward and Leach, 
2010: 56). Here the early and late phase responses are termed “immediate” and “late-phase” response. The 
early phase is largely a result of mast cell degranulation due to IgE binding to surface receptors. The late 
phase on the other hand involves components of the adaptive immune response leading to eosinophil 
recruitment, mucus secretion and a prolonged decrease in FEV1. 
 
1.2.1 IL-5 and eosinophilia 
Asthma can be divided into eosinophilic and non-eosinophilic subtypes. The majority of exacerbations are 
non-eosinophilic and are not prevented by corticosteroid treatment (Jayaram et al., 2006). However 
eosinophils are very much abundant in allergic asthma and IL-5 plays a key role in their differentiation 
and survival. Treatment with mepolizumab an anti-IL-5 monoclonal antibody has been shown to improve 
the quality of life in refractory eosinophilic asthmatics. This was achieved by reducing eosinophils in the 
blood and the sputum thus reducing the frequency of exacerbations (Haldar et al., 2009). A double airway 
transgenic mouse expressing IL-5 systemically in T-cells and eotaxin-1 in the airway epithelium further 
highlight the role of eosinophils and IL-5 in asthma (Ochkur et al., 2007). The mice displayed many 
characteristics of severe asthma in the absence of allergen such as airway remodelling and AHR. Eotaxin, 
an eosinophil chemokine has been shown to be released from asthmatic ASM cells between 2.5 and 6 fold 
more compared to “healthy” ASM cells after stimulation with a variety of pro-inflammatory cytokines 
usually present in asthma in vitro (Chan et al., 2006). 
- 20 - 
Eosinophils can contribute to airway remodelling (see 1.4) by releasing cationic proteins such as 
eosinophil cationic protein (ECP), major basic protein (MBP) and TGF-β (Hisamatsu et al., 1990; Wong 
et al., 1991; Zagai et al., 2007). A component of airway remodelling, ASM proliferation, has been shown 
to be increased by eosinophils isolated from mild asthmatics and not healthy controls (Halwani et al., 
2013). The authors discovered that the interaction was dependent upon cell-cell interactions between ASM 
and eosinophils resulting in their release of cysteinyl leukotrienes and not the release of ECM from the 
ASM. Prevention of eosinophil extravasation into the lung and subsequent adhesion onto ASM could be a 
useful therapeutic approach. 
1.2.2 IL-13 
IL-13 has been shown to play a central role in allergic asthma, directing many of the processes involved in 
the response. Upon exposure to an inhaled allergen, mast cells are activated and IL-13 drives IgE class 
switching in B-cells and that the class switching is more IL-13 dependent in allergic asthma patients 
compared to IL-4 (Van der Pouw Kraan et al., 1998). T cells (van der Pouw Kraan et al., 1996), basophils 
(Li et al., 1996), mast cells (Pawankar et al., 1997) and ASM (Grunstein et al., 2002) are all sources of IL-
13 in the airways. Once released it activates and prolongs the survival of eosinophils and is involved in 
their chemotaxis (Horie et al., 1997). 
Blockade of IL-13 using a soluble fusion protein in a murine model of asthma, post sensitisation but prior 
to ovalbumin challenge, reversed both AHR and mucus production in an eosinophilic and IgE independent 
manner (Wills-Karp et al., 1998). The study also shows administration of recombinant IL-13 can induce 
pulmonary eosinophilia and AHR in mice, two key markers of asthma. At a cellular level IL-13 has been 
shown to alter calcium handling dynamics via an up-regulation of CD38 protein expression in ASM 
leading to enhanced mobilisation following agonist stimulation (Deshpande et al., 2004). CD38 generates 
cADPR production which can directly or indirectly interact with the ryanodine receptor to increase the 
open probability of the channel (Jude et al., 2008). Blockade of cADPR with 8-bromo-cADPR attenuated 
the IL-13 augmented calcium response showing that CD38 may play an important role in the IL-13 
induced asthmatic phenotype. The enhanced mobilisation observed could contribute to airway remodelling 
and a worsening of symptoms (see section 1.4). An overview of the allergic response and airway 
inflammation is displayed in Fig. 1.2.2-1 (Kraft, 2011).  
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1.2.2-1 An overview of the complex inter-cellular interactions in asthma following inhalation of allergens. 
IL-13, TGF-β and TNF-α all play a role in the sensitisation of airway smooth muscle to agonists, 
enhancement of proliferation and the airway inflammatory response (Kraft, 2011). 
 
1.2.3 IL-8 and neutrophils 
The inflammation present in the airways and bronchioles of severe asthma differs from that of mild to 
moderate asthmatics in that neutrophils are the primary inflammatory cell not eosinophils (Wenzel et al., 
1997) and that they remain present even with corticosteroid treatment. Neutrophils release a variety of 
mediators which contribute to both the early and late phases of the asthmatic response. Matrix 
metalloproteinase-9 (MMP-9), elastase, reactive oxygen species, thromboxane A2 and myeloperoxidase 
are all released in the early phase and cause cytotoxicity, mucus hypersecretion, bronchoconstriction on 
bronchial hypersensitivity (Monteseirin, 2009). It has been suggested that neutrophils add to the late phase 
response by secreting IL-8, (murine functional equivalent is KC) their most potent chemokine to promote 
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their own recruitment and activation (Monteseirin, 2009). ASM has been shown to be a source of IL-8 in 
culture following stimulation with TNF-α and IL-1β (John et al., 1998). Originally just thought to be 
released by eosinophils, there is some evidence ECP is also released from neutrophils on a much slower 
time-scale adding to the late-phase cytotoxicity (Monteseirin, 2009). Many of both the early and late-
phase neutrophil factors that alter ASM function stem from changes in intracellular calcium signalling (see 
1.5). 
ASM cells can secrete pro-inflammatory cytokines, chemokines and growth factors in both a paracrine and 
autocrine manner to aid leukocyte activation and adhesion and furthermore to enhance both the ASM 
contractile and proliferative responses (Hirst, 2003). TH2 cytokine stimulation of asthmatic ASM cells 
induces mast cell migration into the muscle bundle possibly via IL-8 and eotaxin. Furthermore, 
supernatant from ASM derived from healthy patients inhibits migration to asthmatic derived ASM cells 
(Sutcliffe et al., 2006).  
1.2.4 TGF-β 
The TGF-β superfamily consists of numerous related extracellular signalling molecules with widespread 
roles ranging from regulation of development (Morty et al., 2009), modulation of the immune response 
(Tiemessen et al., 2003) to proliferation (Cohen et al., 1997). In humans TGF-β consists of three protein 
isoforms encoded by separate genes and expressed in a tissue specific manner, TGF-β1-3. TGF-β1 
(henceforth abbreviated as TGF-β) is the most abundant isoform found in mammals and the prototype for 
this family. 
TGF-β is synthesised as a larger precursor molecule composed of a pro-domain, the active molecule and a 
latency associated peptide. The pro-domain is cleaved but remains non-covalently associated with the 
active molecule after secretion where it is stored in the ECM in its inactive form. Cleaving of the covalent 
bond between the latency associated peptide and the active molecule by a number of different factors 
enables the TGF-β to bind to one of its receptors and initiate signalling. There are three related but 
functionally distinct serine-threonine kinase receptor proteins called TβRI, TβRII and TβRIII. TGF-β 
binds to the constitutively active TβRII which induces a heterotetrameric complex with TβRI, 
phosphorylating it in the process, ultimately leading to a cytoplasmic signalling cascade via Smad 
phosphorylation. 
TGF-β plays a central role in the tissue remodelling process as it can cause fibrosis (Gordon et al., 2008) 
and ASM proliferation (Oenema et al., 2013b). Furthermore the ASM proliferation is mediated via ECM-
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integrin interactions which can be enhanced by M3AChR stimulation, making it all the more relevant in 
asthma. TGF-β also serves as a negative regulator of the inflammatory response and therefore its actions 
are essential in immune homeostasis (Haneda et al., 1999; Kulkarni et al., 1993). Levels of TGF-β have 
been shown to be elevated in the lungs of asthmatics (Redington et al., 1997) and it is believed that this is 
part of a compensatory reaction to prevent excessive inflammation and AHR in response to allergen 
(Groneberg et al., 2004). The tissue remodelling is a deleterious by-product leading to some of the 
irreversible effects of asthma due to its continued presence in the airways.  
Smads are common intracellular mediators of TGF-β signal transduction. They can be divided into three 
sub-classes, receptor-activated Smads (R-Smads), common partner Smads (co-Smads) and inhibitory 
Smads (anti-Smads) (Piek et al., 1999). Smad2 and Smad3 are mediators of the TGF-β signalling cascade 
(R-Smads) and are phosphorylated by TβRI (Macias-Silva et al., 1996; Nakao et al., 1997). Smad4 is a co-
Smad and aids the efficient translocation of Smad2/3 to the nucleus for TGF-β signalling (Nakao et al., 
1997). As mentioned previously (see 1.1.3), a genome wide association study implicated a SNP in the 
Smad3 gene with increased asthma prevalence (Moffatt et al., 2010). Smad2 has also been implicated in 
asthma as over-expression in airway epithelium in a house dust mite (HDM) murine model of the disease 
increased AHR and remodelling markers (Gregory et al., 2010). The TGF-β Smad pathway has been 
shown to control the expression of certain proteins not only on a genomic level but also at an epigenetic 
level (Thillainadesan et al., 2012). The paper outlines the dynamic nature of methylation and 
demethylation and what its role may be in the context of certain cancers. Abnormal signalling of TGF-β is 
very much present in asthma too and dysregulation of specific DNA methylation may play a critical role in 
this. 
1.2.5 TNF-α 
TNF-α has been shown to be greatly elevated in the airways in symptomatic asthmatic patients compared 
to non-symptomatic patients (Broide et al., 1992). Many cells in the airway store TNF-α and have the 
ability to release it upon an antigen entering the lung including mast cells, eosinophils, epithelial cells and 
macrophages (Costa et al., 1993; Gosset et al., 1991; Khair et al., 1994; Plaut et al., 1989). It may then act 
on airway smooth muscle (ASM) to cause bronchoconstriction and infiltration of neutrophils (Thomas et 
al., 1995). The bronchoconstriction may be a result of both calcium sensitisation (Parris et al., 1999) or 
changes in calcium handling (Amrani et al., 1997; Jia et al., 2013; Sathish et al., 2012; Sathish et al., 
2009). A comprehensive pharmacological profile has been performed in guinea pigs, both in vivo and ex 
vivo to discover targets of TNF-α in eliciting bronchoconstriction (Makwana et al., 2012). Both 5-HT and 
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electrical field stimulation responses were enhanced by TNF-α however the methacholine response was 
unchanged, suggesting a pre-synaptic action on parasympathetic nerve terminals. The enhanced response 
to 5-HT was abolished in epithelium denuded trachea and with pre-treatment with ketanserin and atropine. 
A potential mechanism of action is suggested as enhanced 5-HT(2A) mediated acetylcholine release from 
the epithelium. 
In addition to enhancing contraction, TNF-α can influence the synthetic profile of ASM by increasing 
eotaxin-1 generation along with IL-1β (Ghaffar et al., 1999). The enhancement of calcium transients in 
human ASM by TNF-α can lead to proliferation, a feature of airway remodelling. The effect was specific 
to the TNF-α-p55 receptor as TNF-α-p75 specific agonists had no effect (Amrani et al., 1996). It may play 
a role in severe refractory disease as development of antagonists show it may improve quality of life and 
numerous end-points but only in a small subgroup of patients (Brightling et al., 2008). Part of the benefit 
of antagonism in severe refractory disease may be the inhibition of neutrophilia into the lungs, a key 
symptom of severe chronic asthma (Makwana et al., 2012). Exceeding the therapeutic window for TNF-α 
inhibition (via a specific therapy or with glucocorticoids) could be serious and lead to a detriment in the 
body’s immunological response, therefore combined use with other treatments could be beneficial 
(Thomas, 2001). 
1.3 Airway smooth muscle 
In addition to providing airway tone, the airway smooth muscle (ASM) in healthy patients has numerous 
other proposed functions including: a developmental role (rhythmic contractions in utero assist nutrient 
supply and waste removal and are necessary for lung development), structural support, protective to 
noxious stimuli, remodelling to prevent severe bronchoconstriction, production of anti-inflammatory 
mediators and ventilation perfusion matching (Mitzner, 2004; Pandya et al., 2006; Schittny et al., 2000). 
However the evidence for these roles after birth are weak at best. Nevertheless, ASM is clearly of great 
importance in asthma, when its function has been shown to be altered (Benayoun et al., 2003; Hirota et al., 
2009; James et al., 2012; James et al., 2008; Wright et al., 2012b). This has led to the use of bronchial 
thermoplasty to treat asthma by effectively removing or disabling ASM. Three randomised, controlled 
trials show that bronchial thermoplasty can improve quality of life scores, decrease emergency 
hospitalisation and decrease mild to severe exacerbations (Thomson et al., 2012). Controversy still 
surrounds its use as long term safety beyond five years is still unknown and the benefit above long term 
bronchodilators is debateable (Barnes, 2012). Its benefit however in severe asthmatics provides further 
evidence of the role ASM plays in the pathophysiology of asthma. The conducting airways provide the 
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majority of airway resistance in breathing and this is the target area of the treatment, usage in patients with 
poor pharmacological control or drug adherence may see the greatest benefits (Cox et al., 2004). 
Despite the controversy over the role of ASM in the healthy adult population, the evidence is clear 
concerning its involvement in the pathology of asthma. It is therefore important for the development of 
new therapeutics to understand fully the role it plays in disease and how the cell phenotype may be altered 
in asthma. 
1.3.1 Role in asthma 
ASM cells play a central role in contributing to the asthmatic phenotype. Not only is there more present,  
as a multicentre analysis of post-mortem tissue observed increased smooth muscle layer thickness in fatal 
asthmatics compared to controls (James et al., 2008), but they are also functionally different. Asthmatic 
ASM cells are hypercontractile (Matsumoto et al., 2007), more proliferative (Johnson et al., 2001) and 
tend to secrete more and/or different mediators  (Chan et al., 2006; Hirst, 2003). The excessive contraction 
is of greatest importance when considering asthma, as Poiseuille’s equation states that a halving of lumen 
diameter will increase airway resistance by a fold of sixteen. Therefore any excessive airway narrowing 
will significantly increase airway resistance. Other changes in the ASM such as enhanced proliferation and 
the secretion of inflammatory mediators subsequently results in longer-term changes and remodelling of 
the lung with further increases in airway resistance (see sections 1.3.3 and 1.4). 
1.3.2 Contractile function 
Notwithstanding the discussion of its purpose above, the primary role for ASM is to generate tone and 
contraction thus regulating the diameter of the airways. The key proteins involved in this process are 
myosin and actin as well as the regulatory proteins tropomyosin, caldesmon and calponin. Acetylcholine is 
the endogenous neurotransmitter controlling airway tone, and is released from vagal parasympathetic 
nerve endings to bind to M3ACh receptors on the ASM, other bronchoconstrictor agonists of particular 
relevance to asthma, include histamine, prostaglandin D2 and cysteinyl leukotrienes. Their receptors are 
commonly coupled to Gαq which activates phospholipase C (PLC), stimulating the formation of 
diacylglycerol (DAG) and IP3. The former activates receptor operated calcium entry (ROCE, see section 
1.7) and protein kinase C (PKC), whereas the latter initiates release of calcium from intracellular stores 
(Fig. 1.3.4-1). Many receptors also couple to G12/13 with activation of the RhoA/Rho kinase pathway 
which can induce calcium sensitisation (see below).  
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Upon a rise in intracellular calcium it forms a complex with calmodulin, which then activates myosin light 
chain kinase (MLCK). The kinase then phosphorylates the regulatory subunit of myosin (MLC20) allowing 
the myosin head to bind to actin and initiate it’s ATPase activity providing the energy required for 
contraction. Counteracting MLCK is myosin light chain phosphatase (MLCP) which acts by 
dephosphorylating myosin to inhibit the cross-bridge cycling and cause relaxation (Chiba et al., 2010). 
The net activity of both of these enzymes determines the phosphorylation state of MLC20 and degree of 
force production (Sanderson et al., 2008). 
Asthmatics exhibit a hypersensitivity to allergens and this is in part due to calcium sensitisation in ASM 
cells resulting in enhanced bronchoconstriction. Calcium sensitisation is the contraction of smooth muscle 
via a calcium independent pathway and it is thought that this process is primarily mediated by the 
RhoA/Rho Kinase (ROCK) pathway (Fukata et al., 2001). Rho kinase phosphorylates the MYPT1 
myosin-binding subunit which when phosphorylated inhibits the enzymatic activity of MLCP, resulting in 
prolonged phosphorylation of the myosin light chain and contraction (Chiba et al., 2010). Both calcium 
dependent and independent contraction pathways are outlined in Fig. 1.3.2-1. 
There also appears to be effects of disease on the calcium sensitisation pathway. It has been shown that 
TNF-α can induce calcium sensitisation in guinea-pig bronchial smooth muscle independently to MAPK 
and sphingomyelinase, a potential mediator of TNF-α (Parris et al., 1999). Furthermore, the contribution 
of Rho kinase in ACh induced bronchoconstriction is increased following repeated allergen challenge in 
rats (Chiba et al., 1999). Inhibition of Rho kinase with the compound Y-27632 has been shown to reverse 
airway hyperresponsiveness (AHR) to both histamine and prostaglandin F2α following allergen induced 
early and late-phase responses in ovalbumin sensitised and challenged guinea-pigs (Schaafsma et al., 
2006). Together this data shows that the calcium sensitisation pathway may provide novel targets for 
inhibition of allergen induced bronchoconstriction. 
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1.3.2-1 An overview of calcium dependent and independent (sensitisation) contraction in ASM both of 
which are altered in asthma. Calcium sensitisation occurs through inhibition of myosin light chain 
phosphatase resulting in prolonged phosphorylation of the regulatory light chain MLC20. It is believed that 
RhoGEF and RhoA both play important roles in this process and may be altered in asthma. 
 
There are many facets to asthma but ultimately it is the narrowing of the airways that causes the majority 
of the symptoms. Abnormalities of ASM mass and function has been identified as one of the main causes 
of this (Martin et al., 2000) which is why it is so central to much research and the current mainstay therapy 
is bronchodilation. The β2-AR agonists bind to the receptor coupled to Gαs which in turn activates adenylyl 
cyclise resulting in cAMP production and protein kinase A (PKA) activation. PKA can phosphorylate 
many targets of which the net effect is to reduce intracellular calcium as well as oscillation frequency and 
inhibit the contractile machinery (decreasing Ca
2+
 sensitivity) (Bai et al., 2006; Knox et al., 1995). 
The G-protein Gi may also play a role in mediating contraction and relaxation in ASM cells in asthma. 
Animal models of asthma have shown increased expression of Gi and was thought to mediate enhanced 
contraction through Gq and attenuate relaxation through Gs (Hakonarson et al., 1995). However further 
work in mice has shown that overexpressing Gi decreased contractility of the airways in a proposed 
protective mechanism while also inferring β2-AR resistance (McGraw et al., 2007). 
Actin polymerisation plays a key role in contraction as its inhibition results in a reduction in force 
development in tracheal smooth muscle (Mehta et al., 1999) and its expression is increased alongside 
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between the actin cytoskeleton and the ECM through integrins and adhesion junctions enable the 
transmission of force across the tissue determining (in part) airway compliance and responsiveness (Zhang 
et al., 2008b). Furthermore, focal adhesion kinase, a non-receptor tyrosine kinase forming part of the 
adhesion junctions has been shown to phosphorylate Rho GEFs which may lead to calcium sensitisation 
via the Rho kinase pathway (Somlyo et al., 2003). Cytoskeletal reorganisation within the ASM, also 
termed “mechanical plasticity” is probably an essential component of ASM function in order to maintain 
airway lumen diameter (Halayko et al., 2003). It has been postulated that alterations in the process, 
possible by Rho kinase or interactions with the ECM via integrins as previously mentioned, might underlie 
the absence of a bronchoprotective effect of deep inspiration as observed in asthma (King et al., 1999). 
1.3.3 Synthetic function 
Alongside the classical contractile function of ASM they have been shown to contribute to the 
inflammation present in the lungs by secreting cytokines, chemokines and growth factors which recruit 
inflammatory cells into the airways and the surrounding parenchyma as well as inducing glucocorticoid 
insensitivity (Tliba et al., 2009). The synthetic function of ASM can be triggered or enhanced by the 
presence of an allergen, microbe or other antigen. A combination of IL-4, IL-13 and TGF-β, all of which 
are up regulated in asthma, differentially induces the expression of eotaxin-1 over eotaxin-3 from ASM 
(Zuyderduyn et al., 2004). Eotaxin-1 serves as a chemokine for eosinophils showing how the ASM can 
contribute towards bronchoprotection to foreign stimuli. RANTES (regulated upon activation, normal T-
cells expressed and secreted) release can be stimulated in culture by TNF-α and IL-1β and can chemo-
attract eosinophils, memory T-cells and monocytes (Hershenson et al., 2008). As mentioned previously 
IL-8 can be secreted by ASM as well as IL-6, monocyte chemotactic protein 1-3, GM-CSF, IL-1β, IL-11 
and IFNβ (Panettieri, 2003). In response to airway inflammation adhesion molecule expression is induced 
on ASM cells, namely ICAM-1 and VCAM-1 allowing leukocytes to adhere to the muscle and possibly 
aid in activating them on top of inducing ASM proliferation (Lazaar et al., 1994; Panettieri, 2003). The 
overall effect of these synthetic processes are an alteration of the muscle phenotype to that seen commonly 
in asthma such as enhanced contractility and perturbed calcium homeostasis (see section 1.5 below) 
(Amrani et al., 1998; Pepe et al., 2005). These processes have been well defined in vitro however the 
extent of the contribution to the inflammatory response in asthma by the ASM in vivo is still to be fully 
defined. 
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1.3.4 ASM in culture 
As shown, ASM cells display a variety of phenotypes primarily a contractile state 
(differentiated/maturated) and a synthetic state (dedifferentiated/modulated) (Fig. 1.3.4-1). Evidence from 
in vitro studies are starting to outline that ASM cells can exist in varying degrees between these different 
phenotypes within a single population and that the characteristics of each phenotype is altered if they are 
derived from asthmatics (Wright et al., 2012b). It is still unknown whether this phenotypic modulation 
occurs in vivo, but it would go some way to explaining the plethora of responses and functions ASM cells 
are capable of.  
As one might expect, there is a discrepancy between the expressions of certain proteins between both 
states which contribute to the phenotypic modulation. A rise in synthetic organelles such as the Golgi 
apparatus and mitochondria aid the increased proliferative capacity of modulated cells (Halayko et al., 
2008) while a concomitant fall in contractile markers decrease the cell’s responsiveness to contractile 
agonists (Gosens et al., 2002). This can be induced by addition of different stimuli such as platelet derived 




1.3.4-1 Examples of proteins which differ in expression levels between the modulated and maturated state 
in cultured ASM cells, redrawn from Wright et al., 2012b. 
 
Many factors can initiate a phenotypic change in smooth muscle from serum content of the culture media 
and confluency of the cells, to supplementation of cytokines and ECM proteins (Halayko et al., 1999), 
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(1989) reported that smooth muscle specific α and γ-isoactin decreases significantly in the third passage.  
It is therefore very important to design any experiment with ASM carefully and use the appropriate 
conditions to best test the hypothesis. 
1.4 Airway remodelling 
Airway remodelling encompasses the structural changes in the lung observed with asthma and is 
characterised by increased ASM mass, sub-epithelial fibrosis, goblet cell hyperplasia, sub-mucosal gland 
hypertrophy, neoangiogenesis, epithelial apoptosis, altered ECM and increased activated fibroblasts 
(Berair et al., 2013). It is generally believed that these structural changes are largely irreversible (Barnes, 
1996) and therefore are indicative of disease progression and symptom worsening. 
Important work is being carried out to determine the relationship between inflammation, airway 
remodelling and AHR. It is critical to elucidate which aspect increases airway lumen narrowing the most 
and the time course in which they are brought on to successfully prevent it. In asthmatic patients who 
display a late-phase reaction to allergen challenge it has been shown that airway wall cellular 
inflammation increases at 24 hours and resolves by 7 days post challenge. AHR and markers of 
remodelling persist up to this point (Kariyawasam et al., 2007), indicating that although inflammation may 
be required to initiate remodelling and AHR, its presence is not required to sustain it. In an ovalbumin 
mouse model of airway remodelling it was shown that ECM deposition, particularly collagen, was 
increased during persistent challenges and did not resolve up to 1 month post cessation (McMillan et al., 
2004). An elevated number of ASM cells were also maintained after cessation of challenges while 
inflammatory markers TGF-β1, IL-4, IL-5 and IL-13 fell back down. Both of these studies further point to 
the potentially irreversible nature of the remodelling as exposure to antigens or presence of inflammation 
are not required for their persistence. 
It has been suggested that airway remodelling can contribute to AHR as ASM length increases as part of 
the process (Lee-Gosselin et al., 2013). When human bronchial rings were stretched they produced greater 
force in response to methacholine and were more sensitive to contractile agonists. Using computational 
analysis they reasoned that ASM from asthmatics may be increased by up to 10.4% in length. The study 
relies on numerous assumptions but it provides an interesting link between changes in ASM morphology, 
(i.e. increased ASM length as a part of remodelling) and AHR. This paradigm can also be turned on its 
head as it has also been shown that bronchoconstriction alone can induce remodelling (Grainge et al., 
2011). The paper demonstrates increased epithelial proliferation, mucus production and collagen thickness 
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induced by methacholine challenge in asthmatic patients that was prevented by pre-treatment of 
salbutamol, a β2-AR agonist. The conclusion draws a parallel to skeletal muscle where repetitive 
contraction leads to remodelling. Part of their suggestion lies with an increased epithelial stress leading to 
enhanced TGF-β production in the epithelial-mesenchymal trophic unit which can result in remodelling 
(Halwani et al., 2011). An interesting follow up study would be to control for the other pharmacological 
effects of methacholine and salbutamol by stimulating with other contractile agents. Thus ensuring that it 
is contraction inducing the remodelling and not other receptor mediated effects. Further weight has been 
added to this theory using guinea-pig lung slices as bronchoconstriction using methacholine induced TGF-
β release resulting in airway remodelling in the absence of inflammation (Oenema et al., 2013a).  
The increased ASM layer observed in remodelling is thought to be a result of both hyperplasia and 
hypertrophy however it is largely believed the former is of greater significance. The source of the 
additional ASM cells is still controversial as there is conflicting evidence over it being from increased 
proliferation (Johnson et al., 2001; Ward et al., 2008) or prolonged survival (Berair et al., 2013). One 
current idea is that fibrocytes in the peripheral blood are recruited to the ASM bundle by the ASM itself in 
asthma (Saunders et al., 2009) and once there, they are able to differentiate into myofibroblasts and 
eventually ASM (Davies et al., 2003). Another potential source is from the epithelium in a process termed 
“epithelial mesenchymal transition” where the expression of numerous proteins change resulting in a loss 
of epithelial functionality and acquisition of a mesenchymal-like phenotype. There is some evidence this 
may contribute to the airway remodelling observed in asthma using a chronic murine allergen exposure 
model (Johnson et al., 2011). The paper shows that airway epithelial cells lost expression of E-cadherin 
and occludin while gaining expression of mesenchymal markers vimentin, α-sm-actin and pro-collagen-I 
with a concomitant migration into sub-epithelial regions of the airway wall. There is evidence that this 
process may occur in humans using a similar challenge in primary in vitro culture of bronchial epithelial 
cells (Heijink et al., 2010). There is still some controversy to what degree this process occurs in vivo in 
asthma as a further study failed to show the expression of any mesenchymal markers in epithelial cells 
from sections taken from asthmatic donors therefore the phenomenon may just be part of the normal 
epithelial repair process (Hackett et al., 2009). 
1.5 Calcium homeostasis 
Cytosolic calcium is an important regulator for many intracellular functions including those central to the 
asthmatic phenotype. Resting cytosolic calcium concentration [Ca
2+
]i is approximately 100nM; this is 
20,000 times lower than the extracellular concentration and considerably lower than that in the 
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sarcoplasmic reticulum (SR; 500μM). The low resting [Ca2+]i is critical to the normal functioning of the 
cell as numerous mechanisms including contraction, transcription, secretion, migration and proliferation 
are dependent on subtle changes in its levels (Mahn et al., 2010). Calcium homeostasis is controlled by 
several proteins on the plasma membrane controlling its entry and removal from the cell and also by 
proteins on the sarcoplasmic membrane capable of sequestering and releasing intracellular stores (Fig. 
1.3.4-1). 
 
1.3.4-1 An outline of intracellular calcium homeostasis in ASM redrawn with permission from Mahn et 
al., 2010. Upon agonist association with a Gαq coupled receptor PLCβ activation generates IP3 and DAG 
resulting in a rise in [Ca
2+
]i through release from the SR reticulum and receptor operated calcium entry 
respectively. Calcium release from the SR initiates calcium oscillations by increasing the opening 
probability of the ryanodine receptor in a process termed calcium induced calcium release (CICR). In each 
cycle of the oscillations calcium is removed from the cytosol via sequestering back into the SR by 
SERCA2 or extrusion from the cell either by the sodium calcium exchanger (NCX) or the plasma 
membrane ATPase pump (PMCA). To replenish the SR calcium content store operated calcium entry is 
initiated using the “sensing” protein STIM1 in association with Orai1 and the TRPC channels. 
 
Upon Gαq receptor activation by an agonist calcium is released from intracellular stores via IP3 which then 
increases the opening probability of the ryanodine receptor resulting in further calcium release and the 
initiation of calcium oscillations (see section 1.5.1 below). The calcium signal causes myosin light chain 
kinase activation resulting in muscle contraction (see Fig. 1.3.2-1). The subsequent elevation of [Ca
2+
]i 
initiates numerous other responses including activation of pro-inflammatory transcription factors such as 
NFAT (nuclear factor of activated T cells) and NF-кB, leading to changes in gene expression. The 
termination of these processes in part relies on the ability of the cell to bring [Ca
2+
]i back to resting levels. 
It can do this either by extrusion of calcium from the cell via the sodium/calcium exchanger (NCX) or the 
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plasma membrane calcium ATPase pump (PMCA), or by pumping it into intracellular stores via 
sarcoendoplasmic Ca
2+
 ATPases (SERCA). SERCA provides the sole mechanism for sequestering free 
cytosolic calcium into the sarcoplasmic reticulum and therefore strongly dictates the rate of recovery to 
resting levels. A third mechanism involves mitochondrial buffering and is described in further detail in 
section 1.5.2. 
Recent studies have shown that the tight regulation of protein expression controlling calcium homeostasis 
is controlled to a degree at the transcriptional level, at least in cardiac muscle (Ritchie et al., 2011). Early 
Growth Reponse-1 (EGR1) can modulate the expression of SERCA2 (Arai et al., 2000), NCX (Wang et 
al., 2005) and Stim1 (Ritchie et al., 2010) in cardiac myocytes and cell lines. EGR1 is a receptor 
dependent transcription factor showing the capability for ligands to completely remodel the calcium 
handling dynamics and potentially alter the cell phenotype. 
1.5.1 Calcium oscillations 
There is a highly non-linear relationship between [Ca
2+
]i and force production in smooth muscle due to the 
1:4 stoichiometry of calmodulin-Ca
2+
. In light of this and because of the large diversity of stimuli which 
can result in bronchial hyper-reactivity it was postulated a while ago that dysregulation of calcium 
homeostasis may be a unifying underlying cause (Triggle, 1983). Calcium independent mechanisms 
contributing to AHR must also be considered, see 1.3.2 above. 
In culture near maximum concentrations of contractile agonists cause a biphasic increase of [Ca
2+
]i in a 
population of ASM cells. The first phase is transient and results from intracellular calcium release whereas 
the secondary phase is sustained and dependent on extracellular Ca
2+
 (Murray et al., 1991). More powerful 
techniques has since shown the detail of signalling within each individual cell is far more complex. Upon 
agonist stimulation calcium oscillations initiate from IP3 associating with its receptor causing SR Ca
2+
 
release resulting in an increase in the RyR opening probability as discussed above. The IP3R also increases 
its opening probability upon calcium binding to a high affinity site initiating a propagating calcium wave 
along the cell which is regenerative in nature due to further calcium-induced calcium release from the SR 
(Liu et al., 1996; Prakash et al., 1997). The oscillations occur due to a second, lower affinity Ca
2+
 binding 
site on the IP3R which reduces its opening probability when the [Ca
2+
]i is high enough (Iino, 1990). Some 
Ca
2+
 is lost from the cell through the PMCA pump and the NCX, the signal maintains its regenerative 
aspect through replenishing the SR via store operated calcium entry (SOCE), see section 1.7. 
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The frequency and duration of calcium oscillations correlates with agonist concentration and ASM 
contraction however the amplitude of each oscillation remains relatively constant (Sanderson et al., 2008). 
The oscillations between cells are asynchronous therefore they do not generate synchronised phasic 
contractions as observed in some other smooth muscle tissue (Ressmeyer et al., 2010). The current 
hypothesis is that it is the sum effect of the frequency of all these asynchronous oscillations within each 
cell that cause tonic contraction in the ASM and that the onset of contraction appears to be almost 
simultaneous with the onset of calcium oscillations upon agonist stimulation. 
It is thought that the mean global cellular rise in calcium ions, integrated from many local oscillations, 
plays a role in signalling for slower Ca
2+
 dependent processes (Prakash et al., 2000) as well as their 
frequency. The oscillations usually start from one side of the cell and propagate along its entire length. In 
calcium free conditions agonists can initiate oscillations but not sustain them longer than a few cycles 
showing that calcium influx is required to fill the intracellular stores (Prakash et al., 1997; Sanderson et 
al., 2008). The time taken to do this, which is in part dependent upon SERCA2 activity, can dictate 
oscillation frequency (Sneyd et al., 2004) and therefore potentially affect the functional outcome. The 
importance of store release in this process is highlighted by the fact SERCA2 inhibition results in a 
rundown of store content and reduces oscillation frequency (Perez-Zoghbi et al., 2007). This paper also 
showed the positive correlation between oscillation frequency and contraction, indicating this is in part 
how contraction is regulated by different agonist concentrations. It is thought that agonist induced 
oscillations involve both IP3R to initiate the response and determine the baseline characteristics and cyclic 
ADP-ribose (cADPr) acting via RyR to modify the response, although it is not a requirement for it 
(Sanderson et al., 2008). cADPr is a nucleotide metabolite whose synthesis and degradation is catalysed 
by CD38 in ASM and has also been suggested to alter calcium homeostasis during inflammation, 
reviewed in (Deshpande et al., 2005). 
High resolution microscopy has revealed that calcium oscillations have distinct spatial characteristics 
which add another level of informational coding. It has been postulated that a superficial buffer barrier 
exists in which components of the sarcoplasmic reticulum divide the cytosol into at least two discrete 
signalling spaces. Thus serving to create a variable calcium gradient immediately below the plasmalemmal 
membrane and also acting as an amplifier of signalling via calcium induced calcium release (CICR) 
(Janssen et al., 1999; van Breemen et al., 1995). 
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1.5.2 Mitochondria  
Mitochondria are essential to life, producing adenosine triphosphate (ATP) which is required to provide 
energy for numerous cell functions. It is also involved in protein, steroid and lipid synthesis as well as 
cellular signalling cascades (McBride et al., 2006). Mitochondria has also been shown to play a role in 
Ca
2+
 handling, helping to shape calcium signalling patterns and buffer high concentrations to prevent 
excitotoxicity (Carafoli, 2010; Parekh, 2003; Vasington et al., 1962). 
Mitochondria in conjunction with the SR divides the cytosol into distinct microdomains as either can 
occur both peripherally or centrally within the cell allowing an extra depth to calcium signalling (Rizzuto 
et al., 2006). Its close proximity with both the SR and plasma membrane allows the mitochondria to shape 
the [Ca
2+
]i response to agonists via its buffering function (Delmotte et al., 2012). By actively up taking 
calcium from the cytosol it has been shown that mitochondria increase the dynamic range of IP3 induced 
SOCE (see section 1.7) and could therefore play a role by lowering its activation threshold (Gilabert et al., 
2001). Further manipulation of SOCE is possible by the mitochondria as suggested by a study using 
calcium indicators specific for the ER lumen, mitochondria and cytosol (Arnaudeau et al., 2001). By 
systematically preventing uptake into either the SR or mitochondria with antagonists and stimulating the 
cell with histamine the paper postulates that the mitochondria can locally refill areas of the SR creating 
internal local calcium gradients. A benefit of this could be allowing the plasmalemmal SR to deplete and 
activate SOCE, while replenishing the internal SR to continue cytosolic calcium oscillations for 
contraction and nuclear signalling.  
Interestingly, treatment with the inflammatory cytokine TNF-α causes an increased rise in [Ca2+]i in 
response to agonist stimulation, while causing a decrease in [Ca
2+
]myt by inhibiting the mitochondrial 
uniporter (MCU) (Delmotte et al., 2012) which uptakes calcium from the cytosol (De Stefani et al., 2011). 
Calcium levels within the mitochondria also act to modify catabolic processes by stimulating the 
dehydrogenases; pyruvate (Denton et al., 1972), iso-citrate (Denton et al., 1978) and 2-oxoglutarate 
(McCormack et al., 1979). Thus mitochondria can affect cellular calcium signalling and subsequent 
changes in calcium within the mitochondria can affect metabolism. Changes in the mitochondria have 
been shown to be relevant in asthma as ASM have an increased mitochondrial mass and oxygen 
consumption compared to both COPD patients and healthy controls (Trian et al., 2007). The increase in 
mitochondrial mass is a result of a calcium dependent increase in mitochondrial biogenesis which in turn 
lead to a mitochondrial dependent increase in asthmatic ASM compared to the other groups. The findings 
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presented show that both the mitochondria or the altered calcium handling in ASM (discussed in detail in 
section 1.6) could be used as therapeutic targets for airway remodelling in asthma. 
1.5.3 Lysosomal calcium stores 
The complexity of calcium signalling is further enhanced by the interaction of the endoplasmic reticulum 
with lysosomal calcium stores. They are IP3 and RyR independent and release Ca
2+
 in response to 
NAADP, originally found in sea urchin eggs (Churchill et al., 2002). It has been postulated that NAADP 
and cADPR may link the cellular metabolic state to calcium signalling mechanisms via this store 
(Berridge et al., 2003), as can the mitochondria, however there is no clear role described currently in 
ASM. 
1.6 Calcium handling proteins 
1.6.1 SERCA2 
There are three members of the SERCA family each with different splice variants, in the ASM SERCA2b 
is the most highly expressed (Mahn et al., 2009). There are many proteins involved in regulating the 
activity and expression of SERCA2b with much of the research to date being focussed on its role in 
cardiac function. Phospholamban is the most studied regulator of SERCA2 and in its unphosphorylated 
form it lowers the affinity of SERCA for calcium. In the heart clear links have been shown between super 
or chronically active phospholamban inducing dilated cardiomyopathy (MacLennan et al., 2003). Pro-
inflammatory cytokines in the asthmatic lung lead to increased agonist induced [Ca
2+
]i so a natural 
presumption would be dysregulation of intracellular calcium homeostasis at some level and it was 
hypothesised that phospholamban expression or activation may be increased. However it was shown that 
human ASM does not express the phospholamban protein (Sathish et al., 2009) and that its regulation may 
involve CaMKII. The same paper also reports pro-inflammatory cytokines IL-13 and TNF-α reducing 
SERCA expression upon incubation overnight. Further data shows TGF-β reducing SERCA expression 
for up to 7 days post 24 hour incubation with ASM cells (Ojo,O., Thesis, 2011, University of London). 
Both of these sets of data can help to describe why chronic inflammation which is present in asthma can 
lead to disruption of calcium homeostasis.  
Impaired function of SERCA2 matches its reduced expression in vitro as stimulation of asthmatic ASM 
cells by bradykinin or ryanodine resulted in an attenuated rise in [Ca
2+
]i  and a subsequent slower recovery 
to baseline compared to healthy controls (Mahn et al., 2009). Further evidence is given to the importance 
of SERCA in asthma by reducing its levels using targeted siRNA. The paper shows that by reducing 
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SERCA2 in the healthy cells it is possible to reproduce many of the phenotypes shown in asthmatic 
cultured cells such as enhanced secretion of inflammatory cytokines, proliferation and motility. Mahn et al 
have therefore provided compelling evidence that reduced expression of SERCA2 is present in asthmatic 
airways and that the level of reduction can have functional consequences in ASM cells in culture.  
The SERCA pump is an ATPase and requires ATP to function which is produced by the mitochondria. 
Efficient energy production and expenditure may be regulated at a transcriptional level and it has been 
shown the mitochondrial transcription factors A (TFAM) and B2 (TFB2M), which are key regulators of 
ATP production also regulate nuclear transcription of SERCA2 (Watanabe et al., 2011). The latter report 
also demonstrated that the transcription factor SP1, which is known to regulate SERCA2 transcription, has 
a very close binding site to TFAM though they act independently. TFAM and TFB2M mRNA levels are 
decreased in the failing heart (a disease in which SERCA2 is also decreased) and their expressions are in 
part controlled by the co-factor peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α) 
(Watanabe et al., 2011). PGC-1α has been shown to be vital for the heart to meet increasing demands for 
ATP and in mice lacking it cardiac dysfunction occurs (Arany et al., 2005). It has been postulated that 
stimulation of PGC-1α via PPAR-γ agonists could provide a new therapeutic approach (Sano et al., 2005). 
Given the close pathology of calcium homeostasis in heart failure and asthma this could be an avenue 
worth investigating. 
1.6.2 ORMDL3 
There is a strong association with the onset of childhood asthma and a single nucleotide polymorphism 
(SNP) on chromosome 17q21 relating to ORMDL3 transcript levels (Moffatt et al., 2007). The 
polymorphism has been specifically associated in asthma without rhinitis and found to be also linked to 
COPD patients (Balantic et al., 2013). ORMDL3 is expressed on the ER which has been shown to have an 
important role in sensing cellular stress via the unfolded protein response (UPR) (Zhang et al., 2008a). 
ORMDL3 can alter calcium homeostasis in the ER and facilitate the UPR possibly by binding to and 
inhibiting SERCA2b (Cantero-Recasens et al., 2010). It is unknown why the ORMDL3 SNP is only 
associated with childhood asthma however this could possibly be due to hormonal effects counteracting its 
perturbation of calcium homeostasis. 
1.6.3 TRPC 
The mammalian transient receptor potential (TRP) channel proteins consist of six families containing 
TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin), TRPP (polycystin) and 
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TRPML (mucolipin). The TRPC subfamily is further divided into seven members, TRPC1-7. Each 
member of the subfamily contains six transmembrane spanning domains and assemble as homo or 
heterotetramers to form cation selective channels (Pedersen et al., 2005). TRPC3, TRPC6 and TRPC7 are 
grouped together as they share a higher degree of sequence homology compared to the other four as well 
as forming multiple heteromers with each other (Cheng et al., 2010; Hofmann et al., 2002) and being 
responsive to DAG, making them receptor operated calcium channels (ROC). TRPC1, C3, C4 and C6 are 
expressed in human ASM (Corteling et al., 2004; Karner, 2010). There is also evidence TRPC7 is 
expressed at low levels in a portion of the population (Karner, 2010). Both TRPC3 and TRPC6 can be 
activated by DAG in a membrane delimited fashion (Hofmann et al., 1999). 
It has been shown that TRPC3 is less tightly regulated and has higher constitutive activity than TRPC6 
due to the N-linked glycosylation pattern. Evidence shows that TRPC6 is dually glycosylated within the 
first and second extracellular loop whereas TRPC3 is monoglycosylated (Dietrich et al., 2003), see Fig. 
1.6.3-1. In a further publication by the group they back up this suggestion by showing increased 
expression of TRPC3 leads to increased basal calcium current and knocking TRPC3 with siRNA in 
TRPC6
-/-
 cells returned the enhanced basal and response to OAG back to wild type levels. The paper 
proposes they form dimmers in which TRPC6 regulates the basally active TRPC3 (Dietrich et al., 2005). 
Increasing expression of TRPC3 in wild type cells or reducing TRPC3 in the TRPC6 knockouts with 
siRNA abolished the increased cation entry, leading to the conclusion that both channels are functionally 
non-redundant and TRPC6 is required to regulate muscle tone. 
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1.6.3-1 Structural features of TRPC channels (Vazquez et al., 2004a). Potential glycosylation sites are 
labelled. The 70kDa TRPC6 splice variant terminates at the N-terminus mid-way through the coil-coiled 
domain. The two larger truncated splices of the full length TRPC6 are missing the first hydrophobic 
segment of the protein. 
 
TRPC6 channels are non-selective cation channels allowing the entry of calcium and sodium ions into the 
cell (Godin et al., 2007). It is thought that the sodium entry through TRPC6 results in membrane 
depolarisation and activation of voltage dependent L-type calcium channels or the sodium calcium 
exchanger (NCX) (Cloutier et al., 2003; Eder et al., 2005). The Godin 2007 paper shows that reducing 
TRPC6 with siRNA did not alter OAG induced intracellular Ca
2+
 movement in primary cultured ASM 
from guinea-pigs. They suggest that TRPC3 homotetramers mediate the OAG response in the absence of 
TRPC6 after siRNA treatment. Unfortunately the paper does not inhibit or knockdown NCX or L-type 
calcium channels as one would expect TRPC6 would still be contributing to calcium entry following OAG 
stimulation indirectly via one of these two entry mechanisms following Na
+
 influx. Such an additional 
experiment would help delineate the contribution of calcium or sodium ion entry via TRPC6 on the net 
calcium influx. Their data also contradicts previous studies in our lab showing TRPC6 siRNA 
administration significantly ablates the OAG response as analysed by 100s analysis of variance (ANOVA) 
(Karner, 2010). 
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There are two TRPC3 splices, a shorter form missing some of the N-terminus lacking from an upstream 
exon weighing 97.37 kDa and a longer isoform at 105.55 kDa. The number of functional TRPC6 splices is 
contentious, there are likely to be three or four. There was no evidence of TRPC3 or TRPC6 splice 
variants expressed in murine or canine pulmonary or renal artery smooth muscle preparations reported in a 
previous publication (Walker et al., 2001). Very little work has been done so far on profiling the 
expression and function of the various TRPC splice variants’ expression in ASM. It would be of great use 
to quantify this expression and gain a clearer idea of which splices assemble into dimers with each other 
and how that translates into channel coupling and function. 
The roles of TRPC3 and TRPC6 in calcium entry are contentious and discussed in further detail in section 
1.7. An obligatory role of Src kinases has been found in DAG activation of TRPC3 in HEK293 cells 
(Vazquez et al., 2004b). A dominant negative form of Src kinase completely suppressed receptor and 
OAG dependent TRPC3 activation. SOCE however was unaffected and shown not to be Src dependent, in 
contrast to other findings in fibroblasts and platelets (Babnigg et al., 1997; Rosado et al., 2004). Findings 
made in cell lines must be interpreted with caution, particularly when considering function of TRPC 
channels as they are influenced by so many different factors. 
Neither TRPC3 nor TRPC6 message RNA expression is altered in ASM cells derived from a range of 
severities of asthma compared to control (Karner, 2010). The asthmatic cytokine TNF-α has been shown 
to increase TRPC3 expression and SOCE thought to be associated with it (White et al., 2006). The lack of 
changes observed in mRNA may be a result of the inflammatory cytokine stimulus being removed and 
therefore is not necessarily representative of the in vivo situation. The combination of an increased 
expression of TRPC3 and decrease in SERCA2 following stimulation with pro-asthmatic cytokines means 
a relatively severe disruption of calcium homeostasis is likely to exist in asthmatic ASM cells. What is yet 
to be shown though is whether this has any significant consequences in a whole organism and if this can 
be manipulated into an animal model of asthma. 
The lack of specific antibodies, agonists and antagonists makes the study of TRPC proteins particularly 
difficult. Additionally their complex dimerisation and association with other proteins such as Orai1 add to 
their functional diversity making it difficult to elucidate the role of each TRPC protein. Their role in Ca
2+
 
influx in ASM and the link to contraction and proliferation make them a potentially valuable target for 
asthma and warrants perseverance in their research (Perez-Zoghbi et al., 2009). 
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1.6.4 Na+/Ca2+ exchanger 
Upon agonist stimulation and a rise in [Ca
2+
]i removal mechanisms are activated to bring the concentration 





 exchanger (NCX) which utilises the trans-membrane Na
+
 gradient to efflux one calcium ion in 
exchange for three sodium ions which is an electrogenic process. The transporter can also work in reverse 
to pump calcium ions into the cell, a phenomenon described to occur in ASM mediated by STIM1 to help 
control calcium homeostasis (Liu et al., 2010). The close association of NCX with calsequestrin 
containing regions of the SR (Moore et al., 1993) and potentially TRPC3 (as shown in HEK293 cells) 
(Rosker et al., 2004) further suggests its role in calcium homeostasis (Sathish et al., 2011). 
The most comprehensive study of NCX in human ASM within the context of asthma showed that only 
NCX1 and not NCX2-3 are expressed at the protein level (Sathish et al., 2011). The cytokines TNF-α and 
IL-13 both significantly elevated its protein expression in an NF-κB and MAPK dependent manner. 
Importantly, treatment with the cytokines increased the inward (often termed reverse mode) exchange 
mode of the pump to a greater degree than the outward exchange mode and inhibition of its expression 
decreased both the peak and rate of fall of [Ca
2+
]i following histamine stimulation. The paper provides 
clear evidence how the NCX pump may play a role in the altered calcium homeostasis in asthma. 
1.7 Store and receptor operated calcium entry 
1.7.1 SOCE 
Store operated calcium entry (SOCE) also known as capacitative calcium entry (CCE) involves the 
refilling of the sarcoplasmic reticulum store of calcium from the extracellular fluid following agonist 
induced emptying (Putney, 1986). As stated previously, this entry is required to sustain calcium 
oscillations which are critical in cellular signalling (Prakash et al., 1997; Sanderson et al., 2008). 
Numerous mechanisms have been postulated since the discovery of this phenomenon including the 
vesicular fusion of store operated channels with the plasma membrane via exocytotic machinery, a 
diffusible messenger (such as Ca
2+
 influx factor) or the conformational coupling of the IP3 receptor to the 
plasma membrane (Parekh et al., 2005). Mounting evidence has since shown Stromal interaction molecule 
1 (STIM1), the Orai group of proteins and the TRPC channel family mediate this effect (Feske et al., 
2006; Liao et al., 2007; Peel et al., 2008; Putney, 2005; Zhang et al., 2005). 
Stromal interaction molecule 1 (STIM1) acts as a Ca
2+
 sensor on the SR and translocates to the plasma 
membrane upon store depletion (Zhang et al., 2005) where it interacts with Ca
2+
 permeable channels. It is 
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comprised of a single membrane spanning domain and a helix-loop-helix motif (EF hand) close to the 
luminal C-terminus which acts as the calcium sensor. It is thought that STIM1 interacts with Orai1, a 
plasma membrane protein containing four transmembrane segments (Feske et al., 2006). The paper shows 
that a homozygous single missense mutation in severe combined immune deficiency patients leads to the 
lack of SOCE. In turn there is no activation of nuclear factor of activated T-cells (NFAT) transcription 
giving rise to the phenotype. In a smooth muscle specific knockout of STIM1 this finding was backed up 
as PDGF failed to activate NFAT in the knockout mice as was sustained PDGF induced Ca
2+
 entry 
(Mancarella et al., 2013). 
It was originally thought that Orai1 forms a pore through the channel but recent evidence has shed doubt 
on the theory and proposed that it combines with TRPC3 or TRPC6 to form a regulatory subunit (Liao et 
al., 2007). The interactions between Orai1 and TRPC channels would dictate their ability to perform both 
ROCE and SOCE depending upon their expression and perhaps presence in lipid rafts (Liao et al., 2009). 
Caveolar expression plays a role in SOCE in ASM cells, when caveolin is knocked down with siRNA 
Ora1 expression is also reduced with a concomitant decline in SOCE (Sathish et al., 2012). The paper also 
demonstrates how SOCE can be altered by inflammation in asthma as exogenous application of TNF-α 
increased SOCE. Part of the mechanism behind this could be increased STIM1 aggregation resulting in 
greater puncta size (Jia et al., 2013). 
1.7.2 ROCE 
ROCE is defined as the portion of calcium entry into the cell which is attributed to the continued presence 
of agonist and can be abolished experimentally by an antagonist of the receptor. The influx of Ca
2+
 is 
independent to the SR Ca
2+
 content, unlike SOCE and are mediated by TRPC channels. It has been shown 
that ROCE occurs in untreated ASM cells upon stimulation with ACh and that treatment with TNF-α 
causes a switch to a more SOCE dominated calcium entry mechanism (White et al., 2006). The switch in 
function is coupled with an increase in TRPC3 expression which decreases ion channel coupling to PLC 
and increases its sensitivity to store depletion. Very little work has been done to date to separate the 
functions of SR sensitive and insensitive calcium entry through TRPC channels and they may prove to 
serve a role in regulating a change in calcium signalling in the presence of inflammation. 
1.8 TRPA1 
TRPA1 is an excitatory ion channel located on sensory neurons and is activated by numerous agonists 
including; mustard oil, garlic, reactive oxygen species and cigarette smoke (Bautista et al., 2006; Caceres 
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et al., 2009; Jordt et al., 2004). TRPA1 activation can lead to neurogenic inflammation in the lung (Andre 
et al., 2008) and it was found when ablating its protein expression using a homozygous knockout, 
ovalbumin induced leukocyte infiltration, mucus production, cytokine infiltration and bronchial 
hyperreactivity were all dramatically reduced (Caceres et al., 2009). The results of this study were all put 
down to its neurogenic inflammation however it has since been found to be able to contribute to non-
neuronal inflammation in mice (Nassini et al., 2012). 
Current respiratory research into TRPA1 is centred primarily on its role in the tussive response to both 
exogenous and endogenous agents (Grace et al., 2012). In light of the recent finding that it is expressed on 
numerous cells including cultured ASM, fibroblasts and epithelial cells new mechanisms contributing to 
asthma and other respiratory diseases via altered cation entry may be discovered. 
1.9 Current therapies 
1.9.1 β2-adrenergic receptor agonists 
β2-adrenergic receptor (β2-AR)  agonists form a vital part of many asthmatic’s mainstay treatment as they 
offer a quick onset of action relaxing ASM and they have a good safety profile. The agonist shifts the 
equilibrium of the receptor in favour of its activated form from its resting inactive state thereby increasing 
the number of receptors associated with the Gs protein and GTP (Johnson, 2001). The activated receptor 
results in numerous downstream signalling events but importantly an increase in cAMP followed by 
activation of PKA results in muscle relaxation.  
The first generation of these drugs including salbutamol only have a maximum duration of action of four 
hours. Therefore long acting β2-AR agonists (LABA) were developed particularly for patients whom 
attacks were worst at night or morning. LABAs are able to elicit a prolonged response compared to other 
drugs of the same class, for example salbutamol, because of their enhanced lipophilicity and potential 
enhanced dissociation constant with the receptor (Lotvall, 2001). The increased lipophilic nature of the 
compounds results in them staying in the phospholipid bilayer of the cell membrane and reaching the 
receptor in a prolonged manner and are not washed away so easily as hydrophilic compounds. 
1.9.2 Postulated limitations of LABAs 
The safety of formoterol and other LABAs has been called into question following increasing evidence 
showing an increased risk of mortality (Rodrigo et al., 2009). The β2-AR has constitutive activity in the 
absence of an occupying agonist (Hanania et al., 2010) and administration of inverse agonists (an agonist 
binding to a constitutively active receptor to stabilise it and reduce the activity) show positive signs in 
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murine models including decreased inflammation and mucous metaplasia (Lin et al., 2008; Nguyen et al., 
2008). A further follow up study from the same group demonstrated that the same effect is achieved in β2-
AR null mice, indicating that it is the absence of constitutive signalling by the inverse agonists and not 
biased agonism causing the beneficial effects (Nguyen et al., 2009). 
Interestingly it has recently been shown that prolonged exposure of β2-AR agonists can lead to a 50% 
decrease in SERCA2a protein in the heart (Ryall et al., 2008). It is thought that this reduction in SERCA2a 
is due to a decline in gene transcription possibly via glycogen synthase kinase-3β (GSK-3β) which has 
been implicated as a negative regulator of SERCA2 gene transcription (Michael et al., 2004). Ryall et al 
showed a 40% decrease in its phosphorylation upon β2-AR stimulation thereby enabling more of the active 
form to directly interact with the promoter region of SERCA and inhibit its transcription. 
Ojo (Thesis, University of London 2011) has shown that both formoterol and salbutamol decrease the 
expression of SERCA2 in healthy cultured ASM cells in a dose dependent fashion (see figure 1.9.2-1). 
The β2-AR antagonist ICI-118551 inhibited the reduction suggesting the effect is via the receptor. 
Additionally stimulation with forskolin producing a similar rise of cAMP as formoterol also decreased 
SERCA2 expression indicating that it is a cAMP dependent effect. Finally pre-incubation with the 
ERK1/2 inhibitor U0126 blocked formoterol reducing SERCA indicating that ERK is involved in the 
signalling cascade. Under the same conditions the steroidal asthma treatment dexamethasone did not cause 
a decrease in SERCA. The next experiments now need to delineate the full intracellular signalling cascade 
from receptor activation to mRNA translation and whether this phenomenon occurs in vivo. 
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1.9.2-1 Changes in SERCA2 protein expression following stimulation with formoterol or forskolin for 24 
hours, data values (mean ± SEM) represent SERCA2 expression levels expressed relative to untreated 
ASM cells, n=4-5 (Ojo, Thesis, University of London 2011). 
 
1.9.3 Steroids 
Corticosteroids form part of the first-line treatment for asthma and low doses control the symptoms well in 
many patients provided they adhere to a daily dosing regimen (Barnes, 2013a). Glucocorticoids diffuse 
into the cytoplasm where they can either: Bind with the glucocorticoid receptor alpha splice variant 
(GRα), homodimerise and then bind to glucocorticoid response elements (GRE) on steroid-responsive 
genes (Rhen et al., 2005). The resulting complex either recruits co-activator or co-repressor proteins which 
can alter the structure of chromatin through acetylation and switch on anti-inflammatory genes or switch 
off inflammatory genes. Or they can interact directly with transcription factors such as NF-κB or with 
membrane associated proteins to impart ant-inflammatory actions in a non-genomic manner (Rhen et al., 
2005). 
A small fraction of patients are resistant to corticosteroid treatment and they have been characterised by 
having a longer duration of symptoms, lower morning lung function and a greater degree of bronchial 
reactivity however these features are not exclusive to this patient subpopulation (Carmichael et al., 1981). 
Several mechanisms have been identified which can lead to corticosteroid resistance including genetic 
susceptibility, defective GR binding and nuclear translocation, increased expression of the non-functional 
GR receptor splice variant GRβ, increased transcription factor activation or abnormal histone acetylation 
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to new drugs being developed to restore sensitivity such as inhibitors of p38 mitogen-activated protein 
kinase (MAPK) (Bhavsar et al., 2010) or antioxidants to enhance HDAC2 activity (Kirkham et al., 2006). 
In a study looking at the function of the SR in aged rat myocardium it was found that dexamethasone 
improved SERCA function approximately 2-fold and decreased the time taken for relaxation (Narayanan 
et al., 2004). A similar study has not been performed in ASM but if the finding translates then it would go 
further to explain the beneficial effects observed with the drug in asthma.  
1.9.4 Anticholinergics 
Anticholinergics or antagonists to the muscarinic acetylcholine receptor (mAChR) have long been used in 
asthma therapy due to their bronchodilatory actions inhibiting vagally induced smooth muscle 
constriction, historically taken by smoking deadly nightshade plant extracts containing atropine (Jackson, 
2010). Acetylcholine production however may not be restricted to just parasympathetic nerve 
neuromuscular junctions but also from epithelial and immune cells (Wessler et al., 2008). As such it is not 
surprising that muscarinic receptors are involved in more than just bronchoconstriction and have been 
implicated in airway remodelling and inflammation (Kistemaker et al., 2012). It is thought that airway 
constriction via M2AChR receptors releases TGF-β stored in the ECM via integrin interactions which 
enhances ASM remodelling (Oenema et al., 2013b). Anti-inflammatory effects of anticholinergics have 
also been observed (primarily in COPD) and are thought to be attributed to their ability to reduce the 
release of chemotactic mediators from macrophages (Buhling et al., 2007), limiting neutrophil chemotaxis 
(Vacca et al., 2011) and reducing muscarinic dependent release of chemotactic factors from epithelial cells 
and ASM (Gosens et al., 2009; Koyama et al., 1998). The long acting antagonist tiotropium is used in 
asthma therapy and has been shown to be at least as effective at bronchodilation as β2
-
AR (Gross, 1986) 
and could prove to be even more beneficial given the anti-inflammatory and remodelling effects. 
1.9.5 PDE inhibitors/Xanthine derivatives 
Theophylline, a phosphodiesterase (PDE)-4 inhibitor was originally used as a bronchodilator due to its 
cAMP raising effect (see section 1.3.2) and antagonising the adenosine receptor1 and 2. As β2-AR 
agonists have come into use as first line therapy its use as a bronchodilator has declined and it is 
prescribed now due to the anti-inflammatory effects and HDAC2 activation to restore steroid sensitivity 
(Barnes, 2013b). The high expression of both PDE3 and PDE4 in leukocytes and their cAMP mediated 
inflammatory effects make them a useful target in inflammatory diseases. At low therapeutic doses 
theophylline reduces the late-phase asthmatic response as well as neutrophil and eosinophil numbers 
(Kraft et al., 1996; Lim et al., 2001; Sullivan et al., 1994). The PDE4 mediated anti-inflammatory 
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mechanisms of theophylline are also responsible for many of its side effects which makes it a difficult 
target for drug research. Alternatives with improved safety profiles such as doxofylline (Shukla et al., 
2009), modified compounds to reduce side effects (Kawasaki et al., 2014) or PI3 kinase inhibitors to 
improve HDAC2 activity offer more desirable solutions (To et al., 2010). Dual inhibition of both PDE3 
and PDE4 can offer positive interactions regarding both bronchodilation and anti-inflammatory effects to 
improve the therapeutic index (Abbott-Banner et al., 2014). Still many have failed in the clinic however 
there are promising candidates such as RPL554 which is well tolerated due to its rapid plasma clearance 
and it elicits at least as effective bronchodilation as salbutamol with the addition of significant anti-
inflammatory effects and mucociliary clearance in man (Franciosi et al., 2013). 
1.9.6 Anti-leukotrienes 
Cysteinyl leukotrienes (cysLTs) are primarily synthesised in eosinophils and mast cells, they are 
derivatives of arachidonic acid metabolism by 5-lipoxygenase (5-LO) and exhibit both broncho-
constriction and pro-inflammatory effects (Okunishi et al., 2011; Scott et al., 2013). There are two defined 
receptors for the Cysteinyl leukotrienes LTC4, LTD4 and LTE4 which are CysLT1 and CysLT2. A third, as 
yet unidentified receptor has been postulated to be responsible for the inflammatory contribution of LTE4 
(Austen et al., 2009). LTA4, the precursor to the aforementioned cysLTs can also be hydrolysed to 
produce LTB4, the principle leukotriene found in macrophages and neutrophils (Okunishi et al., 2011). 
There are two targets within this class of drugs either antagonising the cysLT receptor-1 (CysLT1) or 
inhibiting 5-LO. Only one study to date has compared the effectiveness between the two targets and the 5-
LO inhibitor zileuton showed statistically significant greater improvements in both symptom scores and 
peak flow rate (Kubavat et al., 2013). The result is possibly due to its less specific action of inhibiting the 
production of cysLTs rather than antagonising just CysLT1 (Scott et al., 2013). Anti-leukotrienes are not as 
effective at reducing inflammation as inhaled corticosteroids (Israel et al., 2002) nor reducing 
bronchoconstriction as LABAs (Nelson et al., 2000) therefore they are not part of the first-line of therapy 
in asthma. Their advantage lies however in greater patient adherence due to being taken as a once daily 
pill rather than an inhaler which has been shown to translate to equivalent effectiveness to steroids as a 
first-line therapy and LABAs as an add-on in a “real world” study (Price et al., 2011; Scott et al., 2013). 
Further rationalised research targeting the arachidonic acid derivative pathway could lead to improved 
therapies in this class of drugs especially in specific patient sub-populations such as neutrophil rich or 
exercise induced asthma. 
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1.10 Animal models 
The low availability of asthmatic human tissue combined with the ethical considerations of performing 
invasive procedures on human subjects necessitates the use of animal models in asthma. When used in 
conjunction with in vitro and ex vivo techniques their usage can be reduced to a minimum while still 
gaining vital insights into whole-body physiological responses. The greatest understanding of the field can 
be made by drawing conclusions from a wide variety of approaches and integrating the results as shown 
when investigating contraction in ASM (Wright et al., 2012a). 
There are a plethora of different models available to study the various mechanisms thought to be driving 
the asthmatic phenotype however due to the disease’s mixed aetiology none can fully replicate the human 
condition (Wanner, 1990). It is therefore wise to pick specific research questions you want answered about 
the disease and tailor the model specifically to answering that question. By doing this you can gain 
important insights into the various mechanisms one step at a time while minimising the compounding 
effects of each model’s flaws. 
A wide variety of animals have been used to study asthma, each with their own benefits and pitfalls. Non-
human primates provide the closest resemblance to human physiology and models have been developed 
which closely match many markers of human asthma at a pathophysiological, cellular and molecular level 
(Ayanoglu et al., 2011). In terms of the chronic natural disease only horses suffer from a spontaneously 
occurring pathology akin to asthma, heaves. However this may be more closely related to COPD due to 
the neutrophilic nature. It has been shown that horses with heaves have increased airway remodelling 
associated with an increased smooth muscle mass and myocytes proliferation (Herszberg et al., 2006). The 
horse therefore is in a unique position to allow some direct cross-species comparisons to human asthma 
however the extent of the similarities still needs to be further defined. In light of ethical reasons it is better 
to use lower order animals such as rodents in place of primates. 
It has been shown that guinea-pig lungs provide a more suitable model for human airway pharmacology 
than both rats and mice (Ressmeyer et al., 2006). Along with rats and dogs but not mice they also show all 
three of the physiological changes in lung function following inhalation of allergens; early phase response, 
late phase response and airway hyperresponsiveness (Zosky et al., 2007). A major drawback to all of these 
species however is their limited use in mechanistic models due to the low number of inbred strains and 
genetic knockouts, a trait where mice come into their own as research tools. A detailed knowledge of the 
mouse genome (Dietrich et al., 1996) makes it easy to manipulate and produce transgenic strains. 
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Murine models of asthma involve sensitisation to an antigen followed by an exposure to that allergen to 
produce a well characterised TH2 driven inflammatory response involving elevation of antigen specific 
IgE, eosinophilia and bronchial hyperresponsiveness (Zosky et al., 2007). Ovalbumin has been the most 
widely used antigen historically but now more clinically relevant to human antigens are being used such as 
house dust mite (HDM) (Cates et al., 2004). A secondary advantage to using a HDM exposure protocol is 
that an adjuvant such as aluminium hydroxide is not required to prime a TH2 driven response. The 
ovalbumin model relies on TH2 priming using an adjuvant (Brewer et al., 1999) however this also serves 
to potentially distant the observed responses further from that seen in the clinical setting. 
Different lengths of model also need to be taken into account depending what end points need to be 
evaluated. Acute models are good for examining AHR and the inflammatory infiltration to the airways 
however if remodelling is to be investigated a chronic exposure model is needed (Johnson et al., 2004a; 
McMillan et al., 2004). Remodelling involves altered ECM composition (Dolhnikoff et al., 2009), 
subepithelial fibrosis (Tang et al., 2006), enlargement of the ASM bundle (James et al., 2012) and goblet 
cell hyperplasia (Rose et al., 2006) as described in section 1.4. ASM hypertrophy and fibroblast 
accumulation have been negatively correlated with pre and post-bronchodilator FEV1 values outlining the 
impact of remodelling on lung function (Benayoun et al., 2003). T-cells and eosinophils can induce 
epithelial apoptosis via secretion of TNF-α and IFN-γ and necrosis via eosinophil cationic protein (ECP) 
(Trautmann et al., 2002). Loss of the epithelial layer can result in reduced mucous clearance which 
coupled with enhanced goblet cell hyperplasia further occludes the airways. They also provide the initial 
barrier to spasmogens and can metabolise inflammatory mediators so their loss can further contribute to 
AHR by providing more direct access to nerve terminals (Bertrand et al., 1993). 
1.11 Summary 
The following investigation centres on the findings that the intracellular handling of calcium ions in ASM 
cells derived from or induced by an asthmatic environment is altered (Jia et al., 2013; Karner, 2010; Mahn 
et al., 2009; Mahn et al., 2010; Sathish et al., 2012; Sathish et al., 2009; White et al., 2006). The recurring 
theme of these publications involves increased [Ca
2+
]i either at rest, or following changes in ROCE or 
SOCE as a result of changes in the expression of critical calcium handling proteins on the SR and plasma 
membrane. Evidence shows that SERCA2 protein expression is reduced in a disease severity dependent 
manner in asthma (Mahn et al., 2009) and that both TRPC3 and TRPC6 are altered by administration of 
cytokines implicated in asthma (Karner, 2010; White et al., 2006). The work in this thesis furthers the 
current literature by exploring the impact of inducing an asthmatic phenotype (by stimulating with 
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cytokines) in healthy ASM cells on TRPC3, TRPC6 and SERCA2 expression, what these changes have on 
calcium handling and starting to unravel how these changes are mediated. By investigating the impact of 
the addition of inflammatory cytokines on healthy ASM and knocking down SERCA2 protein expression 
in naive mice, insights might be drawn over cause versus effect regarding the role of calcium homeostasis 
and the asthmatic phenotype. 
The safety of β2-AR agonists has been called into question (Rodrigo et al., 2009) and there is evidence a 
decrease in SERCA2 expression may play a role (Ojo, 2011; Ryall et al., 2008). The work presented here 
explores this phenomenon further to see whether changes in SERCA2 and subsequent calcium dynamics 
could explain the safety issues in the clinic. 
An array of ASM cells derived from patients with differing asthmatic severities (healthy, mild and 
moderate) have been immortalised in Andrew Halayko’s lab. The aim was to characterise them to ensure 
they retained their original phenotype during the immortalisation process as immortalised ASM cells are 
being used more commonly in this field without proper characterisation. The cells are immortalised by 
random insertion events of the human telomerase gene therefore the populations produced are 
heterogeneous. The large amount of cells present should provide a normalising effect on any detrimental 
insertions however there is a distinct possibility of phenotypes being lost or altered making 
characterisation essential. 
The resulting changes in calcium transients observed experimentally could be indicative of changes in 
calcium oscillations which are key to encoding many of the phenotypes in ASM that are altered in asthma 
such as; enhanced proliferation, transcription and secretion of inflammatory mediators, contraction and 
migration (Mahn et al., 2010). A better understanding of the processes and proteins involved in these 
changes could lead to the identification of new targets to prevent such changes and therefore the asthma 
pathogenesis. 
1.12 Hypotheses 
In this thesis I set out the following hypotheses: 
1. That inflammatory mediators (TNF-α, TGF-β and IL-13) promote an asthmatic phenotype in 
ASM in part by altering the expression of key calcium handling proteins (SERCA2, TRPC3/6) 
leading to a dysregulation of calcium homeostasis. 
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2. That a murine in vivo model of reduced expression of SERCA2 will exhibit characteristics of 
asthma and these will be further enhanced after sensitisation and challenge with ovalbumin. 
3. That the increased morbidity associated with chronic β2-AR agonist use in asthma is due to a 
cAMP/PKA dependent reduction in SERCA2 expression. 
4. That the immortalisation of ASM cells though random insertion of the hTERT gene will lead to 
retention of most but not necessarily all asthmatic disease specific phenotypes in the cell. 
1.13 Aims 
There were four broad aims of this thesis which are encompassed by each of the four results chapters: 
1. The aim the first chapter was to discover the effects of the inflammatory cytokines TNF-α, IL-13 
and TGF-β on the expression and function of calcium handling proteins in healthy ASM cells and 
how these are mediated. 
2. The aim of the second chapter was to investigate whether the enhanced asthmatic phenotype 
observed in vitro when reducing SERCA2 protein expression is translated in vivo in a murine 
model of asthma. 
3. The aim of the third chapter was to investigate how β2-AR activation in ASM leads to SERCA2 
down regulation and whether this occurs in vivo. 
4. The aim of the final chapter was to characterise immortalised human ASM cells derived from a 
mixture of asthmatic disease severities to see if they retained their phenotypes. 
  
- 52 - 
Chapter 2 Materials and Methods 
2.1 Isolation and culture of human ASM cells 
ASM cells were obtained from patients in accordance with procedures approved by the South East London 
Research Ethics Committee by deep endobronchial biopsy, REC reference number: 10/H0804/66. 
Informed written consent was obtained from the patients prior to the procedure. Biopsies were excised 
from the right middle and lower bronchi using Olympus cupped forceps (model FB-35-C1).  
2.1.1 Patient criteria:  
All: Aged 18-70 years. 
Asthmatics: History of typical symptoms over at least two years with a minimum 12% reversibility and/or 
a methacholine bronchial challenge of <8mg.ml
-1
. All asthmatics used to generate the immortalised cell 
lines were deemed “moderate” in severity as their predicted FEV1 values fell between 70-90%. 
Healthy: Life-long absence of symptoms, and lung functions within normal limits. 
Exclusion criteria: Patients on leukotriene receptor antagonists, current smokers, pregnant/lactating 
females or past/present disease deemed to affect outcome of study. 
2.1.2 ASM dissection 
ASM bundles were isolated by dissecting away the surrounding tissue under a microscope in HBSS in 
DMEM containing 10% FBS, L-glutamine (2mM), sodium pyruvate (1mM), non-essential amino acids 
and fungizone (2µg.ml-1) (referred henceforth as DMEM + all). They are then cleaned with HEPES (no 
Ca
2+
, no EGTA and 1g/L glucose) solution twice and digested using the following enzymatic solution: 
In 2ml HEPES (no Ca
2+
, no EGTA and 1g/L glucose). 
 4mg colagenase Type XI (0.2% w/v) 
 2mg papaine (0.1% w/v) 
 2mg trypsin inhibitor (0.1% w/v) 
 20µl DTT 100mM stock (1mM) 
HEPES solution was removed and the tissue incubated in the enzymatic mix for 30 minutes at 37°C, 
inverting every 5 minutes 6-8 times. The cells were then washed three times in warm HEPES by spinning 
the cells down at 100g, aspirating and resuspending. A further three washes were then carried out in the 
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same way using DMEM + all media. Cells were dispersed using a flame polished glass pipette into a 
T12.5 or T25 culture flask containing DMEM + all media depending on the size of the pellet. Cells were 
then cultured at 37°C and 5% CO2 replacing the media after 24 hours. Depending on the quality of the 
biopsy the cells were ready for their first passage in 10-14 days. 
2.1.3 ASM phenotype confirmation 
To confirm the cells grown in culture are ASM they were stained at an early passage soon after P0 and 
again at later passages to show they haven’t differentiated too far from their explanted state. The cells 
were confirmed as ASM cells via immunocytochemistry staining using specific markers; calponin, desmin 
and α-actin (Halayko et al., 1996). Calponin is a thin filament protein that regulates smooth muscle 
contraction, desmin is an intermediate filamentous protein found in smooth muscle and smooth muscle α-
actin stains for cytoskeletal actin filaments in smooth muscle cells. Depending on the treatment of the 
cells, such as to what level of confluency they were allowed to reach before splitting and whether or not 
they are serum starved these (and other) markers will appear in varying degrees (Wright et al., 2012b). 
ASM cells were grown on 13mm diameter cover slips to approximately 30-50% confluency and fixed 
using 4% (w/v) paraformaldehyde and 4% (w/v) PEG6000 in PBS-ME (3mM EGTA, 2mM MgCl2) at 
room temperature for 30 minutes. The cells were then washed twice in cold PBS-ME and permeabilised 
using 0.1% Triton X-100 for 1 minute, washed a further two times and then blocked with 5% filtered BSA 
(w/v) in PBS-ME at room temperature for 1 hour. After a further two washes primary antibody at a 1 in 
100 dilution in 1% filtered BSA was added at 4°C overnight. The cover slips were again washed twice 
with a further two, 5 minute washes before adding the secondary Alexafluor secondary antibody at a 1 in 
300 dilution for 2-3 hours at room temperature in the dark to prevent photobleaching. The cells were 
washed twice again with the further two 5 minute washes and incubated for 20 minutes at room 
temperature with phalloidin:TRITC (a toxin which binds to F-actin, thus revealing the cytoskeletal 
arrangement of the cell). After repeating the previous wash step cells were incubated with Hoechst33342 
(Life Technologies™) for 10 seconds, washed again and mounted onto glass slides using Mowiol 
Mounting Media (10% w/v Mowiol 4-88 and 25% v/v glycerol in 0.1M Tris) and left to set overnight at 
RT in a dry dark place.  Mowiol 4-88 is a polyvinyl alcohol which prevents bleaching of the fluorescent 
probes. The Hoechst33342 counter-stains the nuclei by binding to double stranded DNA and emitting a 
blue fluorescent light around 461nm. 
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All the cells used in the following experiments stained positive for all three markers, an example is shown 
in Fig. 2.1.3-1 below: 
 
2.1.3-1 Staining for ASM cell markers; sm-α actin (A), desmin (B), calponin (C) and phalloidin (D). 
Picture D has been counter stained to show the nuclei using Hoechst stain. Cells in pictures are derived 
from the healthy patients. 
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2.2 Cell culture medium 
Different recipes of cell culture medium were used during isolation, culture and experiments depending on 
the requirements of the cells. Hank’s Balanced Salt solution (HBSS) containing gentamycin (Gibco) and 
amphotericin B (Thermo Scientific) were used to collect the biopsies from the patients. 
During the maintenance of cell lines they were allowed to grow to approximately 80% confluency before 
splitting for experiments or into a new flask. The media used for during this phase is Dulbecco’s Modified 
Eagle Medium (DMEM) containing 1g/L glucose, 10% FBS, L-glutamine (2mM), sodium pyruvate 
(1mM), non-essential amino acids, gentamycin (50µg/ml) and amphotericin B (2µg/ml). Splitting was 
performed by removing all of the culture media, washing the flask with warm sterile phosphate buffered 
saline (PBS), adding a small volume of 0.025% trypsin/EDTA (ethylenediaminetetraacetic acid) and 
incubating for 3-5 minutes at 37°C. The trypsin was subsequently neutralised by adding a surplus of 
culture media (containing serum) and the cell suspension was centrifuged at 200g for 5 minutes. The 
supernatant was removed and the cell pellet is resuspended in an appropriate amount of media to continue 
the cell line at a desired cell density in the flask of choice. 
Prior to each experiment cells were growth arrested for 72 hours to ensure they are all at the same stage of 
the cell cycle and of a uniform phenotype when the experiment begins. The media used to achieve this 
(serum free media) contained BSA (1%), transferin (5µg/ml), insulin (1µM), ascorbate (100µM) and all of 
the contents above in the maintenance media with the exception of FBS. 
2.3 Protein isolation and measurement 
ASM cells were seeded in culture flasks and grown to approximately 80% confluency and growth arrested 
for 72 hours prior to the start of the experiment in serum free media. Cells were then subjected to various 
experimental conditions for the specified length of time at 37°C 5% CO2, 95% air. 
To terminate the experiment culture dishes were placed on ice and the media is swapped for ice cold PBS 
to wash and slow any further reactions. The cells were then lysed using 1x lysis buffer (Cell Signaling) 
containing 1x protease inhibitor (Sigma) at room temperature for 10 minutes with regular vortexing, 
before returning to ice. Samples were centrifuged at 10,000g for 3 minutes and the supernatant stored at -
80°C. 
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2.3.1 Total protein assay 
To measure the protein concentration in each sample to allow equal protein loading in each lane of the 
western blot, the Bichinchoic Acid (BCA) assay was used (Pierce) (Smith et al., 1985). A serial dilution of 
bovine serum albumin with a top concentration of 2mg.ml
-1
 was used as the standard curve to compare the 
unknown samples against and the samples are diluted down to fall within that range. The assay relies on 




 in the presence of protein. The BCA 
solution containing 4% copper sulphate was added for 30 minutes at 37°C to give a purple chromophore 
with a maximum absorbance of 574nm which can be read on a spectrophometer (Anthos HT II Life 
Technologies™, UK). The yield of the purple chromophore is linearly related to the amount of protein 
present and using the standard curve the graph can be interpolated to calculate the concentration of the 
unknown samples. 
2.3.2 Western blotting 
Western immunoblots were used to compare relative protein expression levels between the protein of 
interest and a control protein unaffected by the experiment. 10-40µg of protein lysates were run through a 
4-12% Bis-Tris gel (Life Technologies™) at 180V for approximately one hour. Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis separates proteins according to their molecular weight by disrupting 
their secondary structure and adding an even negative charge across the polypeptide chain. Thus larger 
proteins carry a stronger charge. Once the gel has run and the samples have separated they are 
subsequently transferred onto a nitrocellulose membrane using the Life Technologies™ X Cell II Blot 
Module and ran at 30V for one hour. Membranes were then blocked in 5% milk in TBS Tween-20 for one 
hour at room temperature. Primary and secondary antibodies were also prepared in 5% milk in TBS 
Tween-20 with the primary antibody incubation lasting approximately 18 hours at 4°C and the HRP 
conjugated secondary antibody for 1-2 hours at room temperature. Membranes were washed in TBS 
Tween-20 in between. An enhanced chemiluminescence (ECL) agent, commonly either ECL-Plus or 
Femto ECL (GE Healthcare Life Technologies™ and Pierce respectively) were used as the horseradish 
peroxidase substrate depending on the amount of protein of interest present. Autoradiography film 
(Kodak) was exposed until the bands emerged and subsequently developed. Analysis was performed using 
ImageJ v.1.44p. 
The film and developer technique was later upgraded to using the Bio-Rad ChemiDoc MP system where 
the chemiluminescence is measured directly by a cooled-charge-coupled device camera, vastly improving 
the dynamic range and sensitivity.  
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2.3.3 ELISA 
Enzyme linked immunosorbant assays are used to quantify the amount of a particular protein within a 
sample. Briefly, a primary antibody directed against the protein of interest was added to a 96 well plate 
and incubated at room temperature overnight. Bovine serum albumin (BSA) was added to block unspecific 
binding, and then sample and the standards provided were added to the appropriate wells. The samples had 
to be diluted in reagent diluent (BSA) 1:5 so that they fell within the standard curve range. A biotinylated 
secondary antibody directed against the protein of interest binds to the sample/primary antibody complex. 
Horseradish peroxidase (HRP) conjugated to streptavidin was then added which binds to the biotin on the 
secondary antibody. A soluble substrate was then added which changes colour over time, a reaction which 
is dependent upon the amount of HRP present. When the desired colour change has occurred the reaction 
was stopped by adding sulphuric acid and the plate is measured at 450nm minus the reading at 570nm to 
correct for optical imperfections in the plate. Between steps excess unbound samples were washed off 
using 0.05% Tween 20 in PBS. The detection limits of the ELISAs can be found below. 
 
Assay Type Biomarker Detection limits 
BCA Total Protein Total protein 0.1-2.0 mg.ml
-1
 




2.4 Calcium signalling 
2.4.1 Using the plate reader 
Calcium responses to bradykinin were measured using a GloMax®-Multi Detection System plate reader 
(Promega, Madison, USA). Briefly, cells were cultured in 48-well plates and serum starved for 72 hours. 
Serum was removed and each well washed with PBS (esterase activity in the culture media provides a 
source of baseline fluorescence) which in turn was removed and Fluo-4NW dye and probenecid added. 
The final concentration of 2.5mM probenecid inhibits the extrusion of dye from the cells via anion 
transporters. Materials and instructions were supplied as the Fluo-4 NW Calcium Assay Kit (Life 
Technologies™). 
The plates were incubated at 37°C for 40 minutes, followed by room temperature for 40 minutes and then 
read using the following protocol: 
For each well; Baseline recording - 0 sec delay  
     20x readings 
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     1 sec interval 
  Calcium transient - 25µl injection 0.5µM (final concentration) bradykinin 
     0.5 sec delay 
     180x readings 
     1 sec interval 
 
Excitation wavelength is 490nm and emission wavelength is 510-570nm. 
The technique was trialled on several lines and treatments and although it was relatively high throughput 
as 48 well plates could be read in a couple of hours the data was extremely variable within each condition. 
Fig. 2.4.1-1 (top) shows the high variation generated by stimulating identically treated control cells with 
0.5μM bradykinin. Such a high variability reduced the power of the experiments to such a degree that 
differences between treatments observed previously using the microspectrofluorimeter were no longer 
observed (Fig. 2.4.1-1 bottom). 
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2.4.1-1 Calcium transients generated using the GloMax®-Multi Detection System in response to 0.5μM 
bradykinin. Top: Unstimulated control data from 16 replicates shows very high variability. Bottom: 
Comparing unstimulated (black), 10ng.ml
-1
 TGF-β (red) for one week and IL-13 and TGF-β both 10ng.ml-
1
 for one week. Points represent mean ± SEM. 
 
2.4.2 Using microspectrofluorimeter 
Cells were grown to 80% confluency on 13mm cover slips and serum starved for 72 hours as previously 
described. The cover slips were loaded for 45 minutes with 1µM Fura PE 3-AM (Sigma) and mounted 
onto a RC-25 perfusion chamber (Warner Instrument Co) and perfused with HEPES buffer comprised of; 
130mM NaCl, 4mM KCl, 1mM MgCl2, 2mM CaCl, 5.5mM D-glucose and 10mM HEPES. When the dye 
is inside of the cell cytoplasmic esterases hydrolyse the membrane permeant AM ester derivatives trapping 
the indicator in the cytosol (Vorndran et al., 1995). Fura-PE3 undergoes a shift in its peak absorption 
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wavelength of 380nm to 340nm when binding to calcium while the peak emission wavelength is constant 
at 510nm. The chamber was mounted on an inverted epi-fluorescence microscope (Nickon ECLIPSE 
TE2000) with a x20 UV objective lens. A 75W Xenon arc light source (Cairn Optosource) was used to 
excite the dye and a computer controlled monochromator (Cairn Optoscan monochromator 2.11) switched 
the wavelengths between 340nm and 380nm with 15ms dwelling time. The emission signal was detected 
by a photomultiplier detector and changes in intracellular calcium ions measured as the ratio of emission 
intensities at >510nm caused by 340nm and 380nm excitation respectively. Twenty-five data points were 
collected each second and averaged to produce 1 value per second using the Cairn Research Acquisition 
Engine Software v.1.7. 
Once a steady baseline had been achieved, 100 seconds of control readings were taken followed by 200 
seconds of perfusion with the agonist. If a subsequent agonist was to be used then a 400 second washout 
period was given in between. Measurements were taken as the difference between the peak response and 
the baseline reading immediately before. The decay rates were calculated by fitting the data points from 
the peak to baseline with a single, 3 parameter exponential decay fit (Mahn et al., 2009). 
2.4.3 Flufenamic acid 
Flufenamic acid (FFA) was originally used as a non-steroidal anti-inflammatory drug due to its inhibition 
of cyclo-oxygenases however its use dwindled due to poor benefits compared to its numerous drawbacks. 
However, it has been continually used to this day in the lab because it regulates many ionic currents within 
the cell (Guinamard et al., 2013). Although this opens up its use to study numerous channels it presents a 
large issue when it comes to interpreting data obtained and therefore any conclusions must be treated with 
caution. On top of the broad range of targets FFA can affect, results on individual channels are 
inconsistent between publications adding further importance on considered deductions from results (Inoue 
et al., 2001; Klose et al., 2011). Flufenamic acid has been shown to act as a TRPC6 agonist (Foster et al., 
2009) justifying its use here. 
There is a dearth of specific agonists and antagonists which can be used as pharmacological tools to 
investigate TRPC channels so when using a compound such as FFA appropriate controls must be used for 
a useful interpretation of the data. 
2.4.4 Store operated calcium entry 
Store operated calcium entry (SOCE), formerly known as capacitative calcium entry (CCE) is the process 
by which intracellular calcium stores are replenished via influx from outside the cell. To make this 
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measurement cells were perfused with HBSS solution containing no calcium, the stores were then emptied 
and reuptake prevented by stimulating with a combination of 1µM ionomycin (Morgan et al., 1994) to 
empty the stores and 1µM thapsigargin to block SERCA2 activity. Finally calcium was reintroduced into 
the perfusate and as it entered the cytoplasm the change in 340nm to 380nm ratio from fura-PE3 excitation 
was measured.  
2.5 Measuring cell proliferation 
Two methods have been used to measure ASM cell proliferation, the MTT assay and the tritiated 
thymidine incorporation assay. Each requires ASM cells seeded at 9x10
3
 cells per well in a 96 well plate, 
grown for 24 hours in full serum containing media then washed with sterile PBS and serum starved for 72 
hours. 
2.5.1 MTT assay 
The yellow tetrazolium salt 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide (MTT) is 
reduced by metabolically active cells by NADPH. The resultant intracellular purple formazan can be 
solubilised and quantified by spectroscopic means at a wavelength of 574nm. After serum starvation the 
cells were incubated with increasing concentrations of FBS (0, 2.5, 5 or 10%) and grown for 48 hours 
before the media was removed and washed with PBS. 100µl of HBSS containing 2mM calcium and 1g.L
-1
 
glucose was added to each well with 10µl of 12mM MTT and incubated at 37°C for 4 hours. 1g of SDS 
was added to 10ml of 0.01M HCl, 100µl of this solution was then added to each well and incubated for a 
further 4 hours at 37°C and read at 574nm. Even though this is strictly a measure of metabolic activity and 
not directly cellular proliferation it has been shown to correlate very well with increases in ASM cell 
number following a graded stimulation with FBS (Hirst et al., 1992). 
2.5.2 3H-thymidine incorporation 
Following serum starvation the cells were incubated with increasing concentrations of FBS, akin to the 
MTT assay for 4 hours and then pulsed with 3.7 Bq of 
3
H-thymidine (Amersham). The cells were then left 
to grow and incorporate the thymidine for 48 hours before being lysed via freezing at -20°C for storage. 
The lysates were then vacuumed onto filter paper and mixed with a scintillation fluid and counted on a 
beta-counter (TopCount NXT, PerkinElmer) as described previously (Mahn et al., 2009). 
2.6 shRNA as an experimental tool 
Introduction of double stranded RNA (dsRNA) to a cell results in RNA interference and suppression of 
protein production, termed post transcriptional modification. An expression vector containing the 
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sequence for the short hairpin RNA (shRNA) was introduced into the cell by electroporation (see 2.6.5) 
where upon it translocates to the nucleus and is transcribed by RNA polymerase. The primary transcript 
contains a hairpin loop which is processed by Drosha and DGCR8 (Lee et al., 2003) to produce shRNAs 
with a 2 base pair 3’ overhang (Zhang et al., 2002). The shRNA is then transported into the cytoplasm 
where it forms a complex with the RNase-III-family enzyme called Dicer in an ATP dependent process to 
generate short interfering siRNA (siRNA) by cleaving the hairpin. The siRNA is incorporated into a RNA 
induced silencing complex called RISC where the two strands of the siRNA are separated leaving the 
single complementary strand available to perform RNA interference. 
When using as an experimental tool a control siRNA which has no homology to mRNA must be used to 
normalise any protein expression changes occurring due to the transfection method. The protocol was used 
as described previously in the lab (Knock et al., 2008).  
2.6.1 Design and synthesis 
RNA interference is a very useful tool employed to discover the function of certain proteins within a cell 
signalling cascade. 
To analyse the role of β-arrestin-2 in the down-regulation of SERCA2 following stimulation of ASM cells 
with salmeterol and the role of Smad2 and 3 in the regulation of various protein expression following 
TGF-β stimulation, a pool of siRNAs were made to target them. If the target protein has multiple splice 
variants a section of the sequence present in all of them was used to design the siRNA using the algorithm: 
n2sn19w n=A/T/G/C, s=G/C, w=A/T designed and optimised by Dr Yasin Shaifta. From the results 
generated a pool of three were selected which contain the highest content of A/T in the final 3’ seven 
positions of the siRNA. 
 
The 19 nucleotide target sequences were compared with the human genome database using BLAST 
(www.ncbi.nlm.nih.gov/BLAST) and any sequence showing ≥15 bp homology to an off-target protein was 
omitted from consideration. 5’ single-stranded overhangs (BamHI and HindIII) were designed on the end 
5’-nn   s(nx18)   nw- 3’
siRNA
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of each 64-65
1
 mer insert as well as a 9-nucleotide spacer between the sense and antisense sequences 
(TTCAAGAGA, italics in Table 2.6-1). A poly-T tail was added immediately prior to the 3’ restriction 
end of the sense oligonucleotide to serve as an RNA polymerase III termination site. The oligonucleotides 
were synthesised by Sigma and resuspended in ddH2O to a stock concentration of 100µM. The sequence 
of all the oligonucleotides designed and their targets are in Table 2.6-1. 
 
 
                                                          
1
 An additional guanine is added immediately 5’ to the start of the siRNA sequence on the sense strand if 
the first base of the siRNA is T or C (underlined in Table 2.6-1). The purpose of this is to increase the 
efficiency of RNA polymerase III transcription. 
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Table 2.6-1 siRNA oligonucleotides 
mRNA Accession 
number 
Hairpin oligonucleotide (target sequence in bold) 
Β-Arrestin-2 NM_004313 F1 5’-GATCCCGCTGTGCTAAATCACTAGAATTCAAGAGATTCTAGTGATTTAGCACAGTTTTTTGGAAA-3’ 
R1 5’-AGCTTTTCCAAAAAACTGTGCTAAATCACTAGAATCTCTTGAATTCTAGTGATTTAGCACAGCGG-3’ 
  F2 5’-GATCCCGACCGTCAAGAAGATCAAATTCAAGAGATTTGATCTTCTTGACGGTCTTTTTTGGAAA-3’ 
R2 5’AGCTTTTCCAAAAAAGACCGTCAAGAAGATCAAATCTCTTGAATTTGATCTTCTTGACGGTCGG-3’ 
  F3 5’-GATCCCGCCAACCTCATTGAATTTGATTCAAGAGATCAAATTCAATGAGGTTGGTTTTTTGGAAA-3’ 
R3 5’-AGCTTTTCCAAAAAACCAACCTCATTGAATTTGATCTCTTGAATCAAATTCAATGAGGTTGGCGG-3’ 
Smad2 NM_005901 F1 5’-GATCCCGATTGCCACATGTTATATATTCAAGAGATATATAACATGTGGCAATCTTTTTTGGAAA-3’ 
R1 5’-AGCTTTTCCAAAAAAGATTGCCACATGTTATATATCTCTTGAATATATAACATGTGGCAATCGG-3’ 
  F2 5’-GATCCCGAGCCACAGAGTAATTATATTCAAGAGATATAATTACTCTGTGGCTCTTTTTTGGAAA-3’ 
 R2 5’-AGCTTTTCCAAAAAAGAGCCACAGAGTAATTATATCTCTTGAATATAATTACTCTGTGGCTCGG-3’ 
   F3 5’-GATCCCGTGTTCGATAGCATATTATTTCAAGAGAATAATATGCTATCGAACACTTTTTTGGAAA-3’ 
 R3 5’-AGCTTTTCCAAAAAAGTGTTCGATAGCATATTATTCTCTTGAAATAATATGCTATCGAACACGG-3’ 
   F4 5’-GATCCCGCCACCTCCTGGATATATCATTCAAGAGATGATATATCCAGGAGGTGGTTTTTTGGAAA-3’ 
 R4 5’-AGCTTTTCCAAAAAACCACCTCCTGGATATATCATCTCTTGAATGATATATCCAGGAGGTGGCGG-3’ 
   F5 5’-GATCCCGCGTCTATCAGCTAACTAGATTCAAGAGATCTAGTTAGCTGATAGACGTTTTTTGGAAA-3’ 
 R5 5’-AGCTTTTCCAAAAAACGTCTATCAGCTAACTAGATCTCTTGAATCTAGTTAGCTGATAGACGCGG-3’ 
   F6 5’-GATCCCGAATGTGCACCATAAGAATTTCAAGAGAATTCTTATGGTGCACATTCTTTTTTGGAAA-3’ 
 R6 5’-AGCTTTTCCAAAAAAGAATGTGCACCATAAGAATTCTCTTGAAATTCTTATGGTGCACATTCGG-3’ 
Smad3 NM_005902  F1 5’-GATCCCGTGAGTTCGCCTTCAATATTTCAAGAGAATATTGAAGGCGAACTCACTTTTTTGGAAA-3’ 
 R1 5’-AGCTTTTCCAAAAAAGTGAGTTCGCCTTCAATATTCTCTTGAAATATTGAAGGCGAACTCACGG-3’ 
   F2 5’-GATCCCGCCCAGCACATAATAACTTGTTCAAGAGACAAGTTATTATGTGCTGGGTTTTTTGGAAA-3’ 
 R2 5’-AGCTTTTCCAAAAAACCCAGCACATAATAACTTGTCTCTTGAACAAGTTATTATGTGCTGGGCGG-3’ 
   F3 5’-GATCCCGCAACCTGAAGATCTTCAATTCAAGAGATTGAAGATCTTCAGGTTGCTTTTTTGGAAA-3’ 
 R3 5’-AGCTTTTCCAAAAAAGCAACCTGAAGATCTTCAATCTCTTGAATTGAAGATCTTCAGGTTGCGG-3’ 
 
siRNA Sequence 
Adrenergic b-2 receptor (s1123) siRNA AAUGUUAACGAUGAAGAAGgg 
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2.6.2 Annealing the oligonucleotides 
The two complementary oligonucleotides were annealed together by adding 1µl of both the forward and 
reverse sequences (100µM stock), 50mM NaCl and 16µl ddH2O in the following 20µl reaction: 
95°C for 20mins 
90°C for 10mins 
 
Temperature was reduced in 5°C increments down to 20°C and held at each temperature step for 10 minutes 
and finished at 4°C. 
Then 2µl of stock single forward and reverse oligonucleotides was denatured at 95°C for 5 minutes with 
50mM NaCl and 16µl ddH2O in a 20µl reaction. They were then loaded either side of the annealed 
oligonucleotides on a 2.5% agarose gel with the φx174 DNA/BsuRI (Hae III) marker 9 (Fermentas). The 
results showed all of the annealing was successful, an example blot is shown below. 
 
2.6.2-1 The annealed products of four oligonucleotide pairs all showing successful annealing. Forward (F), 
annealed (A) and reverse (R) siRNA oligonucleotides were run side by side. 
 
2.6.3 Ligation and transformation 
Ligation was achieved by mixing 270ng of the plasmid vector (pSilencer 3.0-H1, Life Technologies™), 
15μM of the annealed oligonucleotides, 1x T4 buffer, 2 Weiss units of T4 ligase and made up to 10µl with 
ddH2O and left overnight at 16°C. 
Transforming One Shot® TOP10 E. Coli bacteria (Life Technologies™) with the plasmid ensures stable 




F A R F A R F A R F A R
Oligo-pair-1 Oligo-pair-2 Oligo-pair-3 Oligo-pair-4
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incubated on ice for 30 minutes. The bacteria was then heat shocked for 30 seconds at 42°C in a water bath 
and returned to ice for a further 2 minutes. 125µl of Super Optimal broth with catabolite repression (SOC) 
was added and shaken at 37°C for 1 hour. 50μL was spread onto warm LB/agar plates containing 
100μg/mL ampicillin and colonies were then grown overnight at 37°C.  
To make LB broth and agar: 
For 2 litres: 20g Tryptone - pancreatic digest of casein (Becton and Dickinson) 
  10g Yeast extract (Becton and Dickinson) 
  20g NaCl 
  2L ddH2O 
 
For agar: 7.5g agar (Becton and Dickinson) 
500ml LB  
 
Both mixtures were autoclaved to sterilise and dissolve the agar solution. 
Four colonies from each of the three siRNAs in the pool were picked and grown in 5ml LB broth and 
ampicillin overnight at 37°C and purified using the QIAgen Miniprep kit (#27104, QIAgen). 
2.6.4 Verification of insert by digestion and sequencing 
The vector contains the H1 polymerase III promoter capable of generating large amounts of shRNA. The 
plasmids contained two rare EcoR1 sites, one just before the H1 promoter region and a second between the 
BamHI and HindIII restriction sites. Following excision of this region and re-ligation with the new cloned 
shRNA sequences an EcoRI digestion was performed as a quality control check. If the new insertion was 
complete only a single fragment would be produced from the linearised product of 2795bp, however if the 
original insert was still present two fragments would appear on the gel of 122bp and 2653bp. Fig. 2.6.4-1 
shows that all ligations were successful. 
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2.6.4-1 EcoRI digest of eight SMAD2 siRNA mini preps. Lanes 1-4 are from the second pool created and 
lanes 5-8 from the third. All ligations shown were successful. 
 
All of the samples were then sequenced using the Reverse (3.0rev) primer (5’-
GAGTTAGCTCACTCATTAGGC-3’) and only the colonies showing successful cloning were tested for 
knockdown efficiency as shown in the relevant results section. 
 
2.6.4-2 Sequencing result from the second β-arrestin-2 siRNA. When compared with R2 from Table 2.6-1 
there are no differences demonstrating the cloning was a success. 
 
2.6.5 Transfection of ASM cells 
The ASM cells were transfected using electroporation by the AMAXA Nucleofector® kit supplied by 
LONZA. The kit has numerous pre-set programmes with varying electrical waveforms to transfect primary 
ASM cells while minimising cell death, the programme used in this study was A-33. 100μl of their 
Nucleofector® resuspension solution (82μl basic Nucleofector® solution and 18μl of supplement) was 
added to 0.5-2x10
6
 cells pelleted along with either the scrambled siRNA or the on target siRNA. The cells 
were then transfected and resuspended in culture medium to neutralise the toxicity of the resuspension 
2795 bp
1 2 3 4 5 6 7 8
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medium before being seeded in cell culture. While typically between 20-30% cell death occurs, dead cells 
do not adhere and are washed off the following day. Efficiency of the knockdown was confirmed by 
probing for the protein via western blot (see section 2.3.2). 
2.7 Nucleic acid 
2.7.1 RNA extraction and purification 
RNA was extracted from ASM cells following treatment using the QIAgen RNeasy® Mini-kit. RNase free 
consumables were used in addition to cleaning work surfaces with RNase free disinfectant to prevent loss of 
RNA. 
Cells were washed with PBS, lysed with beta mercaptoethanol and buffer RLT and purified by following 
the QIAgen RNeasy® kit. DNA was removed using Turbo DNase (Life Technologies™) one unit per 20μg 
RNA, incubated at 37°C for an hour thus ensuring no trace DNA is amplified during the PCR reactions. 
Purified sample was quantified using the NanoDrop 1000 spectrophotometer (Thermofisher) to determine 
nucleic acid concentration at 260nm and impurities such as protein at 280nm. Samples were deemed of an 
adequate purity with a 260nm to 280nm ratio between 1.8-2.1. 
2.7.2 Reverse transcription 
Quantitative polymerase chain reactions (qPCR) require double stranded DNA, therefore the single 
stranded RNA must be converted to cDNA. 2μg of RNA was added to 400ng of random hexamer mix and 
incubated at 70°C for 5 minutes and left on ice. 10mM dNTPs were then added with the suitable buffer and 
ddH2O and incubated at 25°C for 5 minutes. 400 units of RevertAid H Minus M-MuLV Reverse 
Transcriptase was added and incubated at 25°C for 10 minutes, then at 42°C for 60 minutes and finally the 
reaction was stopped at 70°C for 10 minutes to inactivate the enzyme and chilled on ice. Samples were then 
ready for PCR. 
2.7.3 Quantitative PCR 
TaqMan qPCR tells you the relative quantity of mRNA transcribed from a particular gene of interest 
compared to a house keeping gene which is assumed to be unaltered by the experimental conditions. Two 
primers are designed against exon sequences from the gene of interest and a probe containing a fluorescent 
dye on one end and a quencher on the other. The accumulation of fluorescence from the reporter dye 
(FAM) increases with each PCR cycle in a sigmoidal fashion. As the Taq polymerase extends the primer to 
replicate the cDNA from 3’ to 5’ its exonuclease activity from 5’ to 3’ degrades the sequence specific probe 
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annealed to the cDNA of interest separating the fluorophore from the quencher thus creating a fluorescent 
signal. A threshold level of fluorescence in the linear portion of the curve is applied and the amount of 
cycles taken to reach this is recorded. As the amount of starting material is proportional to the cycles 
required to reach the threshold level of fluorescence expression of the gene of interest can be quantified. 
The reference housekeeping RNA used in these studies was 18S rRNA tagged to a different reporter dye 
(VIC). 
In a 384 well plate a mixture of 10µM forward and reverse primers (6µM for 18S), 2x PCR master mix 
(Applied Biosystems), 100ng cDNA were adjusted to a final volume of 15µl with RNase free water and run 
in triplicate. The reaction was initiated at 50°C for 2 minutes and raised to 95°C for 10 minutes before 40 
cycles of 95°C for 10 seconds and 60°C for 1 minute. Results were recorded on Applied Biosystems ViiA 7 
Real-Time PCR System and quantified using ViiA™ 7 Software (Applied Biosystems). ΔCt was obtained 
by subtracting 18S average Ct values (cycle threshold) from the average Ct values from the gene of interest. 
All values in the results sections are given as relative quantities (RQ) which is the dependent experimental 
variable ΔCT value normalised to its relevant control ΔCT value. 
2.8 Myography 
Ex vivo contraction measurements on isolated bronchioles were carried out using a Mulvany-Halpern type 
small vessel wire myograph (DMT, Denmark). It comprises of two metal jaws, one of which is attached to a 
force transducer, the other to a micrometer arm which can be adjusted manually to stretch the airway. It is 
important when making isometric force measurements to start with tension in the airway walls to prevent 
changes in lumen diameter. Force production and sensitivity to agonists are also dependent on muscle 
stretch so comparable levels must be maintained between treatment groups. 
Bronchioles were incubated at 37°C in Krebs-Henseleit solution, a physiological salt solution containing 
118mM NaCl, 24mM NaHCO3, 4mM KCl, 1.8mM CaCl2, 1mM MgSO4, 0.43mM NaH2PO4 and 5.56mM 
glucose. As with cell culture the bronchioles are gassed with a 5% CO2 to buffer against metabolic changes 
altering the pH of the solution thus maintaining a pH of 7.4. Presence of a responsive bronchiole was tested 
by adding 80mM KCl to the chamber. Thus inducing a contraction by depolarising the smooth muscle cell 
membrane and increasing the opening probability of voltage gated calcium channels, resulting in an influx 
of Ca
2+
 which activates the contractile apparatus via calmodulin. The positive control was repeated twice 
more and the final response was used to normalise subsequent agonist induced contractions as the 
bronchiole contraction settles and becomes more reproducible. The normalisation ensures it is the intrinsic 
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properties of the ASM within the bronchioles being compared and not merely the quantity present in each 
dissected section. The bronchioles were then washed back into Krebs solution, allowed to equilibrate for 30 
minutes and then exposed to semi-log cumulative escalating concentrations of carbachol. 
2.9 Statistics 
All results are expressed as mean ± SEM. In most cases n numbers refer to the number of subjects, but in 
some studies the number of individual experiments. Duplicates/triplicates are defined as repeats from the 
same patient measured in parallel in the same experimental procedure to reduce inherent technical 
variations. Statistical analysis was carried out using SigmaPlot software and GraphPad Prism. When 
comparing means from more than two groups a one-way analysis of variance (one-way ANOVA) was used. 
Two or three-way analyses of variance were used when comparing the sample means of more than two 
groups and examining the influence of two/three categorical independent variables on one dependent 
variable. For example the influence of genotype and sex on airway hyper-responsiveness in knockout and 
wild type mice. Bonferroni’s post-hoc test was used for the in vitro data and the Holm-Sidak post-hoc test 
for the in vivo data. Analysis of means and variance between just two groups was tested by Student’s t-test. 
In all cases a p value of less than 0.05 was deemed as a significant difference between observed sample 
means and a statistical power of >0.8 was acceptable, further analysis is given where necessary by each 
result. 
2.10 In vivo 
All of the in vivo methods used in the in vivo investigation into reduced SERCA2 expression are outlined 
prior to the results in the corresponding chapter. 
2.11 Materials 
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(Fluo-4 NW kit) 
Fungizone (amphotericin B) 
Gentamicin 
Non essential amino acids 
Sodium pyruvate 
L-glutamine 
Dulbecco’s modified Eagle’s medium 
Fetal bovine serum 
Trypsin 
Hank’s balanced salt solution 
MES running buffer 
NuPAGE transfer buffer 
Nitrocellulose membrane (0.2µm pore) 
NuPAGE Bis-Tris Gel 1.0mm 




GloMax®-Multi Detection System 
Millipore 
Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel 
Sigma-Aldrich Company Ltd, Poole, U.K 
Bovine serum albumin 
Insulin 
Calponin clone DE-U-10 
Desmin clone hCP 











Ready-To-Go RT-PCR beads (GeHealthcare Life Technologies™, Buckingham, U.K) 
DNeasy blood & tissue kit (QIAgen, West Sussex, U.K) 
miRNeasy kit (QIAgen, West Sussex, U.K) 
Kodak Biomax film MR1 (Perkin Elmer, Buckinghamshire, U.K) 
BCA Protein assay kit (Pierce, Northumberland, U.K) 
SERCA2 primary antibody (Abcam, Cambridge, U.K) 
GAPDH primary antibody (Abcam, Cambridge, U.K) 
Basic Nucleofector Kit Primary Smooth Muscle (LONZA, Basel, Switzerland) 
Mulvany-Halpern type small vessel wire myograph (DMT, Denmark) 
PCR master mix (Applied Biosystems) 
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Chapter 3 The effect of TNF-α, TGF-β and IL-13 on calcium handling 
proteins and homeostasis in ASM 
3.1 Introduction 
There is increasing evidence that calcium homeostasis is perturbed in the ASM in asthma (Mahn et al., 
2010). There are very few genetic risk factors associated with the disease that has the potential to alter this, 
with the exception of ORMDL3. Therefore the changes are believed to be a result of the inflammatory 
milieu altering the activity of the proteins controlling the homeostasis (Jia et al., 2013; Mahn et al., 2009; 
Sathish et al., 2011; Sathish et al., 2009; White et al., 2006). 
3.1.1 Inflammatory cytokines alter calcium handling proteins 
Many of the altered phenotypes in asthma are dependent upon cytosolic calcium concentrations making it 
an important area to research and a potentially key site for therapeutic intervention. ASM cells derived from 
asthmatic patients display reduced protein expression of SERCA2 compared to healthy controls (Mahn et 
al., 2009). The link between the activity of calcium handling proteins and the asthmatic phenotype are 
demonstrated clearly in this paper. A reduction in SERCA2 in healthy derived cells to levels to that seen in 
asthma using siRNA produces an asthmatic phenotype shown by enhanced proliferation, eotaxin-1 release 
and cell spreading (Mahn et al., 2009).  
Cytokines have the ability to mediate these changes in calcium handling. Overnight exposure to either TNF-
α or IL-13 has been shown to decrease SERCA2 expression in human ASM cells (Sathish et al., 2009). The 
change in protein expression was mirrored with a decline in function as a decrease in the rate of fall of 
[Ca
2+
]i back to basal levels following agonist stimulation was observed in both treatment groups. This is 
believed to be an indicator of SERCA2 activity (Mahn et al., 2009).  In addition to altering SERCA2 
expression treatment of ASM cells with TNF-α possibly results in a switch from receptor operated calcium 
entry (ROCE) to store operated calcium entry (SOCE) in TRPC3 dependent manner (White et al., 2006). 
The asthmatic cytokines IL-13 and TGF-β act synergistically to increase the gene expression of TRPC6 and 
subtly increase TRPC3 (Karner, 2010). However no changes in their expressions were noted in cultured 
biopsies comparing healthy cells to asthmatic cells indicating the inflammatory milieu needs to be present.  
The classical intracellular signalling cascade following TGF-β receptor activation involves the Smad 
family, a set of secondary messengers resulting in changes in gene transcription. Smad2 has been 
implicated in asthma as a murine model over expressing it in epithelial cells resulted in an enhanced 
asthmatic phenotype (Gregory et al., 2010). Additionally a polymorphism in Smad3 leads to increased 
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prevalence of asthma, suggesting that it is involved in signalling pathways exacerbating the pathology 
(Moffatt et al., 2010). 
3.1.2 TRPA1 
A recent paper showed that TRPA1 causes non-neurogenic airway inflammation and stained positive on 
ASM cells by immunohistochemistry (Nassini et al., 2012). TRPA1 is a calcium permeable non selective 
cation channel like TRPC3 and TRPC6 and therefore has the potential to alter ASM phenotypes associated 
with asthma (Mahn et al., 2010). 
A collaboration was formed with Dr Andersson at King’s College London whose expertise lay with the role 
of TRPA1 in nociception to make a preliminary assessment to the function of TRPA1 in ASM cells. 
3.1.3 Aims 
The aim of this chapter was to expand the current field of work by looking into the role of TNF-α, IL-13 
and TGF-β in altering the protein expression of TRPC6, TRPC3 and SERCA2. Furthermore, to investigate 
whether the alterations in protein affect the functional handling of calcium in ASM cells and to elucidate 
possible signalling mediators controlling this.  
In parallel to the main investigation in this chapter an assessment was carried out on cultured ASM cells to 
see whether TRPA1 ligands could induce calcium transients and secondly contraction on isolated murine 
bronchioles. 
3.1.4 Hypotheses 
I hypothesised that the exposure of the aforementioned inflammatory cytokines to healthy ASM cells will 
result in an up-regulation of TRPC6 and TRPC3 while diminishing SERCA2 expression. Ultimately leading 
to altered calcium signalling which underpins the asthmatic ASM phenotype. 
Following the confirmation of TRPA1 on ASM cells (Nassini et al., 2012), I hypothesised that their 
activation would result in a transient increase in intracellular calcium in cultured cells and a contraction of 
murine bronchioles. 
3.2 Methods 
Experiments were carried out as described in Chapter 2 on primary ASM lines derived from healthy 
patients. 
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The methylation data described in the discussion was performed by Dr Lavender’s group following my 
preparation and stimulation of the cells. 
The TRPA1 calcium transients were performed by Dr Andersson following my preparation of the cells and 
the myography performed by Dr Prieto-Lloret with protocol consultation with Dr Andersson. 
The range of time points were chosen because at 24 hours Ca
2+
 dependent responses in ASM cells have 
previously been shown to be altered by cytokine treatment (Deshpande et al., 2004; Ojo, 2011). Up to one 
week time points were also investigated as asthma is a chronic disease and long term exposure of cytokines 
and growth factors have the potential to cause differential expression profiles compared to acute 
stimulation. The concentrations used have all been previously published within this field (Chen et al., 2013; 
Mahn et al., 2009; Matsumoto et al., 2012; Sathish et al., 2009). 
3.3 The role of TNF-α in altering calcium homeostasis 
3.3.1 Changes in protein expression 
Building upon the work carried out by Sathish et al (2009) the protein expression of TRPC3 and TRPC6 
was also investigated following TNF-α stimulation (Fig. 3.3.1-1). TRPC3 protein expression was 
significantly elevated at all three time points with the most consistent elevation after a week (277 ± 38.8% 
of unstimulated control, p=0.01). Interestingly and conversely TRPC6 expression declined at every time 
point measured reaching significance at 72 hours and 1 week stimulation (p<0.01). SERCA2 expression 
was not significantly altered at any time point which lies in contrast to (Sathish et al., 2009) where a 
decrease in expression was observed following overnight exposure. 






3.3.1-1 Healthy ASM cells were stimulated with 20ng.ml
-1
 TNF-α for either 24 hours, 72 hours or 1 week. 
A) Changes in TRPC6 expression, B) Changes in TRPC3 expression (all splices) and C) Changes in 
SERCA2 expression. Bars represent mean ± SEM, n=3-6, *p<0.05, **p<0.01 by unpaired t-test. 
 
In order to clarify the conflicting results with (Sathish et al., 2009) SERCA2 mRNA expression levels were 
measured following six hours stimulation with TNF-α. A small but significant increase in transcription was 
observed (Fig. 3.3.1-2, p=0.03) correlating with the very slight (but non-significant) rise in protein 
expression described in Fig. 3.3.1-1. ΔCt was obtained by subtracting 18S (control gene) average Ct values 
(cycle threshold) from the average Ct values from the gene of interest (SERCA2). RQ is the TGF-β treated 
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3.3.1-2 Changes in SERCA2 mRNA expression in response to stimulation for 6 hours with 20ng.ml
-1
 TNF-
α in healthy ASM cells. Results were obtained by real time PCR and normalised to control, bars represent 
mean ± SEM (n=5, p=0.03) by unpaired t-test.  
 
The changes in protein expression induced by 1 week of TNF-α on calcium handling proteins affects the 
functional handling of calcium within the cell. Cells treated with TNF-α have a significantly greater 
increase in intracellular calcium concentration upon stimulation with 10μM FFA, a putative TRPC6 agonist 
(Foster et al., 2009) (Fig. 3.3.1-3, p<0.001). Upon stimulation with bradykinin, TNF-α treated cells had a 
significantly attenuated elevation in cytosolic calcium compared to untreated cells; 0.06 ± 0.001 Δ340/380 
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3.3.1-3 Ratiometric measurements of cytosolic calcium from control and 7 day 20ng.ml
-1
 TNF-α treated 
healthy ASM cells. Cytosolic calcium ion levels were measured by preloading cells with 1µM Fura PE 3-
AM for >45minutes and stimulating with top left; 10µM FFA or top right; 0.5µM BK, bars represent mean 
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The increase in cytosolic calcium elicited by FFA stimulation after TNF-α treatment is dependent upon 
TRPC3 protein expression. After reducing TRPC3 protein with siRNA no change occurs between the 
unstimulated control and TNF-α treated cells (Fig. 3.3.1-4). 
 
3.3.1-4 Ratiometric measurements of cytosolic calcium from control (clear bars) or 7 day 20ng.ml
-1
 TNF-α 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or TRPC3 targeted siRNA. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes and stimulated with 10µM FFA. Bars represent mean ± 
SEM, n=9-10; ***p<0.001, by one-way ANOVA and Bonferroni’s multi comparison post hoc test. 
 
Upon removal of extracellular calcium from the perfusate an immediate fall in cytosolic calcium is 
observed suggesting a constitutively active calcium entry pathway (McVicker, 2003). It has previously been 
suggested that TRPC3 may play a role in this background non-selective calcium entry (Zhu et al., 1998). 
Cells incubated for a week with TNF-α showed a small but significant increase in this basal entry pathway 
compared to the unstimulated control (Fig. 3.3.1-5, p<0.05). Combined with the increase in TRPC3 protein 
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3.3.1-5 Ratiometric measurements of Fura PE 3-AM were used to determine the constitutive leak of 
calcium ions into the cytosol. Cells were treated with 20ng.ml
-1
 TNF-α for 7 days or control media. The 
change in ratio from a 2mM Ca
2+
 HBSS solution to a calcium free solution was measured, bars represent 
mean ± SEM, n=10-11, *p=0.05. Analysis performed by unpaired t-test.  
 
3.3.2 Store operated calcium entry 
Capacitative calcium entry (CCE) or store-operated calcium entry (SOCE) is triggered when the 
sarcoplasmic reticulum stores are emptied so that they can be replenished. An estimation of this can be 
made by removing extracellular calcium, depleting stores with ionomycin while preventing further reuptake 
with thapsigargin and then reintroducing calcium to the perfusate. Stimulating healthy ASM cells with 
TNF-α for one week increases SOCE compared to control; 0.30 ± 0.03 and 0.19 ± 0.02 Δ340/380nm 
respectively (Fig. 3.3.2-1, p=0.04). To test whether TRPC3 was responsible for the effect the experiment 
was repeated following transfection with a scrambled siRNA control and TRPC3 directed siRNA. The 
positive control was reproducible as TNF-α resulted in a significant increase in SOCE once more (p=0.003) 
(Fig. 3.3.2-2). The TRPC3 siRNA abolished the significant elevation caused by TNF-α (p=0.16) however it 
did not bring SOCE back to the control value. The power of the test was 0.937 with an α value of 0.05 
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3.3.2-1 Ratiometric measurements of cytosolic calcium from control (clear bars) or 7 day 20ng.ml
-1
 TNF-α 
(chequered bars) treated healthy ASM cells. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes. Cells were then perfused with calcium free HBSS, 
intracellular calcium stores were emptied using 1 μM ionomycin and reuptake blocked with 1μM 
thapsigargin. SOCE was measured by the change in ratio of 340/380nm upon the reintroduction of calcium 
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3.3.2-2 Ratiometric measurements of cytosolic calcium from control (clear bars) or 7 day 20ng.ml
-1
 TNF-α 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or TRPC3 targeted siRNA. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes. Cells were then perfused with calcium free HBSS, 
intracellular calcium stores were emptied using 1 μM ionomycin and reuptake blocked with 1μM 
thapsigargin. SOCE was measured by the change in ratio of 340/380nm upon the reintroduction of calcium 
in the perfusion solution Bars represent mean ± SEM, n=10-12;  **p<0.01, by one-way ANOVA and 
Bonferroni’s multi comparison post hoc test. 
 
3.4 IL-13 and TGF-β 
It has been published that treatment with a combination of IL-13 and TGF-β results in a synergistic increase 
in TRPC6 mRNA expression (Karner, 2010). In order to get a broader picture of the effect stimulation of 
these asthmatic cytokines have on the gene expression of calcium handling proteins SERCA mRNA was 
measured following stimulation. As with TRPC6 IL-13 stimulation alone had no effect whereas TGF-β 
caused a robust and significant increase. The combination of the two however had no additional effect 
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3.3.2-1 Changes in SERCA2 mRNA expression in response to stimulation for 6 hours with 10ng.ml
-1
 IL-13, 
TGF-β or a combination of both in healthy ASM cells. Results were obtained by real time PCR and 
normalised to control, bars represent mean ± SEM (n=6-7, p<0.0001 by one-way ANOVA and Bonferroni’s 
multi comparison post hoc test). 
 
3.4.1 Protein expression 
Treatment with 10ng.ml
-1
 TGF-β alone and in combination with 10ng.ml-1 IL-13 for both 72 hours and 7 
days enhances TRPC6 protein expression (Fig. 3.4.1-1, p<0.001). In contrast to previous work from our lab 
(Karner, 2010) where a synergistic increase in mRNA was observed in the combined treatment group, there 
was no additional effect compared to TGF-β alone when measuring protein expression. Interestingly not all 
splices are affected evenly, after 7 days stimulation with the combination of IL-13 and TGF-β the 70kDa 
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3.4.1-1 Healthy ASM cells were stimulated with 10ng.ml
-1
 IL-13, TGF-β or a combination of both for A) 
72 hours or B) 1 week. Changes in total TRPC6 expression were measured by western immunoblot and 
expressed as a percentage of their unstimulated control. Bars represent mean, ± SEM, n=9-17 by one-way 
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3.4.1-2 Healthy ASM cells were stimulated with 10ng.ml
-1
 IL-13, TGF-β or a combination of both for up to 
one week. Changes in the 70 and ≈100kDa TRPC6 splices’ expression were measured by western 
immunoblot and expressed as a percentage of their unstimulated control, A and B respectively. Bars 
represent mean, ± SEM, n=2-9. C) A comparison between the up regulation of the 70kDa and ≈100kDa 
TRPC6 splices after one week combined IL-13 and TGF-β treatment with example trace, (n=5-9, p=0.01), 
by paired t-test. 
  
Stimulation with TGF-β alone or in combination with IL-13 enhances SERCA2 expression up to 72 hours 
of stimulation after which it returns to control levels (48 hours p<0.05 for both, 72 hours p<0.001 
combination, p<0.01 TGF-β, Fig. 3.4.1-3). IL-13 alone did not alter SERCA2 expression. 
 
3.4.1-3 Healthy ASM cells were stimulated with 10ng.ml
-1
 IL-13, TGF-β or a combination of both for 24, 
48, 72 hours or 1 week. Changes in SERCA2 expression were measured by western immunoblot and 
expressed as a percentage of their unstimulated control. Bars represent mean, ± SEM, n=5-14; *p<0.05, 
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The effect of TGF-β on TRPC3 expression requires further investigation. While IL-13 did not affect TRPC3 
expression it appeared as though TGF-β significantly increased expression (p<0.001). However as can be 
observed from the example blot there is a band the TRPC3 antibody detects above the suspected TRPC3 
band showing the exact opposite effect to TGF-β. The band increasing in expression was chosen for 
analysis as it matches the real-time PCR data. Work is currently being carried out by Dr Shaifta to ascertain 
whether the correct band has been analysed by over-expressing TRPC3 tagged to green fluorescence protein 
(GFP) and by knocking TRPC3 mRNA expression down with siRNA.  
 
3.4.1-4 Healthy ASM cells were stimulated with 10ng.ml
-1
 IL-13, TGF-β or a combination of both for 1 
week. Changes in TRPC3 expression were measured by western immunoblot and expressed as a percentage 
of their unstimulated control. Bars represent mean, ± SEM, n=10; ***p<0.001, by one-way ANOVA and 
Bonferroni’s multi comparison post hoc test. 
 
3.4.2 The role of Smad2/3 in the effects mediated by TGF-β 
In order to investigate whether the effects of TGF-β on calcium handling proteins is mediated via Smad2 
and/or Smad3, siRNAs targeting them were designed as described in section 2.6.1. Three different coding 
sequences were designed against each mRNA sequence initially and healthy ASM cells were transfected 
with them via electroporation using the Amaxa Nucleofector® kit. Protein levels were then analysed by 
western blot to determine which siRNA reduced protein expression most efficiently. A scrambled siRNA 
sequence was transfected and measured alongside the tested siRNAs as well as a non-transfected control to 
ensure the electroporation did not affect protein expression. Fig. 3.4.2-1 shows that for Smad2 none of the 
initial three sequences tested gave a sufficient knockdown of the protein so another three were designed and 
tested. Of the second set siRNA6 gave an 83% reduction compared to control. For Smad3 siRNA3 gave the 















































3.4.2-1 Healthy ASM cells were transfected via electroporation with 3μg of three different siRNA 
sequences targeted against A) Smad2 or B) Smad3, along with a scrambled siRNA sequence and just the 
nucleofector solution alone as controls. Western blots were then carried out on the lysed cells to measure 
the efficiency of each siRNA construct. Bars represent protein levels as a percentage of the scrambled 
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3.4.2-2 An example blot demonstrating the TRPC6 siRNA designed by Dr Shaifta knocks down both the 
100kDa and 70kDa splices in healthy ASM cells. Lane 1 - untransfected control, lane 2 - scrambled siRNA 
and lane 3 - TRPC6 targeted siRNA. 
 
3.4.3 The role of Smad2/3 in TGF-β signalling in ASM cells 
As before, TGF-β stimulation for 72 hours increases TRPC6 protein expression, (7.9 fold increase 
compared to control, p<0.01). The effect is partially attenuated by the Smad2 siRNA (2.3 fold increase 
compared to control, not significant) and further diminished by the Smad3 siRNA (1.6 fold increase, not 
significant). When the two are combined together TRPC6 protein expression doesn’t increase at all 
following TGF-β stimulation (Fig. 3.4.3-1). To ensure the transfection had worked efficiently Smad3 and 
Smad2 expression levels were checked (Figs. 3.4.3-2 and 3.4.3-3 respectively). Both proteins were 
significantly reduced when targeted with siRNA (p<0.001) and interestingly Smad3 was also reduced by 
TGF-β stimulation alone (p<0.001), perhaps as part of a negative feedback loop to prevent excessive 
signalling. A full length time course was carried out to confirm this effect (Fig. 3.4.3-4). Little cross-
reactivity between the siRNAs was observed indicating their specificity. 
 
3.4.3-1 Healthy ASM cells were transfected with either scrambled, Smad2 targeted, Smad3 targeted or a 
combination of Smad2/3 targeted siRNA and cultured in the presence or absence of  10ng.ml
-1
 TGF-β for 
72 hours. Total TRPC6 protein expression was then measured. Data represents mean ± SEM, n=4, 











































3.4.3-2 Healthy ASM cells were transfected with either scrambled, Smad2 targeted, Smad3 targeted or a 
combination of Smad2/3 targeted siRNA and cultured in the presence or absence of  10ng.ml
-1
 TGF-β for 
72 hours. Total Smad3 protein expression was then measured. Data represents mean ± SEM, n=3, 




3.4.3-3 Healthy ASM cells were transfected with either scrambled, Smad2 targeted, Smad3 targeted or a 
combination of Smad2/3 targeted siRNA and cultured in the presence or absence of  10ng.ml
-1
 TGF-β for 
72 hours. Total Smad2 protein expression was then measured. Data represents mean ± SEM, n=5, 
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Treatment with TGF-β alone significantly decreased Smad3 expression in ASM cells as measured by 
western blot at 48 hours, 72 hours and 7 days (p<0.001, p<0.05 and p<0.001 respectively). IL-13 had no 
effect on Smad3 expression alone and when combined with TGF-β the effect was comparable to that of 
TGF-β alone (Fig. 3.4.3-4). 
 
 
3.4.3-4 Healthy ASM cells were stimulated with 10ng.ml
-1
 IL-13, TGF-β or a combination of both for 24, 
48, 72 hours or 1 week. Changes in Smad3 expression were measured by western immunoblot and 
expressed as a percentage of their unstimulated control. Bars represent mean, ± SEM, n=4-7; *p<0.05, 
p<0.01 and ***p<0.001 by one-way ANOVA and Bonferroni’s multi comparison post hoc test. 
 
3.4.4 Functional consequences 
Following on from the observed changes in protein expression in various calcium handling proteins after 
stimulation with IL-13 and TGF-β it was important to find out whether this translated into a functional 
effect. Pre-treatment with a combination of IL-13 and TGF-β for one week significantly reduced the 
response to both bradykinin (p=0.0068, n=9, Fig. 3.4.4-1 upper) and FFA (p=0.002, n=4-5, Fig. 3.4.4-2) 
contrasting the TNF-α stimulation. The recovery rate back to the baseline value following BK stimulation 
was significantly slower following one week TGF-β and IL-13 treatment compared to control (p=0.002, 
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3.4.4-1 Ratiometric measurements of cytosolic calcium from control (clear bar) or 7 day IL-13 and TGF-β 
stimulation (grey bar). Cytosolic calcium ion levels were measured by preloading cells with 1µM Fura PE 
3-AM for >45minutes. Cells were stimulated with 0.5µM bradykinin, ratiometric measurements 
(340/380nm) of peak calcium store release (top) and decay rate of signal (bottom). Bars represent mean and 
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3.4.4-2 Ratiometric measurements of cytosolic calcium from control (clear bar) or 7 day IL-13 and TGF-β 
stimulation (grey bar). Cytosolic calcium ion levels were measured by preloading cells with 1µM Fura PE 
3-AM for >45minutes. Ratiometric measurements of peak calcium store release following activation by 
10µM FFA. Bars represent mean and SEM, (n=4-5, p=0.002) by unpaired t-test. 
 
Transfection with a TRPC6 directed siRNA caused a small but significant reduction in FFA mediated rise 
in calcium (p<0.05) suggesting the effect was in part via TRPC6. The TRPC6 directed siRNA combined 
with TGF-β treatment caused no further reduction in FFA mediated calcium mobilisation compared to 
TGF-β, scrambled transfected cells (Fig. 3.4.4-3). 
 
3.4.4-3 Ratiometric measurements of cytosolic calcium from control (clear bars) or 10ng.ml
-1
 TGF-β 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or TRPC6 targeted siRNA. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes and stimulated with 10µM FFA. Bars represent mean ± 
SEM, n=6-10; *p<0.05, p<0.01 and ***p<0.001 by one-way ANOVA and Bonferroni’s multi comparison 
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Consistent with the previous run TGF-β treatment reduced calcium mobilisation in response to BK 
(p<0.001). With the addition of TRPC6 siRNA the control response was blunted and furthermore lessened 
the reduction induced by TGF-β. Both effects were to such an extent that the difference between them was 
lost, suggesting a potential role for TRPC6 in the BK response.  
 
3.4.4-4 Ratiometric measurements of cytosolic calcium from control (clear bars) or 10ng.ml
-1
 TGF-β 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or TRPC6 targeted siRNA. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes and stimulated with 0.5µM BK. Bars represent mean ± 
SEM, n=6-10; *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA and Bonferroni’s multi 
comparison post hoc test. 
 
Combination of the Smad2/3 siRNAs significantly inhibits the increase of TRPC6 protein expression 
following TGF-β stimulation to control levels. To determine whether the reduction in FFA and bradykinin 
response was a Smad2/3 mediated effect, cells were transfected with the combination of siRNAs prior to 
TGF-β stimulation. The reduction in response following stimulation was completely abolished thus 
highlighting the importance of Smad2/3 in the observed effect (Fig. 3.4.4-5). When exploring the role of 
Smad2/3 following bradykinin stimulation, the positive control previously showing a reduced response did 
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3.4.4-5 Ratiometric measurements of cytosolic calcium from control (clear bars) or 10ng.ml
-1
 TGF-β 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or a combination of Smad2/3 targeted siRNA. Cytosolic calcium ion levels were 
measured by preloading cells with 1µM Fura PE 3-AM for >45minutes and stimulated with 10µM FFA. 
Bars represent mean ± SEM, n=9-10; **p<0.01 by one-way ANOVA and Bonferroni’s multi comparison 
post hoc test. 
 
3.4.4-6 Ratiometric measurements of cytosolic calcium from control (clear bars) or 10ng.ml
-1
 TGF-β 
(chequered bars) treated healthy ASM cells. Prior to stimulation cells were either transfected with 
scrambled siRNA or Smad2/3 targeted siRNA. Cytosolic calcium ion levels were measured by preloading 
cells with 1µM Fura PE 3-AM for >45minutes and stimulated with 0.5µM BK. Bars represent mean ± 
SEM, n=9-10; *p<0.05, p<0.01 and ***p<0.001 by one-way ANOVA and Bonferroni’s multi comparison 
post hoc test. 
 
3.4.5 A role for TRPA1 in ASM 
A dose response was performed on cultured healthy ASM cells with the TRPA1 agonist allyl isothiocyanate 
(AITC) measuring the peak rise in intracellular calcium elicited giving an EC50 of 3.5µM (Fig. 3.4.5-1 top). 
Secondly a dose response curve of AITC was performed on murine primary bronchioles mounted onto a 
myograph to investigate whether the rise in intracellular calcium observed in human cultured ASM would 
translate into a contraction. Both wild type and TRPA1
-/-
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response. Following pre-incubation with the TRPV1 agonist capsaicin to desensitise the receptor a dose 
response to AITC was performed. No contractile response was observed in any of the mice for either the 
wild types or knockouts (Fig. 3.4.5-1 bottom). 
 
 
3.4.5-1 Top: Healthy human ASM cells were grown in culture to sub confluence on 96 well plates, serum 
starved for 72 hours and loaded with fura-2 dye for 45 minutes. A dose response to allyl isothiocyanate 
(AITC) a TRPA1 agonist was performed. Dose response curve is from 12 replicates from the same cell 
donor. Bottom: Murine primary bronchioles from three wild type and three TRPA1
-/-
 mice were stimulated 
with 10µM capsaicin for 30 minutes to desensitise TRPV1 channels followed by a dose response to AITC. 
A positive control of 80mM K
+
 was performed prior to the experiment and a dose response to carbachol at 
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3.5 Discussion 
The results in this chapter show that the inflammatory cytokines TGF-β and TNF-α alter the expression of 
calcium handling proteins in healthy ASM and that the observed changes have a functional effect. I 
hypothesised that all three of TNF-α, TGF-β and IL-13 would increase the expression of TRPC3 and 
TRPC6 while diminishing SERCA2 expression resulting in an elevated [Ca
2+
]i at rest and following agonist 
stimulation. Part of this hypothesis was proven correct as TGF-β enhanced TRPC6 and TRPC3 protein 
expression and TRPC3 was also increased by TNF-α. Contrary to the hypothesis IL-13 had no synergistic 
effect when co-stimulated with TGF-β and SERCA2 protein expression was not decreased by any of the 
treatments. The functional result of this was an increase in calcium leak, SOCE and FFA induced calcium 
entry and a reduction in bradykinin stimulated calcium mobilisation to TNF-α. As well as a Smad2/3 
dependent decrease in FFA induced calcium entry and a reduction in bradykinin stimulated calcium 
mobilisation to TGF-β. 
3.5.1 Effects of TNF-α on Ca2+ handling proteins and homeostasis 
Exposure to TNF-α results in an up-regulation of TRPC3 protein expression and an increase in the peak 
calcium response to FFA and the basal leak of Ca
2+
 into the cell. Prior transfection with a TRPC3 directed 
siRNA abolishes the increase to FFA entirely therefore suggesting the influx of calcium is linked to this 
channel. TNF-α stimulation also resulted in a decrease in bradykinin elicited cytosolic calcium 
mobilisation. These results are in partial accordance with (White et al., 2006), who also showed TNF-α 
enhancing TRPC3 mRNA and protein expression. The paper further demonstrated a higher resting cytosolic 
Ca
2+
 concentration following TNF-α stimulation which was dependent upon the presence of extracellular 
Ca
2+ 
and TRPC3. Here it is shown that incubation with TNF-α increases the basal leak of Ca2+ from the 
extracellular perfusate into the cell. The combination of the results strongly indicates that TRPC3 is 
constitutively active allowing a basal flow of calcium ions into the cell, thus opening up the possibility of 
an inverse agonist being used for therapy should TRPC3 be highlighted as a candidate target. As 
highlighted in the introduction TRPC3 is only monoglycosylated in the extracellular loop leading to higher 
constitutive activity compared to the dually glycosylated TRPC6 (Dietrich et al., 2003). In contrast to the 
White et al., 2006 paper TNF-α resulted in a decreased agonist induced calcium mobilisation was observed. 
The augmented response published has been previously shown (Amrani et al., 1995) but again at an earlier 
24 hour stimulation time point compared to the 7 day one used in the present study. The same lab showed 
that 24 hours of TNF-α stimulation leads to decreased SERCA2 expression (Sathish et al., 2009) which 
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would be expected to decrease SR store content and therefore result in a smaller rise in calcium following 
agonist stimulation as observed presently. A decrease in SERCA2 activity at 24 hours or the 7 day time 
point tested here was not observed however a decrease in TRPC6 was which has been attributed to receptor 
operated calcium entry and may explain the discrepancy in the results. 
3.5.2 Store operated calcium entry (SOCE) 
SOCE is the process of re-filling calcium stores following agonist stimulation in ASM cells and has been 
postulated to play a role in bronchial remodelling (Sweeney et al., 2002). 
SOCE following the emptying of the sarcoplasmic reticulum and adding calcium back to the extracellular 
solution was enhanced with TNF-α stimulation. Numerous proteins have been implicated with this 
phenomenon including stromal interaction molecule 1 (STIM1) and Orai1 (Peel et al., 2008; Zhang et al., 
2005). Recent data has shown the inflammatory cytokines TNF-α and IL-13 induce a constitutive increase 
in SOCE in ASM cells by increasing STIM1 puncta size (Jia et al., 2013). This paper postulates STIM1 
interacts with the plasma membrane protein Orai1 to facilitate SOCE as depletion of Orai1 via siRNA 
blunts the response. TNF-α also increases caveolin-1 and Orai1 expression while forming more caveolae, 
thus enhancing the interaction between the plasma membrane (Orai1) and SR (STIM1) and facilitating 
SOCE (Sathish et al., 2012). To elucidate the role of TRPC3 the cells were transfected with siRNA prior to 
stimulation and the elevation in SOCE following TNF-α stimulation was no longer observed as has been 
shown previously for a much shorter stimulation (White et al., 2006). The response was still subtly 
enhanced following TNF-α stimulation and TRPC3 knock down, suggesting that TRPC3 might not a 
necessary component of SOCE. Testing with the TRPC6 siRNA would be interesting as it has been shown 
to interact with Orai1 (Liao et al., 2007) to evaluate the role of the TRPC family in SOCE as none may be a 
necessity but rather used as a method of control during inflammation. Their presence and the ability of 
STIM1 puncta size to increase following TNF-α stimulation may be just a regulatory mechanism. 
Distinguishing the roles of TRPC3 and TRPC6 between each other as well as in receptor or store operated 
calcium entry in ASM cells has historically been a difficult task to undertake. A poor availability of specific 
pharmacological tools and antibodies has stifled advances so far. Gene expression analysis has shown that 
TRPC6 is expressed at approximately 30 fold higher levels than TRPC3 in healthy cultured ASM (Karner, 
2010). TNF-α stimulation affected TRPC6 conversely to TRPC3 causing a robust decrease in expression 
lying in contrast to the findings observed by White et al., 2006 where they observed no change. The 
discrepancy is likely due to the differing time points observed as they looked at 18-22 hours post 
stimulation and at 24 hours we saw an increase which was quite variable. The longer time point of 1 week 
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provided a much more robust decrease in TRPC6 expression. The divergent effects of TNF-α stimulation 
on TRPC3/6 may indicate that the ratio of their expression is important in facilitating the inflammatory 
response. A similar observation has been shown in human erythroid precursor cells in response to 
erythropoietin resulting in a greater intracellular calcium response (Hirschler-Laszkiewicz et al., 2009). 
3.5.3 Effects of IL-13 and TGF-β on Ca2+ handling protein expression 
Previous work in our lab discovered an interesting interaction between IL-13 and TGF-β on TRPC6 gene 
expression (Karner, 2010). Stimulation with IL-13 alone had no discernible effect and TGF-β alone caused 
a small but significant increase in expression however when the two were combined a large synergistic 
increase was observed. A large portion of the transient receptor potential family was tested in this way and 
only TRPC6 reacted in a synergistic manner. At the time no suitable antibodies were available to 
investigate protein expression and only limited work was carried out on the functional consequences of this 
so the present chapter built upon the foundation gained previously. 
3.5.3.1 TRPC6 
IL-13 treatment did not affect TRPC6 protein expression reflecting the previous work on mRNA, also in 
accordance with this TGF-β resulted in a robust up-regulation of protein. The synergistic effect of the two 
in combination however was not observed possibly indicating a pre-translational level of control to prevent 
excessive Ca
2+
 entry into the cell. While analysing the western blots an interesting observation was made, 
one of the TRPC6 splice variants detected were affected differentially to the rest. The more recently 
described 70kDa TRPC6 splice (accession number: AK027769) is enhanced to a greater degree than the 
other three higher weight splices around 100kDa. The 70kDa splice is truncated from the N-terminal coil-
coiled domain onwards and therefore missing the ankyrin repeat segment too. The functional relevance of 
any of the TRPC6 splice variants have yet to be established so the differential regulation of them by 
inflammatory cytokines can only be speculated. Truncation studies involving an N-terminal deletion of the 
ankyrin repeats up to the coil coiled domain in TRPC3 resulted in a trafficking defect (Wedel et al., 2003). 
Furthermore truncation of TRPC6 at the N-terminal ankyrin repeat domain also resulted in faulty trafficking 
to the plasma membrane (Hofmann et al., 2002). Upon co-expression with native TRPC6 or TRPC3 plasma 
membrane trafficking was restored. It is possible that the shorter 70kDa splice interferes with trafficking to 
the membrane and a reduction of the functional channel present. 
3.5.3.2 SERCA2 and TRPC3 
SERCA2 protein expression was enhanced by TGF-β expression for up to 72 hours of stimulation at which 
point it returned to control levels. IL-13 had no effect on its own or in addition to TGF-β on SERCA2 or 
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altering TRPC3 protein expression as had previously been shown for mRNA levels (Matsumoto et al., 
2012). One might have expected SERCA2 to be reduced as TGF-β is raised in asthmatics (Redington et al., 
1997) and the expression of SERCA2 is negatively correlated with asthma severity (Mahn et al., 2009). 
This has been shown previously where SERCA2 was reduced by TGF-β which persisted even after the 
stimulus had been removed (Ojo, 2011). Even though the protein expression data here is in direct contrast 
to that of Ojo, it is consistent with the elevated mRNA levels observed following 6 hours TGF-β 
stimulation. 
TRPC3 is also potentially increased in a similar manner to TRPC6 following TGF-β stimulation so the 
increase in SERCA2 expression may be to counteract an increase in Ca
2+
 leak into the cell. However the 
bands being analysed still need to be confirmed. There are in fact two splice variants of TRPC3 known, 
named one and two weighing 105 and 97kDa respectively. Therefore the two bands could both be TRPC3 
and differentially regulated to allow finer control of function, however this is purely speculative and the 
other band could be due to protein modifications such as glycosylation or simply non-specific binding. 
3.5.4 TGF-β signalling 
The importance of TGF-β signalling in maintaining airway remodelling has been shown in a murine model 
of asthma (McMillan et al., 2005). Therapeutic administration of anti-TGF-β Ab uncoupled the 
inflammatory and remodelling processes by reducing peribronchiolar ECM deposition, ASM proliferation 
and mucus production without affecting established inflammation and cytokine production. Evidence 
towards active TGF-β signalling is also put forward as phospho-Smad2 expression is decreased and Smad7 
increased in lung sections. Over-expressing Smad2 in airway epithelium in a house dust mite model of 
asthma increased airway hyperreactivity, smooth muscle hyperplasia and subepithelial collagen deposition 
(Gregory et al., 2010). The classic signalling pathway downstream of TGF-β activation is Smad2/3 
activation so coupled with the previous evidence it was hypothesised that TGF-β was mediating its effects 
via these two secondary messengers. 
Short interfering siRNAs targeted against Smad2 and Smad3 were designed and synthesised to address this 
aim using a previously tested algorithm as shown in section 2.6.1. Following transfection via 
electroporation protein levels were measured by western immunoblot and of the pool of three siRNAs 
designed the one achieving the best knockdown was selected for further use. In the case of Smad2 a further 
pool of three had to be designed as none of the original set produced a satisfactory reduction in protein. 
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By using these siRNAs alone and in combination it was shown that the increase in TRPC6 induced by TGF-
β stimulation was dependent upon both Smad2 and Smad3. It has been shown in podocytes that TGF-β can 
upregulate TRPC6 protein expression and phosphorylation possibly via a Smad3-ERK-NF-κB pathway to 
increase cytosolic calcium and apoptosis (Yu et al., 2010) which fits the data described here. Smad7 
belongs to a sub-family of Smads known as the “anti-Smads” because of its ability to interfere with TGF-β 
signalling. It has been shown to integrate the input of IFN-γ and TGF-β signalling by binding to the TGF-β 
receptor complex and inhibiting its interaction and phosphorylation of Smad3 (Ulloa et al., 1999). Although 
elevated IFN-γ isn’t a typical feature of asthma it may be present in low levels contributing to AHR (Kumar 
et al., 2006) and serves as an indicator on how a single cytokine’s signalling cascade is integrated with 
others. The results here must be interpreted with caution as the cytokine storm present in asthma involves a 
plethora of mediators in which similar interactions are likely to take place. 
On the same data set Smad2 and Smad3 protein levels were also probed to ensure the transfections worked 
(Figs. 3.4.3-2 and 3.4.3-3). In addition to the positive transfection and knock down (p<0.001 for both) an 
interesting observation was made that TGF-β stimulation significantly attenuates Smad3 protein levels 
(p<0.001) and only subtly reduced Smad2 (not significant). Although phosphorylation levels were not 
measured the 75% reduction in total Smad3 protein levels could be indicative of a negative feedback loop 
to prevent excessive signalling and changes in gene transcription. A full time course of Smad3 expression 
in response to IL-13, TGF-β and the combination of both showed IL-13 alone had no affect at all, TGF-β 
markedly reduced Smad3 expression as did the combination at each time point from 24 hours. The 
summation of these results presents an interesting point; TGF-β increases TRPC6 expression in a Smad3 
dependent manner as shown by reducing Smad3 protein by siRNA. However TGF-β stimulation also 
reduces Smad3 expression to an equivalent level as the siRNA from 24 hours post stimulation but still 
increases TRPC6 expression for up to 7 days. Thus suggesting that Smad3 is important for the initial 
increase in TRPC6 expression but not for its maintenance. To confirm the involvement of Smad3 a 
constitutively active form of it could be used to ensure that the changes in TRPC6 are dependent upon it 
alone and not by other mediators that are activated by TGF-β (Funaba et al., 2000). 
The role of Smad4 was not evaluated in the present study but its role in TGF-β signalling should not be 
overlooked. It has been shown that TGF-β activation of TβRI induces heteromeric signalling complexes of 
Smad2/3/4 which translocate to the nucleus and is required for efficient signal transduction (Nakao et al., 
1997). There are no strong links with it to the asthmatic phenotype in the literature yet and it was shown to 
not be involved in TGF-β induced ASM proliferation (Xie et al., 2007). However it may regulate mucus 
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hypersecretion (Harrop et al., 2013) and due to its intracellular interactions with Smads2/3 it may play a 
subtle modulatory role which could be investigated using the siRNA methods outlined here. 
3.5.5 Effects of IL-13 and TGF-β on intracellular Ca2+ transients 
After one week of treatment with TGF-β and IL-13 there was no observed change in SERCA2 protein 
expression however the peak calcium release to bradykinin was diminished (p=0.0068, Fig. 3.4.4-1 upper) 
which is believed to be an indicator of store content. The pleiotropic actions of TGF-β lead to a wide range 
of possibilities underlying this discrepancy, such as altered expression of phospholipase C. The issue could 
be addressed by trying a range of agonists depleting store content to see whether this is a bradykinin 
specific effect or a true indication of store content. Another possibility is that only the function of SERCA2 
is altered and not its expression which is backed up by the reduced decay rate measuring the rate of 
recovery back to baseline calcium levels (p=0.002, Fig. 3.4.4-1 lower) and is largely dependent upon 
SERCA2 function. There is evidence that CaMKII and ORMDL3 may regulate SERCA2 activity in the 
ASM which could be the targets of TGF-β (Cantero-Recasens et al., 2010; Sathish et al., 2009). 
The decrease in calcium ion entry elicited by FFA following TGF-β and IL-13 treatment was also contrary 
to the initial hypothesis. It has been shown that FFA can activate TRPC6 so following on from the large 
increase in protein expression observed one would expect an increase in cytosolic calcium. It has been 
shown that the expression level of TRPC3 can influence its function and regulation in distinct ways 
(Vazquez et al., 2003). Over-expressing TRPC3 to very high levels in this study ablated its ability to 
perform SOCE while retaining its sensitivity to phospholipase C activation. It has been hypothesised that 
increasing the expression of TRPC3/6/7 may titrate one or more of the regulatory subunits such as 
Orai1which is essential for SOCE (Liao et al., 2007). Another potential explanation could lie with the 
70kDa TRPC6 splice variant which increases further than the functional ≈100kDa splices. As this splice 
increases it could be incorporated into more tetramers and as it is missing a large portion of the N-terminus 
including the ankyrin repeat domain (ARD) necessary for certain subunit assembly and trafficking to the 
membrane the channel may not function correctly.   
3.5.5.1 The role of TRPC6 
The extent of the calcium ion current elicited by FFA going through TRPC6 needed to be addressed due to 
the high promiscuity of the drug. Knocking down TRPC6 with siRNA showed that a small but significant 
portion of the rise in cytosolic calcium was dependent upon the channel’s expression however it was not the 
entire story. Knock down of Smad2 and Smad3 prevented the TGF-β induced effect completely showing 
that although TRPC6 is not the sole endpoint of the signalling cascade, Smad2/3 are critical for this 
- 102 - 
transduction. As shown previously, administration of TRPC3 siRNA completely ablated the increased 
response to FFA following TNF-α treatment and only partly attenuated the increased SOCE response. It 
would be interesting to investigate the effect TGF-β treatment has on SOCE and what role both TRPC6 and 
TRPC3 play by using the siRNAs. It is likely that they are implicated however not essential in the SOCE 
response in unstimulated cells however from the observed data it could be hypothesised that they are altered 
with cytokine treatment enhancing the response. Measuring changes in Orai1 and STIM1 protein 
production would also be necessary to elucidate the exact control mechanisms ASM cells exhibit in the face 
of inflammation. 
The role of TRPC6 in agonist dependent calcium entry following TGF-β treatment was investigated by 
reducing its expression with siRNA and stimulating with bradykinin. The reduction in TRPC6 had no effect 
on the unstimulated cells however the reduction in calcium mobilisation observed after TGF-β treatment 
was blunted. The mechanism behind this could again be attributed to specific expression levels of TRPC6 
being required for optimal function or a role of the 70kDa splice. The TGF-β stimulation increases the 
smaller splice variant which may inhibit receptor trafficking resulting in diminished calcium elevation to 
bradykinin. Upon TRPC6 RNA interference the 70kDa splice is reduced and therefore partially restoring 
the function. Bradykinin stimulation can lead to a biphasic calcium response indicative of both store release 
and calcium entry of which the TRPC channels would play a role in the latter. This was not obviously 
present in the traces attained but could be still occurring and influencing the rate of recovery via direct store 
filling. Repeating the experiment in the absence of calcium in the perfusate would remove the compounding 
effect of SOCE. The roles of Smad2/3 were investigated but no inference could be made due to the positive 
control not working. An interesting additional experiment would be to look at contraction and the possible 
role the TRPC proteins and splices play, linking it to the altered calcium transients. 
Recently further progress has been made in developing a specific TRPC6 agonist owing to its involvement 
in hypoxia induced vasoconstriction (HPV) and idiopathic pulmonary arterial hypertension (PAH) (Yu et 
al., 2009). An agonist (8009-5364) has shown 2.5 fold selectivity for OAG induced TRPC6 over TRPC3 
Ca
2+
 influx which is still only marginal but may shed some more light on the current mechanisms explored 
(Urban et al., 2012). 
3.5.6 Methylation 
The fact that ASM cells derived from asthmatics retain some of their phenotypes and characteristics in 
culture after removal from the asthmatic environment raises some interesting points. One of which is the 
potential role DNA methylation may play in sustaining a modulated state in ASM cells driving remodelling 
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after the inflammation has resolved. Therefore cultured cells derived from asthmatic patients were 
compared to those from healthy patients to see if any of the genes of interest had a correlating methylation 
pattern. Following evidence that TGF-β induces a reduction in SERCA2 expression which is maintained 
after its removal (Ojo, 2011), the effect of TGF-β stimulation on healthy cells was also observed (Fig. 
3.5.6-1). 
 
3.5.6-1 An Illumina® 450K methylation array kit was used in conjunction with Dr Lavender’s group to 
analyse CpG methylation in three ASM cultures derived from moderate asthmatics (red circles), “healthy” 
patients (blue circles) and “healthy” patients stimulated with 10ng.ml-1 TGF-β for 6 hours. Y-axis is % 
methylation at the cytosine. 
 
Lower levels of methylation at the CpG sites correlate with higher levels of gene expression and it is 
considered that a mean fold change of approximately 1.5 is considered to be the minimum for relevant 
expression changes (Dr Lavender) of which none of the genes above met. 
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The SERCA2 gene ATP2A2 expressed no sign of change following TGF-β treatment fitting with the 
protein expression data at the earliest time point. Contrary to the work by (Mahn et al., 2009) there was a 
subtle trend of reduced methylation in the asthmatic derived cells in this gene compared to the healthy cells 
which could result in increased expression. The TRPC3/6 genes bore no correlation regarding methylation 
pattern between the three groups and therefore the changes observed in this chapter are likely to be 
controlled by other mechanisms. Interestingly ORAI1 exhibited increased methylation in both the TGF-β 
treated healthy cells and the asthmatic derived cells compared to the healthy untreated cells. Although the 
protein expression levels of Orai1 following TGF-β treatment weren’t in the scope of the current 
investigation there is some evidence that it may be increased in rat bronchial smooth muscle cells possibly 
contributing to increased SOCE (Gao et al., 2013). The protein expression data presented here would seem 
to back up this finding as increased TRPC3 and TRPC6 expression could also aid the increased SOCE 
observed. The methylation data would seem to contradict these findings however the fold changes observed 
are minimal and as such are likely to have little impact on gene expression. Furthermore only three cell 
lines were investigated resulting in very low power. 
3.5.7 A role for TRPA1 
Preliminary data to some potentially very interesting work was performed in collaboration with Dr 
Andersson with the assistance of Dr Shaifta and Dr Prieto-Lloret. TRPA1 has been shown to be expressed 
on ASM and contributing to non-neurogenic inflammation in the airways (Nassini et al., 2012). It could 
therefore be contributing to this via the ASM bundle. We therefore sought to discover whether it is 
functionally active and capable of causing contraction. Stimulation with its agonist AITC resulted in a 
robust dose dependent increase in peak intracellular calcium concentration as measured by fura-2. The 
concentrations at which rises in calcium were observed were low enough to be reasonably sure they were 
mediated by TRPA1. A TRPA1 antagonist AP18 (data not shown) resulted in a right-ward shift of the curve 
further backing up the interpretation. 
It was then sought to find out whether the elicited rise in calcium would result in contraction in murine 
primary bronchioles and if this was dependent upon TRPA1 expression by using a homozygous knockout 
mouse. No contraction was observed in either genotype mice contrary to our hypothesis. TRPA1 is 
expressed in the mouse smooth muscle and epithelium (Nassini et al., 2012) however its function has yet to 
be tested. A lack of contractile response does not negate the fact that the calcium elevation may be 
important for controlling other ASM functions in health and disease. TRPA1 can be activated by a wide 
range of endogenous by-products of oxidative and nitrative stress (Andersson et al., 2008; Materazzi et al., 
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2008; Sawada et al., 2008) and there are highly elevated levels of oxidative stress in asthma which is 
implicated with exacerbations (Mak et al., 2013). It is therefore plausible that TRPA1 activity on ASM is 
altered in asthma and could contribute to the altered phenotype in ways other than contraction such as the 
synthetic phenotype. Future studies investigating the expression and function of TRPA1 in health and 
asthma on ASM could provide new insights into the pathogenesis and potentially provide a novel 
therapeutic target. 
3.5.8 Caveats 
A major drawback to this study as already mentioned is the lack of pharmacological tools for TRPC 
investigation. FFA was chosen as a TRPC6 agonist based on findings in ciPod and HEK293 cells that it 
signalled independently to TRPC3 (Foster et al., 2009). This is clearly not the case here as using a TRPC3 
siRNA completely abolished the increased FFA response to TNF-α whereas the TRPC6 siRNA only 
partially inhibited the decreased response to TGF-β. 
A second caveat that needs addressing is to better distinguish between agonist stimulated calcium store 
release and the so called receptor operated calcium entry. Stimulation of the cells with bradykinin would 
result in both. Therefore to determine the source of the rise in calcium and hence the involvement of TRPC 
channels if it is coming from the extracellular space the protocol needs to be refined to include the use of 
receptor antagonists and zero extracellular calcium. 
3.5.9 Conclusion 
There is currently only a limited interest in TRPC6 as a target for pulmonary disease shown by the single 
patent of a TRPC6 antagonist by Sanofi-Aventis for use in COPD (Preti et al., 2012). The IC50 value quoted 
of 12nM is promising however specificity of action and further understanding of the role of the TRPC 
proteins in the pathophysiology of asthma are very important if a new therapeutic target is achieved. 
TRPA1 antagonism is an even more promising and further developed target in respiratory research. There 
are compounds in preclinical trials for asthma (Preti et al., 2012) which primarily focussed on their 
antitussive and neurogenic inflammatory effects. However they may be of additional benefit in restoring 
ASM calcium handling. 
It is clear that the physiology of TRPC channels is very diverse and regulated by numerous factors such as 
expression levels and subunit specific tetramerisation. The experiments here show that cytokines implicated 
in asthma alter the protein expression of both TRPC3 and TRPC6 in ASM cells. The observed changes are 
to such a degree that the dynamics of calcium handling within the cell are altered. The delicate intricacies of 
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spatial and temporal specific calcium oscillations are largely lost in cultured ASM cells and it is this that 
integrates the wide variety of cellular stimulations into a functional response. It is important to try and tie 
the altered response observed in these experiments to the altered asthmatic phenotype of ASM cells and the 
signalling pathway in between to generate new therapeutic targets. 
3.6 Summary of results 
 
3.5.9-1 A potential mechanism of the ASM response to long-term TNF-α stimulation based on current 
findings. Upon stimulation with TNF-α there is a switch from ROCE to SOCE (White et al., 2006). This is 
accompanied by a reduction in TRPC6 aiding the ROCE and an increase in TRPC3 aiding SOCE and 
increasing the basal leak of calcium into the cell. TRPC6 has been shown to interact with Orai1 (Liao et al., 
2007) and may confer to low levels of SOCE which are subsequently enhanced by TNF-α and increasing 
TRPC3 expression. The summation of these responses could result in the enhanced bronchoconstriction 
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3.5.9-2 A potential mechanism of the ASM response to long-term TGF-β stimulation based on current 
findings. TGF-β increases TRPC6 expression in a non-uniform manner, preferentially up-regulating the 
smaller 70kDa splice which may exhibit impaired trafficking to the membrane. This process may involve 
epigenetic modifications as it is dependent upon Smad2/3 signalling to initiate but not to maintain. Calcium 
mobilisation to bradykinin was found to be independent to TRPC6 in healthy cells however upon 
stimulation with TGF-β a marked reduction was observed which was dependent partly upon TRPC6 
expression. A reduction in the response to FFA was also observed indicating the enhanced smaller splice 
variant maybe reducing TRPC3 expression at the membrane also. TGF-β stimulation did not affect 
SERCA2 expression but did reduce its function which would further contribute to the smaller agonist 
induced calcium mobilisation. 
 
3.6.1 How data fits with current literature 
Not all of the data in this chapter concurred with the current literature. Due to the poor testing of TRPC 
antibodies by many and differing time-points investigated the work here presents a good addition to the 
field.  
Finding In accordance? Reference 
TNF-α increase TRPC3 and basal 
Ca
2+
 leak and switch from ROCE 
to SOCE. 
Yes White et al., 2006 




No/Yes No, later time-point measured White et al., 2006 
Yes, Sathish et al., 2009 observed decreased 
SERCA2 expression. 
TNF-α doesn’t affect SERCA2 
protein expression. 
No Later time-point measured Sathish et al., 2009 
TGF-β increases SERCA2 
expression up to 72 hours 
stimulation. 
No Ojo, Thesis, 2011 
IL-13 doesn’t affect TRPC3 
protein expression. 
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Chapter 4 Investigating the role of SERCA2 in an in vivo model of acute 
asthma 
4.1 Introduction 
4.1.1 A role for SERCA2 in asthma? 
There is strong in vitro evidence for a role of SERCA2 down regulation and perturbed calcium handling in 
ASM cells contributing to an asthmatic phenotype (Mahn et al., 2009; Mahn et al., 2010). The paper 
demonstrates that SERCA2 protein expression is diminished in cultured ASM cells derived from asthmatics 
compared to those from a non-asthmatic population. Furthermore the degree of SERCA2 reduction 
correlated with disease severity and an asthmatic phenotype could be induced in healthy cells simply by 
reducing its expression with siRNA. The experiments highlighted the possible role of SERCA2 in the 
development or maintenance of the disease warranting further validation via other methods. This chapter 
sought to elucidate whether a reduction of SERCA2 in vivo could induce or exacerbate an asthmatic 
phenotype in a murine model of asthma.  
4.1.2 Modelling asthma in vivo 
Asthma is a heterogeneous disease, and common hallmarks of the disease include changes in lung function, 
specifically, airway hyperresponsiveness (AHR) to spasmogens, pulmonary inflammation and airway 
remodelling.  
Due to these many facets of asthma it is difficult to investigate the disease as a whole; therefore numerous 
models have been developed to piece together information. Delineating intracellular signalling cascades and 
changes in protein expression are most effectively investigated in vitro, whereas ex vivo models are used for 
real-time functional and physiological measurements of ASM including contraction. Finally in vivo models 
investigate how the whole pulmonary and systemic system works as a unit and translates findings from the 
previous two approaches into a whole-organism disease setting (Wright et al., 2012a). 
There are numerous different techniques and models within each of these approaches which are tailored 
towards various end-points. A murine model has been chosen in this instance as the primary aim is to 
investigate the role of SERCA2 in vivo within the context of an asthmatic pathophysiology. Using a 
genomic knockout of SERCA2 is the best way to answer this aim as a straight comparison can be drawn 
displaying the impact of a lowered protein expression. Murine models of asthma are abundant and well 
established and a SERCA2 knockout line already exists.  
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4.1.3 An ovalbumin model of acute asthma  
The mice used in this study were a generous gift from Dr Gary Shull (Cincinnati, USA) who used them to 
investigate cardiac failure (Periasamy et al., 1999). They have a rather unorthodox background of a mixed 
129/SVJ and Black Swiss of which there is no current data of their use within the context of asthma or 
allergy. A preliminary study was therefore of great importance as it has been shown before that various 
inbred mouse strains can respond significantly differently from one another following ovalbumin 
sensitisation and challenge (Ewart et al., 2000). It takes at least ten generations to backcross onto another 
background such as the more conventional BALB/c or C57BL/6 which have a well characterised response 
to ovalbumin (Fernandez-Rodriguez et al., 2010; Pitchford et al., 2004; Riffo-Vasquez et al., 2012). There 
was not enough time to perform this so instead a preliminary test was performed to ensure an allergic state 
could be induced in this strain which was achieved (Ojo, 2011). The mice are a heterozygous knockout as 
the homozygous mice die during embryonic development. SERCA2 protein expression is reduced to 63% 
(p<0.05) of the wild type expression in the heart (Periasamy et al., 1999). The reduction in expression is 
comparable to that seen in moderate asthmatic tissue sections when compared to healthy sections, 67% 
(Mahn et al., 2009). A homozygous knockout would have been useful as an extra comparison to better 
elucidate the role SERCA2 plays in vivo. However as the heterozygous expression closely matches the 
reduced human asthmatic expression this model is satisfactory. 
As the strain of mouse being used was relatively uncharacterised in an asthmatic model setting, ovalbumin 
was chosen as the allergen. Recently more clinically relevant allergens such as house dust mite have been 
preferred as they offer a more tractable insight to the human disease (Cates et al., 2004; Lloyd, 2007). The 
ovalbumin model has been used more extensively and has a proven robust response in the endpoints 
evaluated making it suitable for this investigation. An acute sensitisation protocol was employed initially to 
investigate changes in inflammatory cell and mediator infiltration into the airways and lung function 
parameters such as AHR or changes in compliance and resistance. 
4.1.4 Measuring lung function 
The first measurements of dynamic lung mechanics in mice were made in the late 1980’s where pulmonary 
resistance and compliance was assessed in live, anaesthetised, tracheotomised mice (Martin et al., 1988). 
Measuring lung mechanics in this state provides a high level of precision which comes at the expense of 
losing the natural state of the animal. The phenotyping uncertainty principle explains this trade-off and 
shows how no method is optimal for measuring lung mechanics and sacrifices have to be made at the 
investigator’s discretion (Bates et al., 2003). At the other end of the spectrum is whole body 
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plethysmography, a non-invasive technique which measures enhanced pause (Penh) to indicate airway 
sensitivity. There are clear benefits gained from using a non-terminal procedure such as investigating the 
early and late phase response in the same animal, a clinical feature of asthma which is too often forgotten in 
research (Evans et al., 2012). The use of Penh from whole body plethysmography has come under scrutiny 
for not being representative of airway resistance (Zhang et al., 2009) but advances such as using a 
pneumotachograph in conjunction (flow plethysmograph) have shown the waveform is not dominated by 
conditioning (Lomask, 2006). A bridge between the two extremes has been made in the form of using a 
balloon catheter in the pleural cavity to measure pleural pressure, an indicator of airway resistance, in 
unrestrained guinea-pigs (Meurs et al., 2006). 
4.1.5 Aims and hypotheses 
The aim of this chapter was to investigate whether the enhanced asthmatic phenotype observed in vitro 
when reducing SERCA2 protein expression is translated in vivo. In order to investigate this aim four 
experimental groups were used; wild type sham sensitised mice, wild type ovalbumin sensitised mice, 
SERCA2
+/-
 sham sensitised mice and SERCA2
+/-
 ovalbumin sensitised mice. The parameters measured 
were leukocyte infiltration into and around the airways, cytokine infiltration to the airways, pulmonary 
morphology and total lung resistance, compliance and reactivity. I hypothesised that immunisation with 
ovalbumin would enhance eosinophilia with a concomitant increase in TH2 cytokines, airway reactivity and 
resistance and decrease compliance in both wild type and SERCA2
+/-
 mice. Furthermore, the reduction of 
SERCA2 in the knockout mice would enhance these changes in both the sham and ovalbumin immunised 
animals. Reducing SERCA2 with siRNA in healthy ASM cells resulted in an increase in eotaxin-1 
production after IL-13 stimulation in vitro (Mahn et al., 2009). Therefore an elevated level of eosinophils 
into the airways would be expected in the knockout ovalbumin sensitised mice compared to their wild type 
counterparts as eotaxin is a chemotactic agent for them. No direct relationship between reduced SERCA2 
expression and an increase in ASM contractility has been observed in the literature to date although such a 
relationship is quite plausible. Contraction can be initiated by a rise in [Ca
2+
]i resulting in a calmodulin 
dependent activation of myosin light chain kinase which phosphorylates MLC20 producing cross bridge 
cycling and muscle shortening. The 4:1 stoichiometry between calcium and calmodulin would mean that 
only a small rise in [Ca
2+
]i, caused by a reduction in SERCA2, could lead to a far greater response to 
contractile agonists (Mahn et al., 2010). Changes in lung morphology were also investigated and I 
hypothesised that only a genotype and not a treatment effect would be observed. The duration of the 
challenge protocol employed was such that one would not expect ovalbumin driven remodelling. However 
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as the SERCA2
+/-
 mice have had an altered calcium handling from birth enough time would have elapsed by 
termination to potentially see a thicker smooth muscle layer around the airways. 
4.2 Methods 
Atp2a2 heterozygous knockout Black Swiss/129SVJ mice were used as homozygous knockouts are 
embryonic lethal, they were a gift from Dr Gary Shull. They were generated as described in (Periasamy et 
al., 1999). As predicted by Mendelian genomics, offspring were produced in an approximate 1:1 
heterozygous to wild type ratio when breeding a wild type with a SERCA2
+/-
 mouse. Male and female mice 
were used equally in each treatment group to minimise any gender bias as found in the preliminary study. 
All studies were carried out according to The Animals (Scientific Procedures) Act (1986) and local ethical 
approval from King’s College London. 
Animals were housed in cages according to their gender in environmentally controlled rooms with access to 
food and water ad libitum before and during the experimental period. 
4.2.1 Genotyping wild type and SERCA2 heterozygous knockout mice 
The knockout mice displayed no overt phenotypic difference to the wild type, therefore to differentiate 
between them the mice had to be genotyped. DNA from ear clippings is first isolated using the “DNeasy 
Blood and Tissue Kit” (QIAgen, Crawley) and 50ng of DNA together with “illustra Ready-To-Go™ RT-
PCR Beads” (GE Healthcare Life Sciences) is incubated with 2pM of SERCA primer mix on ice. The 
primer mix was comprised of three primers outlined below: 
Primers (Sigma): 
 Sequence Catalogue number 
Primer 1 5’-CGGCCTTCTAGAATTGCCGGCTG-3’ SY100204245-052 
Primer 2 5’-CTTACGAAAGATATACATGCTGCCAGCAG-3’ SY100204247-031 
Primer 3 5’-GCATGCTCCAGACTCCCTTG-3’ SY100204241-063 
The PCR master mix is amplicated using the following protocol: 
 94°C for 3mins 
 95°C for 30secs 
 59°C for 30secs x40 
 72°C for 30secs 
 72°C for 5mins 
 4°C until gel loading 
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The PCR product is then run through a 2.5% agarose gel at 80V for 90 minutes and bands are compared to a 
molecular ladder (ΦX174 DNA/BsuRI HaeIII Marker, Fermantas). For wild type mice a band is visualised 
at 233 base pairs and for the heterozygous knockouts bands are present at 233 and 180 base pairs. The 
second band in the knockouts represents the insert primer 1 is targeted against which disrupts the gene 
expression. 
  
4.2.1-1 Gel showing the PCR products of SERCA2+/- (lane one) mice and wild type mice (lanes two and 
three). Briefly, tail clippings are digested and genomic DNA isolated using the QIAgen “Blood and Tissue 
Kit” then samples are run on a gel and bands are visualised using ethidium bromide. 
 
4.2.2 Ovalbumin challenge 
Mice were immunised on day 0, 7, 14 and 21 with 30µg/0.4ml chicken ovalbumin (OVA) intraperitoneally 
(i.p.) using aluminium hydroxide (Al2[OH]3)  (Sanofi-Synthelabo, Sao Paolo, Brazil) in saline solution as 
the adjuvent. Mice were then exposed to aerosolised OVA (30mg.ml
-1
) twice daily for 25 minutes on Days 
27-30 in a specially designed 9L ventilated chamber allowing for free movement (see Fig. 4.2.2-1). 
Twenty-four hours after the final challenge mice were anaesthetised with 2g.kg
-1
 urethane i.p. (Sigma). 
Presence of a band here at 180 
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4.2.2-1 The 9 litre aerosolisation chamber the mice are kept in during the 25 minute ovalbumin exposure. 




4.2.3 Lung function 
4.2.3.1 Respiratory lung mechanics 
In this model the method of invasive tracheotomised measurements of lung function were employed 
(Pitchford et al., 2004). Severity of bronchoconstriction was gauged by measuring changes in total lung 
resistance (RL) and dynamic compliance (Cdyn) in response to aerosolised methacholine. Variables such as 
the concentration of methacholine which caused a 200% increase in total lung resistance above saline 
challenge (RL PC200) and peak response (maximum RL) were recorded. Dynamic compliance was 
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obtained from continuous measurement of intrapleural pressure and volume during a normal breathing 
cycle (Ward et al., 2010). It is measured as the slope between zero airflow at the end of inspiration and 
expiration on a volume pressure curve and is indicative of lung tissue and alveolar compliance. In health it 
is often similar to static compliance (the change in lung volume per unit change in distending pressure) but 
in disease it can fall. Total lung resistance describes the restriction of airflow from the atmosphere into the 
alveoli. Poiseuille’s equation describes the factors affecting laminar flow showing that a halving of airway 
lumen radius will increase airway resistance 16 fold: 
  
   
   
 Where R = Resistance, l = Length, r = Radius, n = Viscosity of fluid. 
The values of total lung resistance (RL) and dynamic compliance (Cdyn) are derived by fitting the equation 
of motion to measurements of flow, pressure and volume under the assumption the chest wall presents little 
mechanical load compared to the lung (Irvin et al., 2003): 
    ̇   
 
 
  Where P = Applied pressure, R = Lung resistance (RL),  ̇ = Flow of gas, C = 
Compliance (Cdyn), V = Lung volume relative to functional residual capacity. 
 
 
An increase in RL is generally believed to relate to changes in the conducting airways and alterations in the 
lung periphery such as heterogeneous closing of the small airways and physical properties of the lung 
parenchyma. Decreases in dynamic compliance reflect primarily peripheral events such as airway de-
recruitment (Irvin et al., 2003). 
Mice were laid supine and using blunt dissection techniques a tracheotomy was performed. The trachea was 
exposed, the ventral surface was sliced transversely and a cannula inserted and fixed in place with suture.  
After surgery, the mice were placed in a plethysmograph and the cannula was connected to a 4-way 
manifold with one port attached to a differential pressure transducer (± 20 cm H2O; Validyne Engineering, 
Northridge, CA) for the measurement of mouth pressure (Pao). Two ports were connected to the inspiratory 
and expiratory ports of a volume-cycled ventilator (SAR-830A, model 963217; CWE, Norfolk, United 
Kingdom). Mice were ventilated at 150 breaths per minute with a tidal volume of 0.15mL to 0.2mL and a 
positive-end expiratory pressure of 2.5cm H2O. 
Changes in flow were determined with a Fleish pneumotachograph (size, 00000) connected to a side port of 
the chamber and measured with a differential pressure transducer (± 2 cm H2O; model MP 45-14-871; 
Validyne Engineering). The flow was integrated to give a continuous recording of tidal volume. 
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Transpulmonary pressure was estimated as the difference between mouth pressure and the pressure 
measured at the proximal end of the pneumotachograph to the plethysmograph, inasmuch as the chest wall 
contributes little to the overall compliance of the respiratory system. Breath-by-breath recording of total 
lung resistance (RL; cmH2O/L/s) and dynamic compliance (Cdyn; ml/cmH2O) were calculated by an online 
respiratory analyser on a personal computer (Lung Function Recorder version 7; Mumed, London, United 
Kingdom), (Pitchford et al., 2004).  
 
4.2.3-1 A wiring diagram for the set up to measure lung function as described in the methods. The system 
takes advantage of the rise and fall of the rib cage to generate the positive and negative airflow signals. 
 
4.2.3.2 Measurement of AHR to methacholine 
AHR is determined in the clinic by a methacholine provocation test, administering increasing doses until a 
20% fall in FEV1 is achieved (Lotvall et al., 1998). A similar method has been adopted previously in 
murine models and used here where sensitivity is measured by the concentration of methacholine required 
to increase total lung resistance by 200% above saline induced levels (RL PC200). Additionally the 
provocation concentration to cause a 50% decrease in Cdyn (Cdyn PC50) was used as a measure for 
sensitivity to change in dynamic compliance. 
Aerosols of methacholine (1.56 – 25 mg/mL) were generated from an ultrasonic nebulizer (Aerocare) for a 
period of 8 seconds and administered directly to the lungs via the inspiratory port of the plethysmograph. 
RL was measured prior to administration of saline (0.9%) and following administration of saline or 
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methacholine. The maximum increase in RL to methacholine is expressed as a percentage of the values of 
RL obtained after saline challenge. The concentration of methacholine that induced a 200% increase in RL 
above postsaline RL was used as a measure of airway sensitivity (PC200) and maximum airway obstruction 
(Peak) was used as a measure of ‘reactivity’ (Pitchford et al., 2004). 
4.2.4 Cell counts 
Bronchoalveolar lavage (BAL) was performed by administering 0.5ml of phosphate buffered saline (PBS) 
via the cannula into the lung and then retrieving the fluid into the syringe. This was repeated twice more 
with all three samples being pooled and kept on ice for cell counts. 
4.2.4.1 Total cell count 
Harvested BAL fluid is added in a one to one ratio to Turk’s solution (a mixture of acetic acid and gentian 
violet) which lyses erythrocytes and stains leukocytes blue. The cells are then counted on a haemocytometer 
slide and multiplied by the two-fold dilution factor to give the total BAL cell count. 
4.2.4.2 Differential cell count 
The slides are prepared by adding 100μl of BAL fluid to a cytofunnel and spun onto a slide using a 
centrifuge set at 1000rpm for 1 minute. The slides are then stained by submerging them first in absolute 
methanol for 10 seconds, then in eosin and finally haemotoxin for 10 seconds each. Cover slips are added 
using DPX and the percentage of monocytes, neutrophils and eosinophils are calculated and combined with 
the total cell counts to give estimations of each cell type. 
4.2.5 Cytokine determination 
The concentration of cytokines within the BAL samples was determined by a multiplex fluorescent bead 
assay. The Luminex® bead assay works in a similar fashion to a combination of flow cytometry and 
sandwich ELISAs. Fluorescently dyed magnetic beads each with a distinct “spectral address” relevant to the 
analyte being measured were coated with a specific capture antibody. The assay can be multiplexed with 
detection of up to one hundred different molecules in a single well of a 96-well plate. The coupled beads 
bind with the sample containing all the biomarkers of interest and following a series of washes a 
biotinylated detection antibody was added to bind to the biomarker too. Streptavidin-phycoerythrin was 
finally added to serve as a fluorescent indicator. The beads were then classified to which biomarker they 
have a capture antibody against by using a red 635nm laser to illuminate the fluorescent dye. They were 
subsequently excited by a green 532nm laser to excite the phycoerythrin to generate a reporter signal of 
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which the mean fluorescence intensity is proportional to the amount of analyte bound. The system used in 
this thesis was from Millipore. 
4.2.6 Tissue homogenisation 
The anterior right lung lobe was tied off, removed and stored in at least 5 times the volume with one 
dimension <5mm in “RNAlater” for further analysis. The remaining lobes were stored either in 10% neutral 
buffered formalin (NBF) and used for histological staining. For the preliminary study lung and heart tissue 
were snap frozen in liquid nitrogen after removal. Tissue was subsequently pulverised while still frozen and 
added to 1ml working solution of lysis buffer and protease inhibitor. Due to the larger numbers involved in 
the main study heart and lung tissue was stored in RNA later at 4°C for 24 hours then frozen at -80°C. Once 
ready to be processed the tissue was thawed and added to 1ml working solution of lysis buffer, protease and 
phosphatase inhibitor as before and then lysed using the QIAgen TissueLyser II. Either way the 
homogenate was then centrifuged at 10,000g for 10 minutes at 4°C and supernatant removed, aliquoted and 
stored at -80°C for future analysis. Previous work has shown that this extraction technique can reduce the 
amount of protein phosphorylation detectable which should be taken into account when interpreting the 
results (Johnsen et al., 2010). 
4.2.7 Histology 
Lungs were stored in 10% NBF for at least one week prior to histological analysis. The lobes were cut 
along their lateral axis and set into Paraplast embedded blocks and sectioned into 4µm thick slices using a 
microtome. The sections were removed of any Paraplast and rehydrated by treatment with xylene and 
decreasing concentrations of ethanol. For each stain four mice per group were used and representative 
images were taken blindly and included.  
Hematoxylin and eosin (H&E) staining was used for general structure, Masson’s trichrome for smooth 
muscle and collagen and periodic acid shift (PAS) for goblet cells. For the H&E stain slides were immersed 
in hematoxylin for 2 minutes followed by eosin for 2 minutes, washed in tap water and dehydrated with 
increasing concentrations of ethanol and cleared with xylene. Cover slips were then added with DPX 
mounting solution. 
For the Masson’s trichrome staining samples were re-fixed in Bouin’s solution (75ml picric acid, 25ml of 
40% formaldehyde and 5ml of glacial acetic acid) to improve staining quality for one hour. Slides were then 
washed in tap water and stained in Weigert’s iron hematoxylin working solution for 10 minutes (equal parts 
solution A and B): 
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Weigert’s Iron Hematoxylin Solution: 
 Stock solution A: 
 Hematoxylin    1g 
 95% Alcohol    100ml 
 Stock solution B: 
 29% Ferric chloride in water  4ml 
 Distilled water    95ml 
 Hydrochloric acid, concentrated  1ml 
 
Slides were washed again in tap water and then distilled water and stained with Biebrich scarlet-acid 
fuchsin (Biebrich scarlet, 1% aqueous 90ml, acid fuchsin 1% aqueous 10ml and glacial acetic acid 1ml). 
Slides were washed again in distilled water and differentiated in in phosphomolybdic-phosphotungstic acid 
solution for 10-15 minutes or until the collagen is no longer red. The slides are transferred directly to 
aniline blue solution and stained for 5-10 minutes, rinsed briefly in distilled water and differentiated in 1% 
acetic acid solution for 2-5 minutes. They are finally dehydrated as before and cover slips mounted with 
DPX. 
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4.3 Results 
4.3.1 Characterisation of mice 
 Wild type/Sham SERCA2
+/-
/Sham Wild type/OVA SERCA2
+/-
/OVA 
 M F M F M F M F 
Age 
(Days) 
89.1±7.4 89.1±7.4 89.1±7.4 89.1±7.4 89.1±7.4 105.1±6.5 89.1±7.4 89.1±7.4 
Weight 
(g) 
30.4±1.1 25.9±0.9 31.3±0.9 25.8±1.0 32.8±1.0 26.5±1.1 32.0±0.9 25.4±0.9 
Baseline RL 
(cmH20/s/L) 
1566±199 1785±172 2032±159 1727±174 1621±186 1724±201 1664±172 1959±175 
Baseline Cdyn 
(ml/cmH20) 
0.035±0.003 0.04±0.002 0.041±0.002 0.043±0.003 0.038±0.003 0.039±0.003 0.04±0.002 0.039±0.003 
Table 4.3.1-1 A characterisation of the mice used in the following chapter, sub-divided into their experimental groups and analysed by a three way ANOVA with a Sidak post-hoc 
analysis to see if they differed prior to experimentation. 
 
There were no significant differences in age between the groups. 
There was a significant difference of 5.74 ± 0.73g between the weights of male and female mice used in this chapter (p<0.001). 
There were no significant differences in baseline RL between the groups. 
There were no significant differences in baseline Cdyn between the groups. 
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4.3.2 Expression of calcium handling proteins in lung homogenate 
Following genotyping as described in 4.2.1 it was important to establish whether the disruption of one of 
the Atp2a2 genes was enough to reduce protein expression in the lung as shown by Periasamy et al., 1999 
in the heart. The knockout of one allele was enough to significantly reduce SERCA2 protein expression in 
whole lung homogenate (Fig. 4.3.2-1). The reduction in SERCA2 protein expression in both the sham 
mice (0.80±0.27 compared to 0.46±0.13) and ovalbumin immunised mice (2.76±1.15 compared to 
2.03±0.87) was similar to previously published results. A two way ANOVA showed that genotype 
significantly affected expression (p=0.03) however immunisation did not (p=0.13) and there was no 
interaction (p=0.34). 
 
4.3.2-1 SERCA2 protein expression levels compared to GAPDH. Lanes from left to right indicate wild 
type/sham, Atp2a2
+/-
/sham, wild type/OVA and Atp2a2
+/-
/OVA. Bars represent mean±SEM, n=4. 
 
The expression level of TRPC3 and TRPC6 could not be successfully quantified because of the lack of 
sensitivity/specificity of the commercially available antibodies used. 
4.3.3 Effect of ovalbumin immunisation on inflammatory cells 
The extent of inflammatory cell infiltration into the lung was quantified in bronchoalveolar lavage fluid 
and subsequent enumeration using differential cell staining as described in section 4.2.4. The two 
questions being addressed were; did the immunisation increase the inflammatory infiltrate and did the 
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independent variables impacted each cellular infiltrate endpoint. The immunisation status of the mice 
significantly affected the recruitment of the total cell count (p<0.0001), macrophages (p=0.01), neutrophils 
(p=0.004) and eosinophils (p<0.0001) (Fig. 4.3.3-1). As each inflammatory cell type tested was 
significantly enhanced in the airways of ovalbumin immunised mice it is clear the model was successful. 
The second independent variable being tested was the genotype of the mice and this had no significant 
effect on any of the four dependent variables tested; total cells (p=0.95), macrophages (p=0.58), 
neutrophils (p=0.14) and eosinophils (p=0.85). A trend was observed for increased neutrophil recruitment 
in SERCA2
+/-
 mice compared to the wild type mice however no interaction was observed (p=0.82).  
 
4.3.3-1 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge A) total inflammatory cells, 
B) macrophages, C) neutrophils and D) eosinophils were assessed in the BAL fluid. Data represents mean 
± SEM of n=22-28 per group. No pattern bars represent wild type mice, chequered bars represent 
SERCA2
+/-
 mice, white bars were immunised with the sham control and grey bars with ovalbumin. A two 
way ANOVA was performed with a Sidak post hoc analysis. The P values illustrated represent the main 
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The total protein concentration in the BAL was used as an indication of plasma protein extravasation and 
oedema in the airways. Immunisation with ovalbumin resulted in a significant increase in plasma 
extravasation in both the wild type and SERCA2
+/-
 mice (p=0.002 and respectively p<0.001, Fig. 4.3.3-2). 
A two way ANOVA showed a significant difference in mean values between immunisation status 
(p<0.001) but not genotype (p=0.59) with no significant interaction. 
 
4.3.3-2 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge total protein levels were 
assessed in the BAL fluid. Data represents mean ± SEM of n=13-16 per group. No pattern bars represent 
wild type mice, chequered bars represent SERCA2
+/-
 mice, white bars were immunised with the sham 
control and grey bars with ovalbumin. A two way ANOVA was performed with a Sidak post hoc analysis. 
The P values illustrated represent the main effect of immunisation. 
 
4.3.4 Effect of ovalbumin immunisation on H&E staining 
To determine whether the cellular inflammatory response of the airways as shown by cells recovered from 
the BAL (above) was comparable to that in the surrounding lung parenchyma, tissue sections were taken 
and stained with H&E. The stain gives a good structural overview as the haematoxylin gives nuclear 
definition with a deep blue and the eosin provides a contrasting red counter-stain (Fig. 4.3.4-1). 
Reflective of the infiltrate in the airways following challenge to ovalbumin, there was also a large increase 
of inflammatory cells in the surrounding parenchyma. A notable increase of polymorphonuclear 
leukocytes was also observed in the sham/SERCA2
+/-
 mice compared to the sham/wild type which was 











































4.3.4-1 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge lungs were removed and 
preserved in 10% formalin and 4µm paraffin embedded tissue sections were stained using H&E staining. 
Images are representative of their respective groups taken blindly from a sample of four mice per group on 
a x20 objective. 
 
4.3.5 Effect of ovalbumin immunisation on smooth muscle and collagen deposition 
Masson’s trichrome stain was used to stain collagen (blue), smooth muscle (red) and nuclei (black) in the 
lung segments (Fig. 4.3.5-1). ASM was present in equal abundance surrounding the airways in all four 
treatment groups and in a similar morphology showing no signs of hyperplasia, thickening or migration. 
Levels of collagen also appeared to be unchanged by both immunisation status and genotype. 
Polymorphonuclear leukocyte infiltration 
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4.3.5-1: Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge lungs were removed and 
preserved in 10% formalin and 4µm paraffin embedded tissue sections were stained using Masson’s 
trichrome for collagen. Images are representative of their respective groups taken blindly from a sample of 
four mice per group on a x20 objective. 
 
4.3.6 Effect of ovalbumin immunisation on cytokine levels in the BAL 
A luminex bead assay was performed measuring six proteins; KC, IL-13, eotaxin-1, IL-17, TNF-α and 
MIP-1α. The assay detected concentrations from 3.2 pg.ml-, this level of detection was not achieved for 
the mean data for any of the groups measuring IL-17, TNF-α or IL-13 (Fig. 4.3.6-1). 
There was a significant increase in the levels of KC, eotaxin-1 and MIP-1α following allergen challenge in 
the immunised mice (p<0.001, p<0.001 and p=0.02 respectively). Genotype only significantly impacted 
the levels of KC in the BAL (p=0.008) where an interaction was also observed between it and the 
immunisation status (p=0.02) which was further highlighted by the Sidak post-hoc test. The reduced 
SERCA2 expression in the knockout mice further enhanced the raised KC levels following immunisation 
(p<0.001). Eotaxin-1, akin to the eosinophil data observed no genotype affect (p=0.92).  
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4.3.6-1 Sham mice were immunised with 0.4ml saline and aluminium hydroxide once a week for four 
weeks then challenged to 3% ovalbumin twice a day for four days. Twenty-four hours post final challenge 
levels of cytokines were assessed in the BAL fluid. Data represents mean ± SEM of n=15-16. No pattern 
bars represent wild type mice, chequered bars represent SERCA2
+/-
 mice, white bars were immunised with 
the sham control and grey bars with ovalbumin. A two way ANOVA was performed with a Sidak post hoc 
analysis; *p<0.05, **p<0.01, ***p<0.001. 
 
4.3.7 Effect of ovalbumin immunisation on lung function parameters 
Wild type and SERCA2
+/-
 mice both exhibited concentration dependent increases in total lung resistance 
following methacholine administration (Fig. 4.3.7-1, upper graph). Immunisation with ovalbumin 
significantly enhanced the percentage increase in total lung resistance above basal levels at 3.12 mg/ml 
and 12.5 mg/ml methacholine, (p=0.05 and p<0.001 respectively) in the SERCA2
+/-
 mice but not the wild 
type mice.  
Dynamic compliance (Cdyn) was dose dependently decreased by methacholine in all four groups (Fig. 
4.3.7-1, lower graph). Immunisation with ovalbumin significantly reduced Cdyn in the wild type mice 
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of BHR in wild type immunised mice following antigen challenge. The effect of immunisation was only 
subtly enhanced in the knockout mice with a significant reduction at 3.12 mg/ml methacholine (p<0.001). 
 
 
4.3.7-1 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge airway resistance (RL, upper 
graph) and dynamic compliance (Cdyn, lower graph) were measured. Data represents mean ± SEM of 
n=19-24 per group. Data analysed by repeated measures two-way ANOVA; **p<0.01 WT/sham vs 
WT/OVA and #p<0.05, ###p<0.001 KO/sham vs KO/OVA. 
 
The RL PC200 is the concentration of methacholine required to increase airway resistance 200% above 
the saline induced baseline level. A two way ANOVA with genotype and immunisation as the fixed 
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not between genotypes or an interaction between the two (p=0.42 and p=0.47 respectively). Following 
sensitisation with ovalbumin there was an increase in sensitivity to methacholine in both the wild type and 
knockout mice. The SERCA2
+/-
 mice, following immunisation, exhibited a significantly enhanced 
sensitivity to methacholine increasing their airway resistance whereas the wild type mice did not (p=0.006 
and p=0.11 by Sidak post-test respectively, Fig. 4.3.7-2, upper). 
Dynamic compliance was similarly affected by immunisation to ovalbumin as analysed by two way 
ANOVA, showing an increased sensitivity demonstrated by a lower concentration of methacholine 
required to decrease compliance by 50% from baseline (Cdyn PC50, p=0.0002, Fig. 4.3.7-2, lower). 
Genotype however did not affect the result (p=0.30) and there was no interaction with immunisation status 
(p=0.74). Contrary to airway resistance however there appeared to be no difference between the changes 
in sensitivity between the wild type mice and the SERCA2
+/-
 mice following immunisation.  
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4.3.7-2 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge airway resistance was 
derived from analysing changes in flow using a pneumotachograph. Data represents mean ± SEM of 
n=19-24 per group. A two way ANOVA was performed with a Sidak post hoc analysis **p<0.01. 
 
4.3.8 The impact of gender and immunisation on heterozygous SERCA2+/- mice 
It has been shown previously that gender can affect the asthmatic phenotype (Choi, 2011; Melgert et al., 
2005). Therefore the data was analysed for gender differences for the different variables measured. 
4.3.8.1 Impact of gender on neutrophil infiltration into the airways 
An interesting dichotomy appeared when reanalysing the cellular recruitment to the lungs after analysing 
for gender and analysing by three way ANOVA with a Sidak post-test. Immunisation significantly 
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shown with the combined data in Fig. 4.3.3-1 a reduction of SERCA2 in the knockout mice led to a trend 
of enhanced neutrophilia in the sham immunised mice. Following ovalbumin immunisation, there was no 
significant change between the wild type and knockout female mice (p=0.12). On the other hand there was 
significantly more neutrophils in the BAL of male knockout ovalbumin immunised mice compared to their 









p=0.004, Fig. 4.3.8-1 below). The enhanced neutrophilia in the knockout ovalbumin immunised mice is 
also shown by significant increase compared to the sham knockouts (p<0.001), the immunisation effect 
was not significant in the wild types (p=0.259). Immunisation status significantly affected eosinophil 
recruitment (p<0.001) while contrary to the neutrophil data gender and genotype did not have an impact 
(p=0.34 and p=0.87 respectively). 
 
 
4.3.8-1 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge neutrophil (A+B) and 
eosinophil (C+D) levels were assessed in the BAL fluid (A+C) males and (B+D) females. Data represents 
mean ± SEM of n=9-15 per group. No pattern bars represent wild type mice, chequered bars represent 
SERCA2
+/-
 mice, white bars were immunised with the sham control and grey bars with ovalbumin. 
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Analysis of the total protein concentration within the airways by three way ANOVA revealed a significant 
immunisation effect (p<0.001) but no significant gender or genotype differences (p=0.98 and p=0.55 
respectively, Fig. 4.3.8-2). The only disparity  between the genders was the more variable increase in total 
protein in the male mice compared to the females following ovalbumin immunisation compared to sham. 
Neither wild type nor knockout male OVA immunised mice had significantly greater total protein levels in 
the BAL fluid compared to their sham controls however the female mice did (p=0.009 and p=0.004 
respectively). Four of the samples from the male groups were contaminated with blood leading to very 
high protein levels being recorded which were omitted from analysis. The repeats in this group therefore 
dropped from eight to six resulting in less power (0.987 females, 0.567 males) in the statistical test and a 
higher chance of a false-negative outcome i.e. a type two error. 
 
  
4.3.8-2 Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge total protein levels were 
assessed in the BAL fluid. Data represents mean ± SEM of n=6-8 per group in duplicates. No pattern bars 
represent wild type mice, chequered bars represent SERCA2
+/-
 mice, white bars were immunised with the 
sham control and grey bars with ovalbumin. Data analysed as a three way ANOVA with genotype and 
immunisation as the fixed effects and a Sidak post-hoc analysis. 
 
4.3.8.2 Impact of gender on cytokine recruitment to the airways 
KC is one of the major chemokines for neutrophil recruitment into the lungs and their presence in the male 
mice airways reflected this. Akin to the neutrophils there was a significant interaction between 
immunisation status and genotype (p=0.018, Fig. 4.3.8-3). A post-hoc test showed a significant 
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Further following the pattern of the male neutrophilia data a significant difference existed between the 
wild type OVA sensitised mice and the knockout OVA sensitised mice (p=0.003). 
Regarding eotaxin-1 presence in the airways there was a significant immunisation and gender effect 
(p<0.001 and p=0.01 respectively) but no genotype effect. The male ovalbumin immunised mice displayed 
enhanced eotaxin-1 levels within the BAL fluid compared to the females. Several sham immunised groups 
fell below the detection limit for MIP-1α expression therefore comparisons should be made with caution. 
That said, the female mice exhibited an immunisation effect (p=0.004), whereas the male mice did not. 




4.3.8-3 Sham mice were immunised with 0.4ml saline and aluminium hydroxide once a week for four 
weeks then challenged to 3% ovalbumin twice a day for four days. Twenty-four hours post final challenge 
levels of cytokines were assessed in the BAL fluid. Data represents mean ± SEM of n=7-8. No pattern 
bars represent wild type mice, chequered bars represent SERCA2
+/-
 mice, white bars were immunised with 
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4.3.8.3 Impact of gender on airway resistance 
The larger impact of genotype on the male mice present in the neutrophil recruitment to the BAL fluid was 
also present in lung function parameters measured (Fig. 4.3.8-4). The male knockout mice were the most 
affected in terms of airways sensitivity to methacholine as measured by Cdyn PC50 and RL PC200. A 
three way ANOVA was performed with gender, genotype and immunisation status as the fixed effects and 
a blocking factor to control for variability between different experimental days. A significant gender 
(p=0.003) and immunisation effect (p=0.005) was observed. Sidak post-hoc analysis revealed a significant 
difference between male knockout sham and OVA immunised groups (p=0.023). 
A three way ANOVA performed on the Cdyn Log PC50 data showed a significant gender (p=0.002), 
immunisation (p=0.0001) and some gender genotype interaction (p=0.061). A Sidak post-hoc analysis 
revealed significant differences in the female wild type and knockout, sham versus ovalbumin (p=0.001 
and p=0.01 respectively). There were no such differences observed in the male mice between 
immunisation status in either the wild type (p=0.193) or knockout (p=0.086). The sham treated male 
knockout mice had a lower Cdyn PC50 compared to their wild type counter parts suggesting an inherent 
sensitivity which was further enhanced after ovalbumin immunisation. 
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4.3.8-4: Mice were immunised with 30µg ovalbumin once a week for four weeks then challenged to 3% 
ovalbumin twice a day for four days. Twenty-four hours post final challenge log RLPC200 (upper) and log 
Cdyn PC50 (lower) were derived from analysing changes in flow using a pneumotachograph. Data 
represents mean ± SEM of n=8-13 per group. *p<0.05, **p<0.01, ***p<0.001. Data was analysed by three 
way ANOVA with gender, genotype and immunisation as the fixed effects and a Sidak post-hoc analysis. 
 
4.3.9 Myography 
Airway sensitivity and reactivity between the wild type and knockout mice were measured ex vivo by wire 
myography in response to the muscarinic acetylcholine receptor agonist carbachol (Fig. 4.3.9-1). 
Intrapulmonary sections of primary bronchioles were dissected from wild type and SERCA2
+/-
 naive mice. 
The sections were then mounted on a myograph and challenged with 80mM K
+
 three times. Rising 
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80mM K
+
 response. Data represents mean ± SEM, n=5. There was no change in EC50 between wild type 
and knockout mice 276 nM (95% CI: 200-381)  and 270 nM (95% CI: 190-384) respectively (p=0.97 
analysing logEC50 by t-test). There was also no change in the maximum response between the wild types 
(139 ± 8.7 and 130 ± 8.8 % of high K
+
 respectively, p=0.74 by t-test). The 1μM carbachol dose was 
repeated in calcium ion free extracellular solution to isolate the store release component of calcium 
mobilisation. Genotype did not affect the subsequent contraction. 
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4.3.9-1 Intrapulmonary sections of primary bronchioles were dissected from wild type and SERCA2
+/-
 
naive mice. The sections were then mounted on a myograph and challenged with 80mM K
+
 three times. 
Rising carbachol concentrations were added to make a response curve with peak tensions normalised to 
the final 80mM K
+
 response. Data represents mean ± SEM, n=5, grey bars represent knockout mice. 
Student’s t-test was performed to analyse difference between means following 1μM carbachol in the 
presence (left) or absence (right) of Ca
2+
 in the Kreb’s solution (lower graph).  
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4.4 Discussion 
The results outlined in this chapter reveal a subtle role for SERCA2 in this in vivo model of asthma. There 
is an increased neutrophilia in the naive knockout mice compared to the wild types which is greatly 
enhanced only in the males following sensitisation and challenge to ovalbumin. The presence of KC in the 
airways is reflective of this and is also elevated in the male mice with reduced SERCA2 expression. A 
concomitant subtle increase in sensitivity to methacholine was observed in allergic mice that was again 
greatest in male SERCA2 knockout mice.  
Initially it was confirmed the knockout mice had a reduced protein expression of SERCA2 in the 
homogenised lungs as had been shown previously in the heart (Periasamy et al., 1999). Interestingly it 
appeared as if immunisation with ovalbumin also increased SERCA2 expression however this was not 
significant.  
4.4.1 Inflammatory cell infiltrate 
Immunisation with ovalbumin in the wild type mice resulted in a robust, significant increase in the total 
cell infiltrate and each of the three leukocytes measured within the BAL. Although this allergic model has 
been very well established previously (DiGiovanni et al., 2009; Fernandez-Rodriguez et al., 2010; Reddy 
et al., 2012) no work had been performed on the Black Swiss 129/SVJ mixed strain. Therefore a window 
had to be established to investigate the potential effect of genotype which was achieved in the 
corresponding preliminary work (Ojo, 2011). 
No genotype immunisation status interaction was observed in the recruitment of eosinophils into the 
airways contrary to the hypothesis derived from the in vitro data involving the chemotactic agent eotaxin-1 
(Mahn et al., 2009). In that publication a reduction of SERCA2 expression lead to an increase in eotaxin-1 
following IL-13 stimulation. Following ovalbumin challenge in both genotype groups there was a two fold 
increase in total protein in the airways of which approximately 70% of the leukocytes were eosinophils. 
Such a large, possibly saturating response may have masked any genotype differences in both the 
eosinophilia and total protein end-points. A milder immunisation and challenge protocol was tested in the 
preliminary run but no significant change in leukocyte recruitment or airway function was observed. 
Further characterisation work is required to optimise the response in this mouse strain. It is possible that 
the less than 50% reduction in SERCA2 protein expression observed in these mice was not sufficient to 
influence cell recruitment and cytokine release in the pooled data of this model of allergic inflammation.  
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Neutrophil recruitment was elevated following immunisation in both the wild type and knockout mice 
compared to the sham groups. A subtle elevation was also apparent in the knockout mice compared to the 
wild types however the genotype did not affect the result (p=0.14), nor was there an interaction with the 
immunisation status. In a subset of severe asthmatic patients the airway remodelling observed has been 
linked with a neutrophilic inflammation (Gupta et al., 2010; Wenzel et al., 1999). The increase in 
neutrophilia recovered from the airways in the BAL is reflected by elevated levels of polymorphonuclear 
leukocytes in the surrounding lung parenchyma demonstrated by the H&E staining. The lack of observed 
genotype impact on the BAL fluid cell data could be because of the sampling technique used. Cells were 
stained using haematoxylin and eosin and differentiated by eye-sight. Although this method is 
reproducible with a trained eye a further quantification using a neutrophil specific stain such as neutrophil 
elastase, followed by blind quantification would provide a more robust analysis. 
It is interesting that there appears to be a subtle increase in neutrophilia in the sham immunised knockout 
mice, thus suggesting that it is purely a result of the reduced SERCA2 expression. As the knockouts are 
global and every cell type will have a reduced expression it is impossible to know what specifically is 
driving the infiltration. If the inflammation present in the parenchyma is neutrophilic it is possible that the 
ASM cells are contributing more KC (John et al., 1998; Pang et al., 1998), a neutrophil chemotactic as a 
result of reduced SERCA2. Equally the reduction in SERCA2 could lead to the neutrophils themselves 
have a higher propensity for migration or enhanced KC release from the epithelium or inflammatory cells. 
It has been shown that in mice neutrophil chemotaxis mediated by CXCR2 (KC is a ligand for) is in part 
dependent upon TRPC6 expression (Lindemann et al., 2013). It is plausible TRPC6 is increased in the 
SERCA2 knockout mice or the enhanced chemotaxis is a more general result of altered calcium handling 
affecting downstream mediators such as AKT or MAPK. Using a conditional SERCA2 (flox) allele to 
specifically knockdown expression in ASM or elsewhere would help to answer this question (Andersson 
et al., 2009). The inducible nature of the knockdown would also circumnavigate the problem of other 
calcium handling proteins such as TRP channels and the sodium/calcium exchanger compensating for 
reduced SERCA2 expression from birth, thus masking potential effects. Reducing SERCA2 in vitro using 
siRNA and stimulating with a KC inducing agent such as IL-1β in ASM could also shed light on the 
neutrophilia observed. 
4.4.2 Chronic ovalbumin challenge 
Chronic models have been developed to look at airway wall remodelling which can manifest itself early in 
a patient’s life (Barbato et al., 2006) and plays an important role in the pathophysiology of the disease. It 
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is classified as an increase in airway wall thickness, comprised of collagen deposition, goblet cell 
hyperplasia, myofibroblast hyperplasia and epithelial hypertrophy (Busse et al., 1999; Knight, 2001). Both 
ovalbumin (McMillan et al., 2004) and house dust mite (Johnson et al., 2004a) can be used to investigate 
this aspect of the disease. 
As hypothesised, using a model of acute asthma resulted in no treatment effect on airway remodelling as 
observed by collagen and ASM deposition. A chronic model to induce airway remodelling would have 
been very interesting to use with these mice as it resembles the clinical features of asthma more readily as 
well as providing a more accurate tool for testing drug effectiveness (Evans et al., 2012). Unfortunately 
due to problems in the animal house severe delays were incurred on the in vivo aspect of the investigation, 
resulting in time for only the acute asthma model to be used. 
The enhanced ASM proliferation observed in vitro when SERCA2 protein expression is diminished using 
siRNA (Mahn et al., 2009) provides rationale that remodelling would be enhanced in this model after 
chronic allergen exposure. I hypothesised that in the sham SERCA2
+/-
 mice there would be pulmonary 
morphological changes compared to the wild type mice as a result of reduced SERCA2 expression from 
birth. There appeared to be no difference in the smooth muscle layer between the two groups disproving 
the hypothesis. Perhaps due to compensatory mechanisms as mentioned previously ensuring that the 
dynamics of calcium handling remains reasonably unaltered in spite of the reduced expression. Culturing 
the smooth muscle cells from the knockout mice and measuring calcium transients with fura would show 
to what extent the homeostasis is altered. 
4.4.3 Cytokine data 
Interestingly no IL-17, TNF-α or IL-13 was detectable in the BAL fluid in any of the groups contrary to 
the rise often seen following ovalbumin sensitisation and challenge (Asano et al., 2010; Li et al., 2012; 
Melgert et al., 2005; Quan et al., 2012; Xu et al., 1997). None of these previous publications used the 
129SVJ/Black Swiss mice used in the present study and therefore the lack of response may be due to 
genetic variation within the strain. It could also be due to a suboptimal time point being used to sample the 
inflammatory cytokines. The articles previously stated all sacrificed the mice 24 hours after the final 
challenge, similar to as performed here so it is unlikely to be the case but this would need to be 
investigated in this particular strain. High IL-17A concentrations have been observed in severe asthmatics 
with high IL-8 and neutrophilia and it has been suggested that TH17 cells contribute to this (Bullens et al., 
2006). As the current model supports a severe asthmatic phenotype with enhanced neutrophilia it is 
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therefore surprising IL-17 levels were not detectable within the BAL fluid however this may again be a 
strain dependent effect. C3H mice produce very little IL-17A in response to allergen challenge whereas 
A/J mice are much more susceptible (Lajoie et al., 2010). 
The levels of the chemokines, eotaxin-1 and KC present in the murine airways were consistent with the 
pulmonary recruitment of eosinophils and neutrophils respectively. As with the eosinophils there was a 
possibly saturating recruitment of eotaxin-1 observed following ovalbumin sensitisation and challenge. 
Any putative “left-ward shift” in the dose response curve would be unobserved as maximal levels of 
recruitment are being achieved in both genotypes. ASM cells derived from healthy patients which had 
SERCA2 protein expression reduced to similar levels as observed in these knockout mice exhibited 
enhanced eotaxin-1 production upon IL-13 stimulation (Mahn et al., 2009). The fact that no additional 
eotaxin-1 was present in the naive SERCA2
+/-
 mice compared to the wild type could be explained by the 
lack of detectable IL-13 in the airways.  
Unlike the neutrophil data analysed from the BAL, a genotype effect and interaction with immunisation 
was picked up in the KC protein levels measured by luminex bead assay (p=0.02). The technique is a more 
powerful analysis and the finding further backs up the previous point raised that a type 2 error may have 
occurred and that a genotype immunisation interaction does exist in the neutrophil recruitment. The 
enhanced KC production in the OVA/KO group compared to the OVA/wild type group (p<0.001) is a very 
interesting finding and indicates a role for calcium homeostasis controlling the secretion of KC into the 
airways which may be altering neutrophil recruitment into the lungs. 
Macrophage inflammatory protein-1α (MIP-1α/CCL3) was barely detectable in the BAL fluid but did 
appear to be elevated following immunisation however due to most of the data being below the detection 
limits of the assay steadfast conclusions cannot be drawn. It has been shown before that it is increased 
following ovalbumin sensitisation and challenge however the levels obtained in this study were markedly 
lower (Li et al., 2004). It can be produced by most mature hematopoietic cells such as neutrophils, 
dendritic cells, mast cells and T and B cells and act on its CCR1 receptor to aid the chemotaxis of 
monocytes, T-cells, neutrophils and eosinophils (Maurer et al., 2004). MIP-1α production usually requires 
activation from cytokines such as TNF-α so the low levels may be a result of reduced TNF-α present as 
none was detectable in the BAL, possibly as a strain dependent genetic effect of the mice used. 
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4.4.4 Lung function 
Ovalbumin immunised and challenged mice demonstrated a trend towards increased airways 
responsiveness to methacholine as determined by changes in total lung resistance and dynamic 
compliance, however significance was only achieved in a few parameters tested. Airway responsiveness to 
methacholine (as expressed as % change in total lung resistance) was significantly elevated following 
ovalbumin immunisation in the SERCA2
+/-
 mice but not in the wild types. Reflective of this the knockout 
mice displayed an increased sensitivity to methacholine shown by the significant decrease in RL PC200 
(p<0.05 Fig. 4.3.8-4). It is difficult to determine whether airway hyper-responsiveness occurs through 
inherent changes in the ASM manifested as enhanced sensitivity to spasmogens or via alterations in the 
pulmonary environment (e.g. mucus secretion, oedema, loss in airway surface tension, inflammation). A 
study using tracheal preparations from ovalbumin sensitised mice and a variety of agonists suggested that 
AHR involves specific changes in the muscarinic pathway in ASM, possibly at the coupling to contractile 
machinery (Fernandez-Rodriguez et al., 2010). Only methacholine, a muscarinic acetylcholine receptor 
agonist was used, so the AHR observed after ovalbumin sensitisation fits with this work. As knockdown 
of SERCA2 would result in changes downstream to the receptor the observed sensitivity should remain 
after stimulation to an array of contractile agonists. 
A greater genotype difference in methacholine responsiveness as measured by changes in total lung 
resistance was observed compared with changes in  dynamic compliance suggesting that the effect was 
primarily in the proximal airways (Irvin et al., 2003). It is thought that this is a result of airway narrowing 
whereas Cdyn is more influenced by the elastic recoil of the lungs (Takeda et al., 2001). One might expect 
that using the chronic model would result in a larger decrease in dynamic compliance as more remodelling 
occurs which could primarily affect the smaller airways. 
4.4.5 Effect of gender 
Another important genetic variation in asthma is the effect gender plays on its pathogenesis. It is well 
described that boys have a higher incidence of asthma than girls however around adolescence and puberty 
the pattern is reversed and females have the higher incidence (Choi, 2011). It has been hypothesised that 
this occurs because of slower pulmonary development in males, sex hormones, as those from males have 
been shown to suppress asthma whereas female sex hormones aggravate it and perhaps gender specific 
environmental exposures (Almqvist et al., 2008; Osman, 2003). The mice used in this study were on 
average 90 days old at the time of experimentation. Male mice typically reach puberty at seven weeks and 
 - 142 - 
females at six weeks therefore the mice used in this study were into their adult life. The murine oestrous 
cycle lasts between 4-5 days therefore litter matching between groups was important to reduce variation. 
Contrary to the evidence in human asthma it was the male knockout mice in this particular strain which 
demonstrated the more overt asthmatic phenotype. In the ovalbumin sensitised male mice the knockouts 
had a significantly greater KC and neutrophil infiltration into the airways and a much higher sensitivity to 
methacholine increasing airway resistance and decreasing dynamic compliance. Genotype and gender on 
the other hand had no impact on eosinophil recruitment however there was a gender-immunisation 
interaction regarding eotaxin-1 but no association with the genotype. Thus suggesting the enhanced effect 
of reduced SERCA2 expression was a neutrophil specific phenomenon. Additionally the naive male 
knockout mice had a significantly lower Cdyn PC50. The data partly fits in with previous data published 
using a similar protocol investigating sex differences in BALB/c mice (Melgert et al., 2005). The paper 
concludes that female mice are more susceptible to inflammation however the male mice are more 
sensitive to methacholine measured by a decreased PC300 Penh value. In a study using gonadectomised 
male rats a decrease in Ca
2+
 transient amplitude and a prolonged decay rate was observed in 
cardiomyocytes which was restored with testosterone replacement therapy (Curl et al., 2009). It was 
suggested that this could be due to a decrease in SERCA2 expression or function in which case you might 
expect female SERCA2 knockout mice to have even less SERCA2 function manifested as an enhanced 
phenotype in this model which wasn’t the case. It has been shown that the amount of α-SMA is similar in 
male and female mice and there is no interaction between gender and immunisation ruling out the 
possibility of the knockout exerting a greater effect in the males due to a larger ASM volume (Blacquiere 
et al., 2010).  
4.4.6 Ex vivo contractile response 
A concentration response curve was performed using myography on naive mice to directly assess the 
contractility of primary bronchioles from wild type and SERCA2
+/-
 mice. Male mice were used as the 
greatest in vivo differences were observed with them however no change in EC50 or maximum response 
occurred. A sub-maximal dose of carbachol was used in the absence of calcium to negate any calcium 
entry and just assess store content which could be lowered in the knockout mice but again there was no 
difference. Although SERCA2 protein expression has been reduced in the knockout mice, from the data in 
this chapter it is impossible to know how much the calcium handling dynamics have been altered. 
Furthermore, a reduced SERCA2 expression and subsequent calcium ion reuptake into the sarcoplasmic 
reticulum by no means guarantees enhanced contraction. The sarcoplasmic reticulum forms a superficial 
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barrier which divides the cytosol into functionally distinct spaces (Janssen et al., 1999). It is changes in 
Ca
2+
 in the deep cytosol and not subsarcolemmal spaces which are more correlated with contraction. Using 
CPA, a SERCA2 antagonist elevated Ca
2+
 in the deep cytosol resulting in contraction but no change in 
membrane currents (Janssen et al., 1999). The SERCA2 knockout mice would be expected to behave in a 
similar fashion. However without knowing the full protein expression changes which may compensate for 
this loss the actual alterations in calcium handling could be more pronounced near the plasma membrane. 
4.4.7 Caveats 
A major drawback to this study and every one like it are that significant differences exist between murine 
and hominine immune system development and activation (Mestas et al., 2004). Additionally the 
pulmonary physiology of mice are vastly different to that in humans primarily due to their differing 
anatomy (Metzger et al., 2008). Therefore any conclusions made cannot be simply assumed to occur in 
humans however with the complementary in vitro data collected from primary cultured human ASM cells 
an overall picture is starting to be built. Furthermore this model is only looking at the contribution of 
SERCA2 in an allergen-induced model of asthma, chosen because of the strong associations with specific 
IgE reactions and hypersensitivity to aeroallergens (Burrows et al., 1989). There are arguments however, 
that atopy is a secondary consequence to asthma, therefore the current model lacks gaining insight into the 
role of SERCA2 into other potential “drivers of susceptibility” (Burrows et al., 1995; Martinez et al., 
2013). 
A second caveat is that the knockdown of SERCA2 was across the whole body and from birth. The in 
vitro data collected focuses upon the impact of reduced SERCA2 expression in ASM only and the impact 
that has on calcium homeostasis and the development of an asthmatic phenotype. The data presented in 
this chapter backs up the hypothesis that a reduction of SERCA2 can enhance many phenotypes associated 
with asthma however it can’t determine how responsible the ASM is for this and to what degree calcium 
homeostasis is perturbed in it. The fact that the reduction occurs throughout the organism’s life span 
allows other calcium handling proteins to potentially change their activity to mitigate the loss of function. 
Work has not been done to see whether SERCA2 reduction precedes the development of asthma but this 
would be an invaluable addition to the field. 
The strain used is also unfortunate as it isn’t particularly responsive to this model compared to C57/BL6 
and BALB/c mice. As discussed before a more pressing drawback is the discrepancy between all murine 
models and the human clinical setting. So the work here, although might not be as striking as would be 
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seen in C57/BL6 mice, provides evidence that SERCA2 disruption can enhance the asthmatic phenotype 
in vivo. 
4.4.8 Future studies 
 Culturing the ASM cells derived from the knockout mice and measuring changes in intracellular 
calcium concentration in response to several agonists to determine the extent calcium handling is 
altered. 
 A chronic ovalbumin challenge protocol to understand the role calcium homeostasis plays in 
airway remodelling in vivo. 
4.4.9 Conclusion 
In conclusion this chapter demonstrates that reduced SERCA2 expression enhances neutrophilia, airway 
resistance and decreases dynamic compliance primarily in male mice. The results are largely in line with 
the hypothesis however none of the changes were as dramatic as expected. Using a chronic model to drive 
airway remodelling is likely to show a greater impact of disrupted calcium handling as the previous in 
vitro data suggests enhanced proliferation and cell spreading (Mahn et al., 2009). 
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Chapter 5 The effect of β-adrenergic agonists on ASM calcium 
homeostasis 
5.1 Introduction 
5.1.1 β2-adrenergic receptor agonists in asthma 
β2-adrenergic receptor (β2-AR) agonists form a vital part of treatment for the majority of asthmatics, as 
they offer a quick onset of action in relaxing ASM and have a good safety profile. These agonists shift the 
equilibrium of the β2-AR in favour of its activated form from its resting inactive state thereby increasing 
the number of receptors associated with the Gs protein and GTP (Johnson, 2001). Receptor activation 
results in numerous downstream signalling events, most importantly an adenylyl cyclase mediated 
increase in cAMP, followed by activation of PKA and muscle relaxation. 
As the first generation of these drugs, including salbutamol, have a maximum duration of action of only 
four hours, long acting β2-AR agonists (LABAs) were developed particularly for patients whom attacks 
were worst at night or morning. However, the safety of formoterol and other LABAs was called into 
question following accumulating evidence of an increased risk of morbidity and mortality (Nelson et al., 
2006; Rodrigo et al., 2009; Salpeter et al., 2006; Spitzer et al., 1992). The level of concern has resulted in 
an (albeit controversial) FDA mandated trial on its safety (Sears, 2013). In a similar fashion, - agonists, 
which improve cardiac contractility in patients with congestive heart failure (CHF) in the short term were 
found to cause increased mortality with chronic use, whereas β-blockers went from being contraindicated 
in CHF to being approved as the drug of choice in treatment (Sorrentino, 2003; Waagstein et al., 1975). 
Thus, parallels have recently been drawn between CHF and asthma, suggesting that “biased agonism” may 
lead to agonists acting on the conventional G-protein secondary messengers to evoke cyclic AMP-
dependent effects but also on the β-arrestin-2 pathway creating secondary effects (Walker et al., 2011). 
5.1.2 The potential of β2-AR to alter calcium homeostasis 
Interestingly it has recently been shown that prolonged exposure of formoterol can lead to a 50% decrease 
in SERCA2a protein in the heart (Ryall et al., 2008). It is thought that this reduction in SERCA2a is due to 
a decline in gene transcription, possibly via glycogen synthase kinase-3β (GSK-3β) which has been 
implicated as a negative regulator of SERCA2 gene transcription (Michael et al., 2004). Ryall et al. 
showed a 40% decrease in its phosphorylation upon β2-AR stimulation, an effect which enables more of 
the active form to directly interact with SERCA’s promoter region and inhibit its transcription. It is 
possible that this secondary effect is mediated via a secondary intracellular pathway such as β-arrestin-2. 
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It has previously been shown that SERCA2 expression is reduced in ASM from asthmatic patients and that 
this contributes to the asthmatic phenotype (Mahn et al., 2009). It would therefore be predicted from the 
above that treatment of such patients with a LABA might further depress SERCA2 expression and worsen 
the condition; this would have clear implications for therapy. Indeed, Ojo reported in his PhD thesis (Ojo, 
2011) that both formoterol and salbutamol decreased expression of SERCA2 in healthy cultured ASM 
cells in a concentration dependent fashion. The β2-AR antagonist ICI-118551 inhibited the reduction 
suggesting the effect is via the receptor. Additionally stimulation with forskolin, producing a rise in cAMP 
similar to that caused by formoterol, decreased SERCA2 expression, suggesting that this is a cAMP 
dependent effect. Finally, pre-incubation with the ERK1/2 inhibitor U0126 blocked formoterol induced 
reduction of SERCA expression, indicating that ERK is involved in the signalling cascade. Under the 
same conditions the steroidal asthma treatment dexamethasone did not cause any change in SERCA (Ojo, 
2011).  
5.1.3 Diverging signalling cascades 
β2-AR receptors are desensitised by protein kinases to regulate and “dampen” signalling, an effect 
associated with an uncoupling of the receptor to its downstream mediators (Pierce et al., 2002). Protein 
kinase A (PKA) was the first kinase shown to cause this response on the mammalian receptor (Benovic et 
al., 1985), although the receptor can also be phosphorylated by another family of kinases called G-protein 
receptor kinases (GRKs) which unlike PKA is specific only for the constitutively active form of the 
receptor or agonist occupied form. As it only phosphorylates the active form of the receptor it is termed 
“homologous desensitisation” whereas PKA can induce “heterologous desensitisation” by phosphorylating 
a separate receptor to the one which activated it (Pierce et al., 2002). Phosphorylation by GRKs can recruit 
β-arrestins to bind to the intracellular tail of the receptor, sterically hindering G-protein coupling and 
targeting it for internalisation. Subsequently, the receptor may undergo three processes: A) It is targeted to 
a recycling endosome where it is dephosphorylated and reinserted into the membrane, “resensitisation”. B) 
It is targeted to a lysosome to be degraded, “down-regulation” (generally a consequence of prolonged 
signalling). C) It forms an intracellular signalosome in a complex with MAPK which is independent of the 
conventional G-protein mediated pathway (Shenoy et al., 2006) and instead dependent on both β-arrestin-
1 and 2. It has been shown that the agonists investigated here and used in asthma therapy, formoterol, 
salbutamol and salmeterol, all induce β-arrestin recruitment, although no signalling preference towards it, 
ERK phosphorylation or to the cAMP pathway has been observed in HEK293 cells (Drake et al., 2008; 
Reiter et al., 2012). Biased agonism is the term given to the phenomenon of receptors activating different 
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intracellular signalling pathways depending on the agonist that binds to them and their subsequent 
conformational change, reviewed in detail (Reiter et al., 2012). The potential “imbalanced efficacy” 
elicited by differing downstream pathways therefore  needs to be considered in this system where both the 
canonical cAMP and the β-arrestin dependent pathways are known to be activated (Fig 5.1.3-1). 
 
5.1.3-1 Biased agonism in the context of the β2-AR. The inactive form of the receptor can induce three 
different active conformations resulting in different signalling outcomes dependent upon their equilibrium 
constants and agonist association. It was previously believed that GPCRs activated secondary messengers 
in a linear fashion, new evidence suggests pathways are more likely arranged as integrated networks as 
described in this figure. 
 
The downstream intracellular signalling pathway from the β2-AR also has many points of divergence, one 
of which is immediately following a rise in cAMP. The discovery that Rap guanine nucleotide exchange 
factors were directly activated by cAMP independent of PKA opened the field of Epac1/2 research 
(Exchange protein directly activated by cAMP) (de Rooij et al., 1998; Kawasaki et al., 1998). Since it had 
been thought previously that PKA was the sole target of cAMP, the existence of Epac helped to explain 
previous data not truly fitting with the conventional model and further demonstrated the complexity of 
GPCR signalling. 
A role for both Epac and PKA regulating ASM phenotype plasticity has been explored, with activation of 
both pathways shown to inhibit platelet derived growth factor induced modulation to a proliferative, 
hypocontractile phenotype (Roscioni et al., 2011b). The mechanistic action of both agonists varied slightly 
as PKA stimulation inhibited both ERK and p70
s6k
 phosphorylation whereas the Epac agonist only 
inhibited ERK (Roscioni et al., 2011a). When epidermal growth factor was used it was only activation of 
the Epac pathway which inhibited the induced proliferation, as a PKA specific agonist had no effect 
(Kassel et al., 2008). The previous reduction in SERCA2 expression by formoterol was shown to be 
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5.1.4 Aims and hypothesis 
The aims of the experiments described in this chapter were therefore to delineate the intracellular 
signalling cascade from receptor activation to mRNA translation and also to determine whether this 
phenomenon occurs in vivo. Specifically, I hypothesised that intranasal dosing of formoterol in mice 
would cause a dose dependent reduction in ASM SERCA2 expression and that this would be mediated by 
the classical Gαs signalling cascade via cAMP activation. 
An observation that in vivo treatment with LABAs does result in down-regulation of ASM SERCA2 
expression could potentially explain the increased morbidity associated with long term use of β2-AR 
agonists in asthma treatment. It was therefore of primary importance to test whether the observed effect of 
formoterol reducing SERCA2 expression in vitro translates to an in vivo setting. 
5.2 Methods 
5.2.1 Dosing formoterol in vivo 
Balb/c mice were dosed intranasally (i.n.) once a day for four days before the lungs were harvested for 
SERCA2 quantification by western blot. Formoterol was dissolved in DMSO solution and diluted down to 
a 1mg.ml
-1
 stock in saline. Mice weighed on average 20g so 25µl of an 80µg.ml
-1
 stock was used for the 
100µg.kg
-1
 group and 25µl of an 8µg.ml
-1
 stock for the 10µg.kg
-1
 group. Final concentration of DMSO 
was 0.8% v/v in 0.9% saline; this solution was used as the vehicle control. Mice were anaesthetised using 
isoflurane and the drug or vehicle control was added drop-wise to the nostrils for inhalation. Doses were 
based on previous i.n. dosing of formoterol (Wyss et al., 2007). 
5.2.2 Protein quantification 
For whole lung protein quantification in the mice, lungs were excised, flushed with 0.9% saline and snap 
frozen in liquid nitrogen. Quantification of SERCA2 protein expression was performed by western blot as 
previously described in chapter 2. 
The following in vitro methods used in this chapter are also outlined in chapter 2 in the relevant sections. 
5.3 Results 
5.3.1 The effect of formoterol on SERCA2 expression in vivo 
Formoterol caused an increase in SERCA2 expression which almost reached significance (p=0.06) by one-
way ANOVA, with the apparent maximum effect occurring at a dose level of 100μg.kg-1 (Fig. 5.3.1-1). 
The experiment has low power and was therefore susceptible to a type 2 error; only a few mice were used 
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initially for a preliminary test in line with the three R’s principles. As the result was opposite to 
expectation, I carried out additional in vitro experimentation before continuation.  
 
 
5.3.1-1 Balb/c mice were dosed intranasally for four days with either 10 or 100µg.kg
-1
 formoterol. On day 
five the lungs were harvested for western immunoblot and SERCA2 protein levels measured and 
expressed as a percentage of the vehicle control. Bars represent mean ± SEM, n=3, p=0.06 by one-way 
ANOVA. 
 
5.3.2 Clarification of β2-AR involvement 
To further clarify whether the observed in vitro effect involves the β2-AR beyond use of pharmacological 
antagonism, an siRNA was used to knockdown the receptor via electroporation. Prior to this a control 
transfection was performed to confirm whether the siRNA was effective, with measurement of mRNA 
expression via qPCR as no suitable antibody for western blot was available (Fig. 5.3.2-1). Transfection 
with the β2-AR siRNA resulted in a significant reduction in its mRNA compared to the scrambled control 
(0.42 ± 0.08 and 1.24 ± 0.16 relative quantity (RQ) respectively, p=0.01) confirming its efficiency and use 
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5.3.2-1 Healthy ASM cells were transfected with 250nM of β2-AR targeted or scrambled siRNA. Cells 
were grown to confluence, RNA harvested and real-time PCR performed. Bars represent mean relative 
quantity (RQ), ± SEM, n=6. Analysed by unpaired t-test, p=0.01. 
 
In contrast to Ojo’s observation (Ojo, 2011), stimulation with 30nM formoterol failed to decrease 
SERCA2 expression as measured by western blot in the scrambled transfected group acting as the positive 
control (Fig. 5.3.2-2, p=0.88). No change was also observed in the β2-AR transfected group (p=0.63). The 
lack of effect observed here led to the question that the transfection process itself may interfere with the 
results and affect SERCA2 expression. Therefore the experiment was repeated again performing a “sham 
transfection” whereby no RNA was introduced into the cells during the electroporation (5.3.2-3). Again, 
no decline in SERCA2 protein expression was observed following formoterol treatment in any of the three 
transfection groups. Surprisingly, transfection with the β2-AR siRNA without formoterol stimulation 
resulted in an increase of SERCA2, although a definitive interpretation of these results is impossible 
owing to the small number of experiments which were carried out. 
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5.3.2-2 Healthy ASM cells were transfected with 250nM of β2-AR targeted or scrambled siRNA. Upon 
reaching sufficient confluency cells were serum starved and treated with 30nM formoterol for 24 hours. 
Bars represent mean ± SEM, n=4. 
 
5.3.2-3 Healthy ASM cells were transfected with 250nM of β2-AR targeted, scrambled siRNA or 
deionised water. Upon reaching sufficient confluency cells were serum starved and treated with 30nM 
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5.3.3 Formoterol dose response 
The lack of agreement between the preliminary data obtained previously in the lab and the results 
described above using the control siRNA made it necessary to re-investigate the original finding of 
formoterol causing a concentration dependent reduction in SERCA2 protein expression without the 
interference of electroporation. Fig. 5.3.3-1 questions the reproducibility of that finding as once again 
SERCA2 was not reduced by formoterol stimulation in healthy ASM cells. Whereas in the earlier 
experiments 30nM formoterol stimulation resulted in a significant reduction of SERCA2 after 24 hours 
incubation, I was not able to repeat this results in numerous different healthy derived cell lines. 
 
5.3.3-1 Healthy ASM cells were stimulated with either 1nM or 30nM formoterol for 24 hours. Changes in 
SERCA2 expression were measured by western immunoblot and expressed as a percentage of their un-
stimulated control. Bars represent mean, ± SEM, n=6. One-way ANOVA; p=0.69. 
 
5.3.4 Effect of cell density 
It has been noted that the degree of confluency in cultured cells can affect their phenotypic properties, (see 
section 1.3.4). When cells are grown in culture they modulate from a contractile to a non-contractile state 
exemplified by a decrease in the contractile markers sm-MHC, calponin and desmin by up to 75% 
(Halayko et al., 1996). Furthermore, l-caldesmon, vimentin, α/β-PKC and CD44 homing cellular adhesion 
molecule all increase one to six fold. The plasticity exhibited is bi-directional as once the “synthetic” cells 
start to reach confluence in culture the protein expression levels of smMHC and sm-α-actin increase back 
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the expression of some markers, therefore stimulating cells consistently in this regard is essential to obtain 
consistent results. A disparity in cell confluence between investigators could underlie the lack of 
consistency. Therefore to test whether the degree of cell confluency alters the effect of formoterol on 
SERCA2 expression ASM cells were seeded at a range of confluences, serum starved and then treated 
with 30nM formoterol. A serial dilution was performed on the initial cell pellet to achieve an approximate 
range of confluency between 40-80% (although this was only qualitatively measured). Upon reaching the 
desired confluency cells were serum starved and subsequently treated with formoterol 72 hours later. 
During this serum deprivation period a further cell division usually took place so all of the approximations 
of confluency are slightly underestimated. Formoterol did not affect SERCA2 expression at any of the cell 
densities tested (Fig. 5.3.4-1, n=2), however a slight positive correlation was observed between SERCA2 
expression and cell density, independent to treatment. 
 
5.3.4-1 Healthy ASM cells were stimulated with 30nM formoterol for 24 hours. Changes in SERCA2 
expression were measured by western immunoblot and expressed as a ratio of GAPDH expression. Bars 
represent mean, ± SEM, n=2. 
 
5.3.5 The effect of salmeterol stimulation on SERCA2 expression 
The original rationale for this chapter is based upon reports of the impact of long-acting β2-AR agonists 
(LABAs) on mortality, and the speculation from others studies that a reduced ASM SERCA2 expression 
may be involved. To investigate whether this was an agonist specific or drug class phenomenon salmeterol 
was tested. In contrast to formoterol stimulation, salmeterol caused a concentration dependent decrease in 
SERCA2 expression. The effect was quite variable and did not reach significance (p=0.08, Fig. 5.3.5-1) 
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5.3.5-1 Healthy ASM cells were stimulated with salmeterol for 24 hours. Changes in SERCA2 expression 
were measured by western immunoblot and expressed as a ratio of GAPDH expression. Bars represent 
mean, ± SEM, n=6, p=0.08 by one-way ANOVA. 
 
5.3.6 Effect of forskolin 
In light of the discrepancy between formoterol and salmeterol reducing SERCA2 expression the 
intracellular signalling pathway was re-examined using forskolin to activate adenylyl cyclase, a 
downstream target of Gs following receptor activation. The experiment had been performed previously in 
the lab and was shown to reduce SERCA2 in line with previous formoterol data (Ojo, 2011). The 
concentrations of forskolin used in this previous experiment were 10µM and 100µM as they were found to 
induce a similar rise in cAMP as 10-30nM formoterol. However, my experiments demonstrated that 
forskolin caused a significant and concentration dependent increase in SERCA2 relative to GAPDH after 
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5.3.6-1 Healthy ASM cells were stimulated with a range of concentrations of forskolin for 24 hours. A) 
Bars represent mean ± SEM, n=3-8, p<0.0001 by one-way ANOVA and Bonferroni’s multi comparison 
post test, **p<0.01, ***p<0.001. 
 
5.3.7  Post cAMP divergence of signalling  
To delineate whether the cAMP mediated increase in SERCA2 expression was dependent upon PKA, 
Epac, or both, the specific agonists used in the previously mentioned publications were used. The protein 
kinase A (PKA) agonist 6-Bnz-cAMP (Biolog) is shown to be specific for PKA over Rap1 activation 
(Christensen et al., 2003) and the Epac agonist 8-pCPT-2’-O-Me-cAMP (Biolog) doesn’t activate PKA 
(Enserink et al., 2002). 
Stimulation with both the Epac and PKA specific agonists caused a transient increase in ERK 
phosphorylation rising at 1 hour post stimulation (598.7 ± 121.7% of control and 438.2 ± 52.5% of 
control, Figs. 5.3.7-1 and 5.3.7-2 lower respectively). Phosphorylation subsequently fell to below control 
levels at 24 hours post stimulation (56.2 ± 16.1% of control and 19.2 ± 6.1% of control, p<0.05 
respectively). SERCA2 protein expression was also elevated by both agonists at both time points 
investigated. The Epac agonist significantly elevated SERCA2 at 1 hour post stimulation (182.5 ± 30.7% 
of control, p<0.05, Fig. 5.3.7-1) and protein expression further increased at 24 hours however this was not 
significant due to higher variance (213.5 ± 65.6 % of control). The PKA specific agonist significantly 
elevated SERCA2 protein expression at both the 1 hour time point (230.9 ± 68.4% of control, p<0.05) and 































 - 156 - 
 
 
5.3.7-1 Healthy airway smooth cells were stimulated with 100µM of the Epac agonist for up to 24 hours. 
Changes in A) SERCA2 expression or B) phosphorylated ERK were measured by western immunoblot 
and expressed as a percentage of their unstimulated control. Bars represent mean ± SEM, n=3-6, **p<0.01 
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5.3.7-2 Healthy airway smooth cells were stimulated with 400µM of the PKA agonist for up to 24 hours. 
Changes in SERCA2 expression were measured by western immunoblot and expressed as a percentage of 
their unstimulated control. Bars represent mean ± SEM, n=3-8, by one-way ANOVA and Bonferroni’s 
multiple comparison post test, *p<0.05, ***p<0.001. 
 
5.3.8 The potential role of biased agonism 
It has been shown that the β2-AR is capable of activating both G-protein dependent signalling and β-
arrestin-2 dependent pathways and that they can occur independently (Drake et al., 2008; Reiter et al., 
2012; Shenoy et al., 2006). The papers found no biased efficacy between salmeterol, formoterol and 
salbutamol in the cell systems they used however that does not rule out the possibility of an ASM cell 
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As elevation of cAMP by forskolin stimulation resulted in a robust increase in SERCA2 (Fig. 5.3.6-1), 
while salmeterol treatment caused a reduction (albeit variable, Fig. 5.3.5-1), an siRNA targeted against β-
arrestin-2 was made to address whether this pathway might underlie the differences. A pool of three 
siRNAs were designed using the algorithm described in (section 2.6.1) and tested for efficiency (Fig. 
5.3.8-1). The second siRNA of the pool resulted in the greatest knockdown so it was used in subsequent 
experiments.  
 
5.3.8-1 Healthy ASM cells were transfected via electroporation with 3μg of three different siRNA 
sequences targeted against β-arrestin-2, along with a scrambled siRNA sequence and just the nucleofector 
solution alone as controls. Western blots were then carried out on the lysed cells to measure the efficiency 
of each siRNA construct, example blot shown. 
 
The variable nature of the effect of salmeterol effect on SERCA2 expression prevented addressing the role 
of β-arrestin-2 in this pathway. The positive control (a reduction in SERCA2 expression using scrambled 
siRNA following salmeterol or formoterol stimulation) was not achieved. In fact a slight increase was 
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5.3.8-2 Healthy ASM cells were transfected with either scrambled or β-arrestin-2 targeted siRNA and 
cultured in the presence or absence of  30nM formoterol or 100nM salmeterol for 24 hours. The ratio of 
SERCA2 protein expression over GAPDH was measured and normalised to the unstimulated scrambled 
transfected control. Data represents mean ± SEM, n=4. 
 
5.4 Discussion 
There is accumulating evidence to suggest that chronic use of long acting β2-AR agonists leads to a 
physiological effect which diverges from their acute action, and may be detrimental. It was hypothesised 
at the beginning of this investigation that the increased mortality observed with formoterol use might, at 
least in part, be attributable to its dysregulation of calcium handling in ASM cells, thus driving them 
towards an asthmatic phenotype. It has been shown previously that a reduction in SERCA2 expression is 
observed in ASM cells derived from asthmatic patients compared to healthy patients and that artificially 
reducing expression can cause this switch in phenotype (Mahn et al., 2009). The hypothesis was founded 
upon previous studies which had reported that formoterol caused a dose dependent reduction in SERCA2 
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5.4.1 LABA administration in vivo 
Our initial studies were thus designed to determine whether the data obtained from cultured ASM could be 
translated into an in vivo model, by treating mice with LABA and measuring SERCA2 expression in 
whole lung homogenates. However, contrary to the in vitro data, preliminary studies showed that 
treatment with formoterol apparently increased SERCA2 expression (Fig. 5.3.1-1).  This unexpected 
finding cast serious doubt on the original hypothesis, although the study was limited in terms of 
physiological differences between mice and humans and use of homogenates of whole lung rather than 
ASM. In the light of the in vivo studies I therefore re-examined the effects of treatment with LABAs on 
SERCA2 expression in human cultured ASM.  
5.4.2 An agonist specific effect? 
Contrary to the studies of Ojo (2011), the data presented here suggest that salmeterol but not formoterol 
may reduce expression of SERCA2 in cultured healthy ASM cells (Fig. 5.3.5-1 and Fig. 5.3.3-1), but in a 
potentially cAMP-independent manner, as forskolin, a cAMP raising agent, increased SERCA2 expression 
(Fig. 5.3.6-1). cAMP activates two downstream pathways, via PKA and Epac (de Rooij et al., 1998; 
Kawasaki et al., 1998). Direct activation of either by use of reportedly specific agonists for PKA 
(Christensen et al., 2003) or Epac (Enserink et al., 2002) also caused an increased SERCA2 expression 
potentially mediated via ERK (Figs. 5.3.7-1 and 5.3.7-2). It has previously been reported that formoterol 
mediates its effect on SERCA2 expression in an ERK dependent manner (Ojo, 2011), so it would be of 
interest to see whether the cAMP mediated increase in SERCA2 expression also involves ERK. The data 
presented here showing a cAMP dependent increase in SERCA2 expression could be a further benefit to 
PDE inhibitors being developed for the treatment of asthma (see section 1.9.5). Both selective and dual 
inhibitors for PDE3/4 elevate cAMP to produce bronchodilation and anti-inflammatory effects, a rise in 
SERCA2 expression as shown here in the ASM will potentially contribute to both of these effects. 
The difference in effect between the two LABAs poses an interesting conundrum which could shed light 
on the underlying process. Salmeterol is a partial agonist at the receptor yet reduced SERCA2 protein 
expression in a variable manner, on the other hand formoterol is a full agonist and had no discernable 
effect (Fig. 5.3.5-1 and Fig. 5.3.3-1 respectively) (Naline et al., 1994). Another interesting difference is 
the possible enhanced attenuation in bronchodilation elicited by short-acting β2-AR agonists by salmeterol 
compared to formoterol (van Veen et al., 2003). As no biased agonism has been observed for either drugs 
(Drake et al., 2008), and the data presented here shows cAMP increasing SERCA2 expression (Fig. 
5.3.6-1) the answer could lie in the fact formoterol activates enough adenylyl cyclase to negate the β-
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arrestin-2 dependent reduction in SERCA2. Whereas salmeterol as a partial agonist does not induce high 
enough levels of cAMP to maintain basal SERCA2 expression. Additionally the impact of cAMP reducing 
[Ca
2+
]i cannot be ignored as it has been demonstrated in vascular smooth muscle cells that [Ca
2+
]i and 
SERCA2b protein expression are positively correlated (Wu et al., 2001). The relationship between 
cytosolic calcium concentration and SERCA2 expression with the results in this chapter lie in contrast as 
one would expect formoterol to lower calcium to a greater degree than salmeterol and hence additionally 
lower SERCA2. The relative impact of this effect could be dwarfed by that of the hypothetical β-arrestin-2 
mediated effect. 
5.4.3 A role for biased agonism? 
As activation of β2-AR caused a variable decrease in SERCA2, but its classical secondary messenger 
cAMP apparently had the opposite effect, it can be reasonably deduced that the receptor activates a 
secondary intracellular signalling cascade. The variable nature of the response to LABAs may therefore 
reflect changes in the balance between the cAMP pathway that enhanced SERCA2 expression and another 
that depresses it.  
Classical receptor pharmacology theories have been largely revised in the last 15 years to accommodate 
evidence showing that different agonists acting on the same receptor can result in distinct signalling 
cascades by evoking multiple changes in receptor conformation (Drake et al., 2008; Evans et al., 2010; 
Reiter et al., 2012). In particular, it is now known that phosphorylation of β2-AR by GRKs leads to 
recruitment of β-arrestin and internalisation of the receptor; this is thought to be a key element of β2-AR 
desensitisation in ASM (Deshpande et al., 2008). It is believed that at low agonist receptor occupancy β2-
AR desensitisation is mediated by PKA and GRK independent, whereas at higher occupancy it is GRK/β-
arrestin-2 dependent and PKA independent (Deshpande et al., 2008; Wang et al., 2009). In addition, 
internalisation by β-arrestin-2 can lead to the creation of a signalosome, independent to PKA activation, 
leading to G-protein independent activation of ERK (Shenoy et al., 2006). The paper further demonstrates 
that ERK phosphorylation at early time points is PKA dependent however a switch to a β-arrestin-2 
dependent pathway occurs after more prolonged exposure. It has been shown that all three of the agonists 
considered here (salbutamol, salmeterol and formoterol) are equally capable of activating either the cAMP 
or β-arrestin-2 dependent pathway in HEK293 cells (Drake et al., 2008). I therefore hypothesised that the 
observed effects of the LABAs on SERCA2 expression in ASM could be related to a balance between 
cAMP and -arrestin pathways. 
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To test this hypothesis, we designed a β-arrestin-2 siRNA and examined whether SERCA2 expression 
declined upon salmeterol stimulation in the control (i.e. scrambled transfected, vehicle stimulated group), 
but increased when β-arrestin-2 expression was suppressed, so that only the cAMP pathway was activated, 
as would be predicated by the hypothesis.  The variable nature of salmeterol decreasing SERCA2 protein 
expression meant there wasn’t a difference observed during the transfection controls, therefore no firm 
conclusions could be drawn with the siRNA (Fig. 5.3.8-2). The previous data showing that the effect of 
formoterol was dependent upon ERK activation (Ojo, 2011) could fit in with the β-arrestin-2 hypothesis as 
it too signals via it. Increasing the number of repeats might be able to provide a clearer picture in this 
response however the validity of the outcome would remain questionable due to the inherent variability. 
Therefore delineating the source of the variation observed and discrepancy between the findings of Ojo 
(2011) was addressed.  
5.4.4 The influence of cell density 
There is evidence that ASM phenotype changes as cells progress through to confluence. It has for example 
been shown that ASM cells at subconfluence express a modulated, proliferative phenotype which becomes 
contractile as they reach confluence (Halayko et al., 1996). Furthermore, there is an increased smooth 
muscle bundle in the airways of asthmatics as a result of both hyperplasia and hypertrophy (Benayoun et 
al., 2003; Chung, 2005; Ebina et al., 1993). It has been postulated that a reduction in SERCA2 protein 
expression causing a higher intracellular basal calcium concentration contributes towards this hallmark of 
the disease (Mahn et al., 2009). It is therefore plausible that SERCA2 expression is altered in differing cell 
densities as cells become more or less proliferative. Hence, the degree of confluence and rate of 
proliferation might explain the discrepancy between the data reported previously by Ojo (2011) and that 
shown here. Although the effect of formoterol did not change over a wide range of cell densities, the basal 
expression of SERCA2 in unstimulated cells appeared reduced in sparser cell populations (Fig. 5.3.4-1). 
The trend towards lower SERCA2 protein expression in the sparsely populated, more proliferative cells 
(Fig. 5.3.4-1) is consistent with the concept that the proliferative phenotype is associated with altered 
regulation of Ca
2+
 handling, which may drive this phenotype until confluence is achieved (Mahn et al., 
2010). 
5.4.5 Conclusion 
Due to the apparent variability of the response to LABAs, and our inability to discover the origin of this 
variability, the results of this study remain inconclusive. However, there is evidence that long term LABA 
treatment can be detrimental (Nelson et al., 2006; Rodrigo et al., 2009; Salpeter et al., 2006), and that, 
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surprisingly, beta-blockers acting as inverse agonists may be beneficial in asthma (Hanania et al., 2010; 
Hanania et al., 2008; Nguyen et al., 2009). In addition, the results shown here and by Ojo (2011) do 
suggest that -agonists do have an effect of SERCA2 expression, although it is highly variable. 
Therefore in spite of the inconclusive nature of these studies, I propose the following speculative model: 
 
5.4.5-1 Stimulation of the β2-AR on ASM cells may cause a dichotomy of response in a time dependent 
manner. Blue arrows indicate pathways increasing SERCA2 expression, green arrows decrease SERCA2 
expression. Acutely the cAMP pathway is activated to control muscle tone and SERCA2 expression may 
be increased to improve the dynamics of signalling. Following chronic activation the receptor is targeted 
to β-arrestin-2 dependent signalosomes and decrease SERCA2 expression potentially inducing or 
enhancing an asthmatic phenotype (Michael et al., 2004; Shenoy et al., 2006). Both pathways are capable 
of signalling via ERK however its involvement in either or both phenomenon remains speculative. 
 
Acute stimulation may result in cAMP elevation to control muscle tone and airway opening with the 
receptor being recycled back to the plasma membrane and chronic activation of the receptor leading to 
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down regulation and β-arrestin dependent gene expression changes. Higher levels of SERCA2 could be 
necessary in the contractile phenotype to ensure rapid reuptake of calcium and better defined calcium 
sparks for discrete temporal signalling (Fig. 5.3.4-1) whereas a decreased expression would lead to, and 
aid a proliferative phenotype by constitutively raised [Ca
2+
]i (Abell et al., 2011) driving ASM migration, 
secretion and proliferation (Mahn et al., 2009; Mahn et al., 2010) owing to the calcium dependence of the 
contractile machinery (Gerthoffer, 2008). 
The increase in SERCA2 expression observed in vivo at the start of this chapter may be driven by the 
acute cAMP pathway and a longer dosing regimen, fitting more closely to the clinical setting, may drive 
the β-arrestin pathway and reduce SERCA2. The variability of the salmeterol-induced reduction of 
SERCA2 may reflect the cusp of switching between the two signalling pathways as some cell lines may 
respond at different rates. It would be of interest to stimulate at a 12 hour time point and for 1 week to see 
if the dichotomy is exposed. 
Previous work in a murine model of asthma with a chronic dosing regimen of inverse agonists shows both 
a decrease in inflammation and mucous hyperplasia which were more pronounced than at earlier time 
points (Lin et al., 2008; Nguyen et al., 2008). Furthermore, β2-AR null mice exhibited a similar beneficial 
effect and was shown to be essential for the full development of the asthmatic phenotype (Thanawala et 
al., 2013). The results reflect the potential detrimental effects of activating the non-contractile β-arrestin-2 
intracellular signalling cascade with current asthma therapies. The use of the inverse agonist propranolol 
as an asthma therapy suffered a recent setback as it showed no benefit over placebo in a double-blind trial 
in improving AHR or quality of life scores (Short et al., 2013). The results lie in contrast with a previous 
open-label uncontrolled trial using nadolol where improvements in AHR were observed (Hanania et al., 
2008). The results demonstrate that biased agonism rather than inverse agonism at the β2-AR may be the 
solution to the current reported problems or more careful selection of the patient sub-group/inverse agonist 
is necessary (Kazani et al., 2013). 
In conclusion a mainstay therapy target for asthma, the β2-AR can modulate the expression of SERCA2 in 
ASM cells. SERCA2 reduction has been shown to induce an asthmatic phenotype which may help explain 
the chronic detrimental effects associated with this drug class. The manner in which this is done and the 
clinical importance of this effect still need to be elucidated but a time-dependent switch in downstream 
receptor signalling could play a role. 
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Chapter 6 Characterising an immortalised airway smooth muscle cells 
characterisation 
6.1 Introduction 
Currently, the vast majority of research performed in vitro on ASM cells utilises primary cell lines derived 
from patients with varying disease severities, and grown in culture for a maximum of three to six passages. 
This is because of the very limited amount of tissue available from biopsies, and the need to enhance 
tissue mass for most forms of experimentation. While such cells can provide an invaluable insight into 
disease mechanisms, they can be misleading due to phenotypic drift during multiple passages (see 1.3.4). 
6.1.1 Immortalisation 
To circumvent this problem we have taken ASM cell lines derived from healthy, mild or moderate 
asthmatics, and in collaboration with Professor Andrew Halayko’s group in Winnipeg, Canada,  attempted 
to create phenotypically stable, disease-specific immortalised cell lines. The initial six ASM cell lines 
investigated in this chapter were sent from our department to Winnipeg for immortalisation, though others 
are ongoing. The hTERT (human telomerase reverse transcriptase) gene was introduced into the cell 
genome by random insertion using a MMLV-based retroviral vector (Moloney murine leukaemia virus). 
Telomerase serves to maintain chromosomal integrity by capping DNA strands with tandem hexameric 
repeats ending in a 3’ single strand overhang (Daniel et al., 2012). In somatic cells telomerase remains 
inactive and as every replication of DNA is incomplete the strand gradually shortens until senescence 
occurs. Dysregulation of telomerase transcription is a critical step in human carcinogenesis enabling the 
capacity for tumours to progress (Kyo et al., 2008). By taking advantage of this and expressing telomerase 
to high levels in somatic cells they can effectively become immortalised by never reaching senescence via 
repeated DNA replication. 
The populations produced from the transductions are heterogeneous, made up of many colonies from 
independent insertion events. The heterogeneity should have a "normalising" effect on the cell lines, 
correcting internally for any insertion-related side effects. Although any insertions into critical genes 
should be normalised by the expected majority of insertion events into introns, there is a reasonable 
likelihood that subtle changes in phenotypes could occur that would not be masked by the population. Due 
to the nature of the immortalisation it is essential to characterise the cells to ensure their disease-state-
specific phenotype is maintained.  
 - 166 - 
6.1.2 Cell lines versus primary cells 
There are numerous additional advantages to creating a set of disease-specific immortalised ASM cell 
lines. The use of siRNAs has been demonstrated previously in this chapter using transfection with 
plasmids. An immortalised ASM line would negate the need for multiple transfections and allow the 
creation of permanent over-expressing or knockout cell lines, saving both time and money. Recruitment of 
patients to continually get tissue via bronchoscopy requires several staff, use of hospital core facilities and 
a large investment of time and money. None of which would be required once characterised lines are 
established and research could be carried out without access to the infrastructure of a hospital. Finally, less 
variation in experimental data would be expected from using the same lines repeatedly. Asthma is a 
heterogeneous disease and ASM cells derived from the same patient sub-sets also show variability due to 
both genetic and environmental factors. Using the same (well characterised) immortalised cell line for 
investigating intracellular signalling pathways for example would be of great use as the reduction in 
variability would lead to much higher experimental power when investigating a hypothesis. An inherent 
problem with this is that it would be much less representative of the population as a whole so care would 
be needed when extrapolating data acquired to the clinical setting. 
The methodology in this chapter was broadly based on a previous study from our lab showing that protein 
expression of SERCA2 in ASM cells is negatively correlated to asthma disease severity (Mahn et al., 
2009). Furthermore, the paper shows a decreased [Ca
2+
]i peak response following bradykinin stimulation 
and a longer recovery time to baseline demonstrating a smaller store content and filling because of less 
SERCA2. Possibly as a further result of decreased SERCA and hence the potentially increased basal 
[Ca
2+
]i, an increase in eotaxin-1 production following IL-13 stimulation and proliferation is also observed 
(Mahn et al., 2009). These indices were used as a benchmark to discover whether the immortalised ASM 
cell lines obtained have retained these asthmatic phenotypes. The data included here were part of a 
preliminary study during the development phase, and there were a number of limitations. 
6.1.3 Aims 
To this end, the aim of this chapter was to discover the extent each cell line investigated fits with 
previously published phenotypic differences between healthy, mild and moderate cultured ASM cells. The 
criteria assessed for each line was: 
 Proliferation – measured by tritiated thymidine incorporation and the MTT assay. 
 Eotaxin-1 secretion following IL-13 stimulation. 
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 Calcium mobilisation following bradykinin stimulation. 
 SERCA2 protein expression. 
 Smooth muscle marker expression. 
Originally all of the data collected was going to be compared back to data collected from their respective 
native lines. Such a comparison would have shown how much the cells were altered by the hTERT insert 
or whether they still represented their native state. The native lines that returned with their immortalised 
counterparts were at a too high passage to grow; therefore these comparisons could not be made. This is 
being addressed for our current studies. 
6.1.4 Hypothesis 
I hypothesised that following immortalisation most of the cell lines would respond in line with the data 
described in (Mahn et al., 2009). Conversely as only single lines were investigated and only two from 
each disease severity, the correlations would not be as clearly defined as previously published owing to the 
natural variation in the parameters assessed.  
6.2 Results 
6.2.1 Smooth muscle markers 
Firstly, the cells had to be confirmed as ASM cells, so they were stained for the typical ASM markers 
smooth muscle α-actin, desmin and calponin (Halayko et al., 1996) by immunocytochemistry. Fig. 6.2.1-1 
shows some example staining from the healthy immortalised cell line htHB96 and the moderate asthmatic-
derived immortalised cell line htHB107 at a low passage. All of the immortalised cells were positive for 
the markers tested. To ensure they maintained their markers after a significant time in cell culture staining 
was repeated after ten passages (Fig. 6.2.1-2). Once again all of the cells stained positive. The quality of 
the staining in the cell line htHB107 deteriorated at the latter passages possibly due to secondary antibody 
issues. 
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6.2.1-1 Staining for ASM cell markers; sm-α actin (A&E), desmin (B&F) and calponin (C&G). Cells in 
pictures A-C are derived from the healthy patient htHB96 and E-F from the moderately asthmatic 
htHB107. Pictures were taken no more than three passages following immortalisation. 
 
6.2.1-2 Staining for ASM cell markers; sm-α actin (A&E), desmin (B&F) and calponin (C&G). Cells in 
pictures A-C are derived from the healthy patient htHB96 and E-F from the moderately asthmatic 
htHB107. Pictures were taken ten passages following immortalisation. 
 
6.2.2 SERCA expression 
The central theme to (Mahn et al., 2009) shows a negative correlation between SERCA2 protein 
expression and asthma severity. Here the protein expression of SERCA2 normalised to GAPDH provided 
mixed results (Fig. 6.2.2-1). The western blots were ran in duplicate with separate cells from the same line 
to minimise erroneous results. The occasion of the repeat (Rep 1 or Rep 2) is listed on the graph because 
on first site there appears to be large variation however the same expression pattern is observed both 
times.  
Both htHB94 and htHB97 derived from mild asthmatics had much higher relative levels of SERCA2 
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line htHB95 had higher levels (3.97 AU) than the two moderate asthmatic lines htHB100 and htHB107 
(1.47 and 1.85 AU respectively) but contrary to previously published results it had lower expression than 
the mild asthmatic lines. The final healthy cell line htHB96 had much lower than expected SERCA2 
expression (1.46 AU). Between the cell lines there was no clear correlation between disease severity and 
SERCA2 expression in these tested immortalised ASM cell lines. 
  
 
6.2.2-1 Immortalised ASM cells were grown to confluence, lysed and SERCA2 protein levels measured 
by western blot. Cell lines were either derived from healthy patients (white), mild asthmatics (light grey) 
or moderate asthmatics (dark grey). Bars represent mean in duplicate. 
 
6.2.3 Calcium release data 
To test the functional impact of any change in SERCA2 expression the sarcoplasmic reticulum stores were 
partially emptied with the agonist bradykinin. The peak rise in [Ca
2+
]i is indicative of store content and the 
rate of recovery back to baseline is in part dependent upon SERCA2 activity. Although the peak rise in 
[Ca
2+
]i following bradykinin stimulation did not correlate well with measured SERCA2 levels they did fit 
more closely with previously published data. The healthy cell line htHB96 had a larger rise in [Ca
2+
]i 
compared to the line htHB107 derived from a moderate asthmatic (0.19 ± 0.02 Δ340/380nm and 0.11 ± 
0.01 Δ340/380nm respectively). The large response in htHB97 which was significantly greater than the 
moderate asthmatic lines htHB100 and htHB107 as well as the healthy line htHB95 (p<0.05, p<0.01 and 
p<0.001 respectively) only partially reflects the predicted pattern expected from the disease state however 
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6.2.3-1 Functional consequences of stimulating immortalised human ASM cells with 0.5µM bradykinin. 
Cells were perfused with HBSS to achieve a steady base-line then stimulated with bradykinin, the peak 
ratiometric measurement (340/380nm) indicating calcim store release was recorded. A) A representative 
calcium transient trace. B) Cell lines were either derived from health patients (white), mild asthmatics 
(light grey) or moderate asthmatics (dark grey). Bars represent mean ± SEM, (n=3-9). Analysis by one 
way ANOVA and Bonferroni’s post test; *p<0.05, **p<0.01, ***p<0.001. 
 
6.2.3.1 Decay rate of intracellular calcium following bradykinin stimulation 
The recovery rate of [Ca
2+
]i returning back to a steady state following bradykinin stimulation and release 
from stores was used to indicate SERCA2 activity (Fig. 6.2.3-2). As with the calcium release data (Fig. 
6.2.3-1) the cell line htHB97 provided the only source of significant statistical variation as analysed by a 
one way ANOVA and Bonferroni’s post-test from the other cell lines. Its rate of recovery was 
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significantly slower compared to the healthy lines htHB96 and htHB95 as expected (p<0.001 and p<0.05 
respectively) but also slower than htHB100 derived from a moderately asthmatic patient (p<0.05). 
 
6.2.3-2 The rate of  stimulating immortalised human ASM cells with 0.5µM bradykinin. Cells were 
perfused with HBSS to achieve a steady base-line then stimulated with bradykinin. A single, 3 parameter 
exponential decay line was fit from the peak ratiometric measurement (340/380nm) to the baseline with 
the gradient indicating rate of re-uptake. A) A representative calcium transient trace. B) Cell lines were 
either derived from health patients (white), mild asthmatics (light grey) or moderate asthmatics (dark 
grey). Bars represent mean ± SEM, (n=2-9). Analysis by one way ANOVA and Bonferroni’s post test; 
*p<0.05, **p<0.01, ***p<0.001. 
 
6.2.4 Eotaxin-1 release 
There are three different isoforms of eotaxin; 1-3 all involved in the chemotaxis of eosinophils. Eotaxin-1 
is secreted from ASM cells and its levels, along with its receptor CCR3 have been reported to be increased 
in asthma and increase ASM migration in vitro (Joubert et al., 2005), this effect is positively correlated 
with disease severity (Pepe et al., 2005). The TH2 cytokine IL-13 is also raised in asthma (see 1.2.2) and 
has been shown to augment the release of eotaxin-1 (Mahn et al., 2009) which is further enhanced with the 
co-culture of asthmatic derived ECM proteins (Chan et al., 2006). 
All of the cell lines released an increasing amount of eotaxin-1 in a concentration dependent manner to IL-
13 stimulation. Comparing the eotaxin-1 release as a percentage of the unstimulated control (Fig. 6.2.4-2) 
shows that in the case of both healthy and both moderately severe derived ASM cell lines an asthmatic 
phenotype increases the amount of eotaxin-1 production for a given amount of IL-13 exposure, however 
there were no statistically significant differences between the lines. The smallest increases in eotaxin-1 
production from the unstimulated controls were observed in the cell lines htHB95 and htHB94 (172.3 ± 
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 cells respectively, Fig. 6.2.4-1). The moderately severe derived 
line htHB107 saw the biggest and most robust increase in eotaxin-1 upon 10ng.ml
-1
 IL-13 stimulation 
compared to basal release (320.1 ± 24.4 % of control, p<0.001). The cell lines htHB96 and htHB97 also 
both released a significantly greater amount of eotaxin-1 following 10ng.ml
-1
 IL-13 stimulation (p<0.001 
and p<0.05 respectively). 
 
6.2.4-1 Immortalised ASM cells were grown, serum starved for 72 hours and stimulated with varying 
concentrations of IL-13 or vehicle control. The cell density was calculated, the cells then lysed and 
eotaxin-1 concentration measured by ELISA. Cell lines were either derived from A) healthy patients, b) 
mild asthmatics or C) moderate asthmatics. Bars represent mean ± SEM, n=2-6 (in duplicate); *p<0.05, 
p<0.01 and ***p<0.001 as measured by one way-ANOVA and Bonferroni’s multi comparison post test. 
htHB95
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6.2.4-2 Immortalised ASM cells were grown, serum starved for 72 hours and stimulated with varying 
concentrations of IL-13 or vehicle control. The cell density was calculated, the cells then lysed and 
eotaxin-1 concentration measured by ELISA. Cell lines were either derived from healthy patients (white 





It has been well documented that there is increased ASM mass in the airways of asthmatics due to both 
hyperplasia and hypertrophy and cultured cells from asthmatic patients retain this enhanced proliferative 
phenotype (Johnson et al., 2001). It has been hypothesised that the increased proliferation maybe a result 
of the decreased SERCA2 expression in asthmatic ASM cells as treatment with a targeted siRNA in 
healthy cells recapitulated the effect (Mahn et al., 2009). Here the tritiated thymidine incorporation assay 
is used to measure cellular proliferation as it is a direct indication of DNA synthesis. 
Every cell line measured showed an increase in proliferation with higher concentrations of FBS (Fig. 
6.2.5-1). Analysing the cells stimulated with 10% FBS as a percentage of the unstimulated controls 
revealed a weak, negative correlation between proliferation and disease severity contrary to previously 
published data and theory (Fig. 6.2.5-2). The cell line htHB107 showed a significantly greater increase in 
proliferation in response to 10% FBS compared to the healthy line htHB95 (301.8 ± 25.2 and 193.3 ± 




























































6.2.5-1 Immortalised ASM cells were grown, serum starved for 72 hours and stimulated with varying 
concentrations of FBS for 4 hours. The cells were then pulsed with 3.7 Bq of tritiated thymidine and left to 
grow for a further 48 hours before being lysed and quantified using a beta counter. Cell lines were either 
derived from A) healthy patients, b) mild asthmatics or C) moderate asthmatics. Bars represent mean ± 
SEM, n=6-12; *p<0.05, p<0.01 and ***p<0.001 as measured by one way-ANOVA and Bonferroni’s multi 
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6.2.5-2 Immortalised ASM cells were grown, serum starved for 72 hours and stimulated with varying 
concentrations of FBS for 4 hours. The cells were then pulsed with 3.7 Bq of tritiated thymidine and left to 
grow for a further 48 hours before being lysed and quantified using a beta counter. Cell lines were either 
derived from healthy patients (white bars), mild asthmatics (light grey bars) or moderate asthmatics (dark 
grey bars). Bars represent mean ± SEM, n=6-12. 
 
6.2.5.2 MTT assay 
Due to the unexpected proliferation results from the tritiated thymidine assay, thought of as the “gold 
standard” in proliferation testing, an MTT assay was performed as a comparison. The MTT assay, 
commonly used as a measure of proliferation, is a measure of metabolic activity rather than proliferation 
as it relies on reduction of the MTT dye to formazan by NADPH dependent enzymes. As metabolic 
activity is increased during cell proliferation the MTT acts as an indirect measurement, therefore 
comparisons with the 
3
H-thymidine assay must bear this in mind. 
As with the 
3
H-thymidine assay every cell line increased their metabolic activity in a concentration 
dependent manner with FBS (Fig. 6.2.5-3). The cell lines derived from both mild and moderate asthmatic 
patients, with the exception of htHB94, displayed an increase in metabolic activity following 10% FBS 
stimulation compared to the healthy derived line htHB96 however only the line htHB97 was significant 
(p<0.001). There was no clear correlation apart from this between the result and disease severity from 
which the cells were derived as both cell lines from severe asthmatics displayed significantly greater 
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6.2.5-3 Immortalised ASM cells were grown, serum starved for 72 hours and stimulated with varying 
concentrations of FBS for 48 hours. The cells are then incubated for 4 hours with 12mM MTT then a 
SDS-HCl solvent is added and incubated for a further 4 hours, plates are read at 574nm. Cell lines were 
either derived from healthy patients (white bar), mild asthmatics (light grey) or moderate asthmatics (dark 
grey). Bars represent mean ± SEM, n=12, analysed by one way-ANOVA and Bonferroni’s multi 
comparison post test. 
 
6.3 Discussion 
Unfortunately, it is clear that interpreting the results outlined here and drawing more meaningful insights 
requires the same experiments to be performed in parallel on the native versions of each cell line. Without 
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process or if they are typical of the patient they were derived from. Attempts were made to grow the 
control cells of each line for comparative parallel testing however they were of a high passage upon 
importation and as well as looking morphologically different, the cells did not grow to passage easily. The 
immortalisation is being carried out again on several new healthy and moderately asthmatic derived cell 
lines at an earlier passage while control cells are kept in the UK. Upon importation of the newly 
immortalised lines the characterisation will be far more accurate and useful. The data outlined here will 
serve as a “characterisation of the characterising process”. 
6.3.1 Staining 
Each line was first stained with typical ASM markers to ensure they still expressed some of the defining 
proteins and they all came up positive. It has been previously published that native ASM cells decrease 
both α and γ-isoactin expression after the third passage (Panettieri et al., 1989). Staining was repeated 
again for all of the markers, including α-actin, ten passages on from immortalisation. Although the 
immunocytochemistry was not quantified there appeared to be no reduction in sm-α-actin present 
indicating they are not subject to the same passage dependent phenotypic drift. 
6.3.2 SERCA2 expression 
A reduction in SERCA2 protein expression in asthmatics was put forward as “fundamental to many 
features of the exaggerated ASM function” (Mahn et al., 2009) with the paper showing a clear negative 
correlation between expression and disease severity. An alteration in calcium handling in asthmatic cells 
was also postulated by Trian et al. (2007) as an explanation to increased proliferation and mitochondrial 
biogenesis observed. 
In the cell lines tested here htHB95 derived from a healthy patient had markedly higher levels of SERCA2 
compared to both moderate asthmatic lines htHB100 and htHB107, fitting with the published hypothesis. 
Beyond that there was no such correlation as both mild asthmatic lines exhibited very high SERCA2 
expression. As western immunoblotting is only a semi-quantitative measure and is very dependent upon 
the quality of antibodies being used a functional measure of SERCA2 expression was employed.  
6.3.3 Calcium transients 
The calcium ion content of the sarcoplasmic reticulum depends upon the net balance between the rate of 
uptake by SERCA2 and the rate of basal leak from the store. Comparisons can therefore be made between 
the peak [Ca
2+
]i response following SR dumping and  the calcium content of the SR and thus indirectly 
gauge SERCA2 activity. A more direct measurement can be inferred by then calculating the rate of [Ca
2+
]i 
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falling back to basal levels following the agonist stimulation as the majority of calcium is pumped back 
into the SR and not out of the cell. This is best demonstrated in Brody’s disease where SERCA2 
expression is not affected only the function is which results in an increase of the half-life of the agonist 
response by three times compared to healthy muscle cells (Benders et al., 1994). 
The peak calcium responses following bradykinin stimulation only partially matched the SERCA2 protein 
expression data. Thus either indicating an uncoupling of expression and function or potentially 
highlighting the limitations to this assumption. The relationships that did match the expression data was 
that between the two lines derived from mild asthmatics and the two from moderate asthmatics. Both mild 
asthmatic lines had higher SERCA2 expression and higher peak responses to calcium. The decay rate back 
to baseline which is a more direct measure of SERCA2 function (Mahn et al., 2009) (but omits the other 
variables of buffering to the mitochondria and pumping out of the cell) however did not match up with 
these results. In both cases the lines derived from moderate asthmatics had a faster decay rate indicating 
greater SERCA2 function which reached significance between htHB97 and htHB100 (p<0.05). 
The healthy cell line htHB96 had quite a low relative expression of SERCA2 but the peak response to 
bradykinin and rate of decay were both considerably higher than that of the moderate asthmatic derived 
line htHB107 and slightly greater than htHB100 which is in line with the original hypothesis. Neither 
difference reached significance and in the case of htHB107 there is a distinct possibility of a type 2 error. 
The n value for this line was only 3 for the peak response and 2 for the decay rate owing to cells detaching 
from cover slips and erroneous results being generated. Increasing the repetitions of the test and hence 
increasing the power of the stats through reduction of variation may uncover a potential difference that has 
been missed. 
6.3.4 Eotaxin-1 secretion 
ASM cells derived from asthmatic patients have been shown to have both an enhanced synthetic and 
proliferative phenotype in culture (Wright et al., 2012c). Eotaxin has been shown to be increased in the 
sputum of asthmatics and positively correlated eosinophilic airway inflammation (Yamada et al., 2000). A 
range of mediators have been shown to influence its production; both the TH2 cytokines IL-4 and IL-13 
can induce eotaxin-1 expression in ASM and although TGF-β has no effect alone, when combined with 
the other two, the response is enhanced (Zuyderduyn et al., 2004). TNF-α shows a similar effect by 
enhancing both IL-4 and IL-13 mediated production (Moore et al., 2002; Odaka et al., 2007). As shown in 
Chapter 3 both TGF-β and TNF-α modulate calcium homeostasis, furthermore reducing SERCA2 
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expression enhances eotaxin-1 release (Mahn et al., 2009). This indicates that the cytokine storm in 
asthma may alter calcium handling, leading to various enhanced synthetic phenotypes such as eotaxin-1 
production. Importantly, to address the aim of this chapter, eotaxin-1 production has been positively 
correlated with asthma disease severity making it a good index for the characterisation (Mahn et al., 2009; 
Pepe et al., 2005).  
The correlation between SERCA2 expression and eotaxin-1 production was relatively poor in contrast to 
(Mahn et al., 2009) however the results alone did match their eotaxin-1 data more closely. Both moderate 
asthmatic derived lines showed greater eotaxin-1 release compared to the healthy derived lines going 
against the causative relationship between it and SERCA2 expression but not necessarily a dysregulation 
of calcium homeostasis as a whole in the cell. 
6.3.5 ASM proliferation 
Contrary to well published data a negative correlation between DNA synthesis as asthma severity was 
observed in most of the cell lines with the exception of htHB95 (healthy) and htHB107 (moderate 
asthmatic). Although not fitting with their previously published population means the relationship between 
SERCA2 expression and DNA synthesis was maintained in htHB96 and htHB94. The healthy derived line 
htHB96 displayed low SERCA2 expression and high proliferation with the mild asthmatic line htHB94 
showing the inverse.  The MTT assay is often used as a parameter for cellular proliferation or viability as 
it measures NADPH dependent metabolic activity. The results obtained show increased activity with 
higher concentrations of FBS akin to the 
3
H-thymidine assay but little similarities between the 
comparative cell line responses. A general trend towards higher metabolic activity was observed in the 
asthmatic cell lines compared to the healthy line however it wasn’t severity dependent. The increased 
metabolic activity displayed in the asthmatic cell lines which isn’t reflected in higher proliferation could 
be in part due to the elevated synthetic phenotype as observed with the eotaxin-1 production.  
The two cell lines derived from mild asthmatic patients showed the least correlation to previously 
published results in regards to the parameters tested. As mentioned in the introduction, asthma is a 
heterogeneous disease and patients meeting only the criteria of a mild phenotype by our selection process 
may not display as many of the “typical” asthmatic phenotypes. The selection criteria for mild asthmatics 
was a predicted FEV1 score of approximately 90% and this is taken at a screening visit up to a month 
before the biopsy is taken. The very nature of asthma manifests itself with variable lung function so many 
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of the patients screened into this group may not differ much from the healthy group or the moderate group 
depending upon their symptoms on the screening visit.  
6.3.6 Conclusion 
The data from the chapter can be approximately summarised in the table below to whether the data from 













Staining Yes Yes Yes Yes Yes Yes 
SERCA2 expression Yes No No No Yes Yes 
Peak Ca
2+ 
No Yes No No No Yes 
Ca
2+ 
recovery Yes Yes Yes Yes No No 
Eotaxin-1 Yes Yes No Yes ≈Yes Yes 
DNA synthesis Yes No No Yes No Yes 
MTT assay - Yes No No Yes Yes 
 
6.3.7 Correlations with SERCA2 expression 
Fig. 6.3.7-1 below shows the data re-arranged to compare each parameter against SERCA2 protein 
expression as the underlying hypothesis states that this factor is the “driving force” for the other asthmatic 
phenotypes. The strongest correlation is with the peak calcium release data and SERCA2 expression with 
an r
2
 of 0.24, the correlation is positive in fitting with the theory that higher SERCA2 expression leads to 
greater SR filling. The rate of calcium decay however is negatively correlated with SERCA2 protein 
expression which is contradictory to the hypothesis that SERCA2 expression heavily dictates the recovery 
rate. It is fitting with the disease state of each line as the healthy derived cells had faster rates of recovery 
therefore the quality of the western blot may be called into question or the regulation of SERCA2 activity. 
Proliferation as measured by tritiated thymidine incorporation and eotaxin-1 release following IL-13 
stimulation were both negatively correlated with SERCA2 expression as expected (r
2
=0.19 and 0.16 
respectively). The severity of asthma does not fit well with either factor so in these circumstances they do 
not serve as a strong model for the disease. 





6.3.7-1 Each parameter tested plotted against SERCA2 protein expression on the x-axis to gauge the 
correlation with the initial hypothesis of reduced SERCA2 expression leading to enhanced asthmatic 
phenotype. Each point represents the mean of an individual cell line, healthy derived cells (clear circles), 
mild asthmatic (light grey quadrilaterals) and moderate asthmatics (dark grey triangles). 
 
As mentioned, such simple conclusions cannot be made with confidence between the cell lines 
characterised as there is no fixed control to act as the benchmark. Without the non-immortalised versions 
of each line to compare against it is impossible to know which has been adversely affected by the 
immortalisation process. A comparison back to the population means using the raw data from (Mahn et 
al., 2009) was attempted to gain further insight but not enough was available to draw further conclusions. 
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Several groups have been using immortalised ASM derived in the same manner as ours to generate 
important insights within the field (Dekkers et al., 2010; Redhu et al., 2009). However, the proper 
characterisation has not been carried out on these lines to discover what phenotypes have remained and 
which have been altered. To fully validate the work this needs to be achieved and it will add extra weight 
to the findings to show the key aspects still match native cells. 
In conclusion, it appears as though the cell line htHB107 has maintained most of the characteristics 
expected of a cell line derived from a moderate asthmatic while htHB95 and 96 (derived from healthy 
patients) have maintained the majority of their disease-specific markers. The mild asthmatic derived cell 
lines htHB97 and htHB100 appeared to be the least characteristic but it is unknown whether this is due to 
the immortalisation process. The experiments outlined here could prove to be very useful in phenotype 
screening of newly immortalised lines to provide a robust research tool. It may prove hard to generate 
immortalised ASM lines showing every hallmark of asthma published therefore additional parameters 
could be added with the aim to develop disease specific sub-types. 
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Chapter 7 Final Discussion 
Recent evidence shows that hospital admissions and mortality associated with asthma in the UK have 
reached a plateau and are showing signs of decline in recent years despite a relatively stable prevalence in 
the population (Anderson et al., 2007). The paper postulates that pharmacological improvements in β2-AR 
agonists and corticosteroid drugs may have played a role in this. Nevertheless there are still patient cohorts 
who do not respond well to current therapy and thus form the driving rationale to further understand the 
pathophysiology of the disease to generate new, novel targets. 
Calcium homeostasis is undoubtedly altered in both healthy derived primary cultures of ASM treated with 
asthma associated cytokines and in naive asthmatic derived primary cultures. We have shown, with others, 
that varying expression levels of key calcium handling proteins in both scenarios are likely to underpin 
these changes. The work here has furthered the field by showing that a disruption of calcium handling 
proteins can enhance an asthmatic phenotype in vivo in terms of AHR and inflammation, specifically 
neutrophilia. We have also started to tease out the role TRPC6 may play in the altered ASM phenotype 
exhibited in asthma and the complex relationship it holds with TRPC3 and calcium entry. The data 
presented here is in accordance with White et al., 2006 where they proposed a switch from ROCE to 
SOCE upon TNF-α stimulation. We confirmed an increase in TRPC3 expression but also showed that 
TRPC6 decreases which fits with the current hypothesis. The exact relationship between ROCE, SOCE, 
TRPC3/6 and SERCA expression is a complicated affair. Evidence suggests that the SR, plasma 
membrane, cytosol and nucleus have a very dynamic relationship and that changes in calcium ion 
concentration can be directed in specific spatial and temporal patterns to encode complex signalling 
messages.   
Measuring the function of SERCA2 in this thesis was performed in an indirect manner by measuring the 
exponential constant as calcium returned to baseline levels after stimulation. Due to technical limitations 
these measurement were acquired at room temperature and not 37°C which may lead to a deviation from 
the true in vivo contribution of it removing calcium from the cytosol (Mackiewicz et al., 2006). The paper 
shows in cardiac myocytes that the contribution of NCX increases from 24°C to 37°C at the expense of 
SERCA in relaxation, therefore changes in function measured in vitro may not be as pronounced in vivo. 
Nevertheless the murine study outlined here shows that a reduction in SERCA2 expression to a similar 
level observed in cultured ASM derived from asthmatic patients does result in an enhanced asthmatic 
phenotype. 
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The scope of this thesis is limited in terms of its ability to extrapolate the changes in TRPC function to 
either synthetic or contractile ASM phenotypes which are altered in asthma. This can form the basis of 
future work to determine the relevance and impact of these findings on the pathophysiology of asthma. 
Furthermore, the in vitro data solely focuses on ASM cells in monoculture and the influence of their in 
vivo surrounding is missing. For example, the ECM can interact greatly with ASM and can modify its 
phenotype such as increasing proliferation as well as the compliance of the airways through integrin 
tethering (Hirst et al., 2000; Johnson et al., 2004b). As demonstrated with the in vivo SERCA2 data, not 
all of the characteristics were translated from Mahn et al., 2009 to the findings in Chapter 4 such as 
enhanced eotaxin-1 production. However a greater sensitivity for an increase in total lung resistance and 
decline in dynamic compliance was observed, a finding only made possible by studying the lung 
functioning as a whole organ. 
From the data gathered in this thesis coupled with previously published work the key messages are: The 
expression of several calcium handling proteins are altered in asthma however the mechanisms behind 
them may differ. SERCA2 protein expression is reduced and maintained in asthmatic ASM cell culture for 
several passages hinting towards genetic or epigenetic mechanisms (Mahn et al., 2009). Although it has 
previously been shown to also be reduced by inflammatory cytokines (Ojo, 2011; Sathish et al., 2009) the 
evidence put forward here lies in contrast with that. The discrepancy at the very least sheds doubt on the 
findings. Conversely TRPC3 and TRPC6 are not altered in asthmatic derived primary ASM cultures 
compared to healthy but drastically and differentially changed in the presence of inflammatory cytokines. 
Therefore future work looking to model “asthmatic ASM” in culture might be improved by using cells 
derived from asthmatics in the presence of exogenously applied cytokines in order to achieve the full 
spectrum of alterations that are probably present in vivo. Secondly, that reducing SERCA2 in vivo 
enhances inflammation and AHR in a murine model of the disease. Whether the reduction is a cause or 
consequence of these characteristics in asthma is yet to be determined. Finally, that the increased 
morbidity observed with chronic β2-AR agonist treatment is not a consequence of cAMP mediated 
decrease in SERCA2 expression leading to calcium handling disruption in ASM as previously 
hypothesised. It may possibly be the result of the non-canonical β-arrestin pathway disrupting calcium 
homeostasis but there is currently insufficient evidence to substantiate this claim. 
The possibility of therapeutically targeting changes in [Ca
2+
]i is attractive as it is a common secondary 
messenger for many of the phenotypes altered in asthma (Mahn et al., 2010). The proteins controlling it 
however are very widely expressed and therefore will potentially have on-target side effect issues. 
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Therefore in order for this potential to be realised the fine intricacies of the signalling pathways must be 
unravelled to discover aspects which are specific for the ASM. 
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